Disease	MyCancerGenome Gene category	genes	Entrez gene name	Gene ID	Drug name	pubchem drug name	pubchem drug id	Other drug names	clinical trial ID	indication of drug-gene interaction	Interaction type
Acute Myeloid Leukemia	CBFB-MYH11	CBFB-MYH11 Fusion	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Lymphoblastic Leukemia	CRLF2	JAK2	JAK2	3717	INCB18424	INCB018424	25126798	N/A	NCT01164163	Purpose: INCB18424 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. %Official title: Study of JAK Inhibition (INCB018424)	inhibitor
Acute Lymphoblastic Leukemia	CRLF2	CRLF2	64109	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	DEK-NUP214	DEK-NUP214	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	DNMT3A	DNMT3A	1788	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Azacitidine	Azacitidine	9444	N/A	NCT00887068	Inclusion criteria: patients in first complete remission that required more than 1 cycle of treatment to achieve the remission, or that have AML evolving from MDS, or that had the following abnormalities: FLT3 mutation, deletion of chromosome 5 or 7, MLL gene rearrangement, or more than or equal to 3 cytogenetics abnormalities.	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	CLARA	N/A	N/A	N/A	NCT00932412	Inlcusion criteria: A morphologically proven diagnosis of AML according to the WHO classification, cytogenetically (standard karyotype, FISH-MLL) and molecularly (FLT3, CEBPA, NMP1) defined.	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT00943943	Official title: G-CSF and Plerixafor With Sorafenib for Acute Myelogenous Leukemia With FLT3 Mutations. %Inclusion criteria: Patients must have relapsed/refractory leukemia with FLT3 (ITD) mutations.	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	midostaurin 	4'-N-benzoylstaurosporine	104937	N/A	NCT01093573	Detailed description:  To correlate treatment response with FLT3 mutational status in a descriptive fashion. To measure in vivo FLT3 inhibition using plasma inhibition assay (PIA) and Flt ligand (FL) levels in patients. 	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	midostaurin 	4'-N-benzoylstaurosporine	104937	N/A	NCT01174888	Detailed description: Characterize the biological activity of midostaurin and bortezomib to potentially increase endogenous phosphatase activity and therefore inhibit aberrant tyrosine kinases by assessing FLT3(fetal liver kinase-2)and KIT tyrosine kinase activity as well as SHP-1 phosphatase activity.	inhibitor
Acute Myeloid Leukemia	FLT3	N/A	N/A	N/A	Clofarabine	Clofarabine	119182	N/A	NCT01252667	Detailed description: Prognostic significance of cytogenetics and genetic markers not detected by traditional karyotype analysis, with special respect to tyrosine kinase receptor mutations (such as fms-like tyrosine kinase 3 [FLT3]), RAS- and nucleophosmin gene mutations along with CCAAT/enhancer binding protein, alpha (C/EBP) mutations.	inhibitor
Acute Myeloid Leukemia	FLT3	N/A	N/A	N/A	Omacetaxine	homoharringtonine 	285033	N/A	NCT01272245	Inclusion criteria:  Prior therapy with hydroxyurea, biological or targeted therapy (e.g. flt3 inhibitors, other kinase inhibitors, azacitidine), or hematopoietic growth factors is allowed.	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Idarubicine	Idarubicine	42890	N/A	NCT01296178	Purpose: Karyotype, the molecular alterations affecting genes FLT3, NPM1 and CEBPA, minimal residual disease by flow cytometry and response to first induction cycle are variables that must be taken into consideration when planning the treatment of first line from a patient with AML.	inhibitor
Acute Myeloid Leukemia	FLT3	N/A	N/A	N/A	TXA127	N/A	N/A	N/A	NCT01300611	Inclusion criteria: with high-risk cytogenetics or presence of flt3 mutation or secondary leukemia from prior chemotherapy	inhibitor
Acute Myeloid Leukemia	FLT3	N/A	N/A	N/A	Tacrolimus 	Tacrolimus 	445643	N/A	NCT01342289	Inclusion criteria: AML with at least one of the following: AML arising from MDS or a myeloproliferative disorder, or secondary AML Presence of Flt3 internal tandem duplications Poor-risk cytogenetics Primary refractory disease	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	PLX3397	N/A	N/A	N/A	NCT01349049	Inclusion criteria: Positive for Flt3-ITD activating mutation during Screening	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT01398501	Purpose: It has been used in other studies for patients with AML with the FLT3-ITD mutation and information from these studies suggests that sorafenib may help to control leukemia. %Inclusion criteria: Subjects with AML with the FLT3-ITD mutation	inhibitor
Acute Myeloid Leukemia	FLT3	N/A	N/A	N/A	Cyclophosphamide	Cyclophosphamide	2907	N/A	NCT01427881	N/A	inhibitor
Acute Myeloid Leukemia	FLT3	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01471067	N/A	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Midostaurin	4'-N-benzoylstaurosporine	104937	N/A	NCT01477606	Purpose: This is a phase II, single-arm, open-label, multi-center study in adult patients with Acute Myeloid Leukemia (AML) and FLT3-ITD as defined in inclusion/exclusion criteria. %Inclusion criteria: Presence of FLT3-ITD assessed in the central AMLSG reference laboratories	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Crenolanib	crenolanib 	10366136	N/A	NCT01522469	Inclusion criteria: Presence of a FLT3-D835 activating mutation irrespective of presence of other mutations like FLT3-ITD. %Exclusion criteria: Absence of FLT3-D835 activating mutation	inhibitor
Acute Myeloid Leukemia	FLT3	N/A	N/A	N/A	Fludarabine Phosphate	Fludarabine Phosphate	30751	N/A	NCT01529827	N/A	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Bortezomib	Bortezomib	387447	N/A	NCT01534260	Official title: Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype	inhibitor
Acute Myeloid Leukemia	FLT3	N/A	N/A	2322	Vorinostat	Vorinostat	5311	N/A	NCT01534260	N/A	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Clofarabine	Clofarabine	119182	N/A	NCT01534702	Inclusion criteria: absence of an activating FLT3-mutation	inhibitor
Acute Myeloid Leukemia	FLT3	FLT3	FLT3	2322	Crenolanib	crenolanib 	10366136	N/A	NCT01657682	Purpose: his study will enroll subjects with relapsed Acute Myeloid Leukemia (AML) with FLT3 activating mutations. %Detailed description: This study will enroll subjects with relapsed Acute Myeloid Leukemia (AML) with FLT3 activating mutations. %Inclusion criteria: onfirmed primary AML diagnosis with presence of either FLT3 ITD and/or other FLT3 activating mutations. %Exclusion criteria: Absence of a FLT3 activating mutation. %Keywords: FLT3	inhibitor
Acute Myeloid Leukemia	IDH1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	IDH2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Lymphoblastic Leukemia	JAK2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	KIT	KIT	KIT	3815	midostaurin 	4'-N-benzoylstaurosporine	104937	N/A	NCT01174888	Detailed description: Characterize the biological activity of midostaurin and bortezomib to potentially increase endogenous phosphatase activity and therefore inhibit aberrant tyrosine kinases by assessing FLT3(fetal liver kinase-2)and KIT tyrosine kinase activity as well as SHP-1 phosphatase activity.	inhibitor
Acute Myeloid Leukemia	KIT	CD30	TNFRSF8	943	brentuximab	N/A	N/A	N/A	NCT01461538	Purpose: brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies. %Official title: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies. %Inclusion criteria: Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy.	inhibitor
Acute Myeloid Leukemia	MLL-MLLT3	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	PML-RARA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	RBM15-MKL1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	RPN-EVI1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
Acute Myeloid Leukemia	RUNX1-RUNX1T1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	inhibitor
anaplastic large cell lymphoma	ALK	ALK	ALK	238	N/A	N/A	N/A	N/A	NCT01110733	Inclusion criteria: Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)	inhibitor
anaplastic large cell lymphoma	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01742286	Official title: Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK). %Purpose: LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose pharmacokinetics when administered orally to pediatric patients with ALK-activated tumors. %Detailed description: LDK378 is a novel inhibitor of ALK	inhibitor
anaplastic large cell lymphoma	ALK	ALK	ALK	238	Crizotinib	crenolanib 	11626560	Crizotinib	NCT01744652	Purpose: Dasatinib is designed to block certain proteins from causing cancer cells to grow out of control. Crizotinib is designed to block certain abnormal genes found in cancer cells. %Inclusion criteria: patients presenting any molecular abnormality of interest, which can include an ALK translocation, ALK amplification, ALK mutation and overexpression	inhibitor
Basal cell carcinoma	SMO	SMO	SMO	6608	LY2940680	LY2940680	49848070	N/A	NCT01226485	Detailed Description: Participants may include those who have previously received treatment with another hedgehog smoothened (Hh/Smo) inhibitor	inhibitor
Basal cell carcinoma	SMO	SMO	SMO	6608	LDE225	LDE225	24775005	N/A	NCT01529450	Purpose: To explore the effects of oral LDE225 on the Progression Free Survival (PFS) of individuals with locally advanced or metastatic BCC who have been previously treated with a non-LDE225 Smo inhibitor.	inhibitor
Bladder cancer	TSC1	P53	TP53	7157	SGT-53	N/A	N/A	N/A	NCT00470613	Detailed description: SGT-53 is a complex composed of a wild type p53 gene	Activator
Bladder cancer	TSC1	RB94	Rb1	5925	SGT-94	N/A	N/A	N/A	NCT01517464	Detailed description: SGT-94,the agent being tested, is a systemically administered complex composed of the RB94 gene	Activator
Bladder cancer	TSC1	P53	TP53	7157	Kevetrin	N/A	N/A	Thioureidobutyronitrile	NCT01664000	Purpose: Kevetrin activates p53	Activator
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Homoharringtonine	homoharringtonine 	285033	N/A	NCT00375219	Official title: Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation. %Secondary outcome measures: Participants' Degree of Suppression of BCR-ABL transcript levels. %Inclusion criteria: The patient will have the T315I BCR-ABL gene mutation	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Nilotinib	Nilotinib	644241	N/A	NCT01061177	Purpose: assess the efficacy and safety of nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive/BCR-ABL positive chronic myeloid leukaemia in chronic phase. %Inclusion criteria: Ph negative cases or patients with variant translocations who are BCR-ABL positive. Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of Philadelphia (Ph) chromosome	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	N/A	N/A	N/A	PM01183	N/A	N/A	N/A	NCT01314599	Inclusion criteria: Accelerated or blastic phase chronic myeloid leukemia (CML, with progressive disease despite treatment with BCR-ABL kinase inhibitors), or chronic myelomonocytic leukemia (CMML).	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Nilotinib	Nilotinib	644241	N/A	NCT01316250	Purpose: nilotinib can overcome imatinib resistance because of greater potency to bind to BCR-ABL. %Detailed description: Imatinib mesylate selectively targets the causative BCR-ABL oncogene in CML. nilotinib can overcome imatinib resistance because of greater potency to bind to BCR-ABL. %Inclusion criteria: Newly diagnosed untreated Philadelphia chromosome-positive CML	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Imatinib	Nilotinib	644241	N/A	NCT01400074	Official title: Efficacy of Nilotinib Versus Imatinib in Adult Patients With Ph+ CML. %Detailed description: Imatinib mesylate (imatinib) binds to the inactive conformation of Bcr-Abl tyrosine kinase suppressing the Ph+ clone in CML. Nilotinib is a novel, oral tyrosine kinase inhibitor with improved potency compared with imatinib	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Nilotinib	Nilotinib	644241	N/A	NCT01400074	Official title: Efficacy of Nilotinib Versus Imatinib in Adult Patients With Ph+ CML. %Detailed description: Imatinib mesylate (imatinib) binds to the inactive conformation of Bcr-Abl tyrosine kinase suppressing the Ph+ clone in CML. Nilotinib is a novel, oral tyrosine kinase inhibitor with improved potency compared with imatinib	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Ponatinib	Ponatinib	24826799	N/A	NCT01570868	Purpose: Ponatinib is designed to block the function of BCR-ABL. %Inclusion criteria: Diagnosis of Ph-positive (by cytogenetics or FISH) or Bcr-ABL-positive (by PCR) CML in early chronic phase CML	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01593254	Inclusion criteria: CP-CML Philadelphia chromosome positive (Ph+) patients with CHR but with BCR-ABL level >10%. %Seconday outcome measures: MR4 = 4- log reduction in BCR-ABL transcript from the standardized baseline	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	Akt1	Akt1	207	Mk2206	MK2206	46930998	N/A	NCT01604772	Purpose: Akt inhibitor MK2206	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	PRI-724	N/A	N/A	N/A	NCT01606579	Inclusion criteria: Patients 18 years or older with Philadelphia chromosome (Ph)-positive or break point cluster region BCR ABL1 positive CML 	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Ponatinib	Ponatinib	24826799	N/A	NCT01650805	Inclusion criteria: Cytogenetic assessment must demonstrate the BCR-ABL fusion by presence of the t(9;22) Philadelphia chromosome. %Keywords: Leukemia, Myelogenous, Chronic, BCR-ABL Positive. %Secondary outcome measures: To compare the proportion of patients achieving a ratio of <10% BCR-ABL to ABL transcript 	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Nilotinib	Nilotinib	644241	N/A	NCT01690065	Exclusion criteria: Patients without bcr-abl gene rearrangement. %Inclusion criteria: Patients with previously-untreated patients having bcr-abl gene rearrangement	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	Brd	Brd4	23476	OTX015	N/A	N/A	N/A	NCT01713582	Official title: Bromodomain (Brd) Inhibitor OTX015	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	BCR-ABL	N/A	N/A	Ponatinib	Ponatinib	24826799	N/A	NCT01746836	Purpose: Ponatinib is designed to block the function of BCR-ABL. %Inclusion criteria: Diagnosis of Ph-positive (by cytogenetics or FISH) or Bcr-ABL-positive (by PCR) CML in early chronic phase CML. %Inclusion criteria: Diagnosis of Ph-positive (by cytogenetics or FISH) or BCR-ABL-positive (by PCR) CML in chronic phase.	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	JAK2	JAK2	3717	Ruxolitinib	Ruxolitinib	25126798	N/A	NCT01751425	Purpose: Ruxolitinib is designed to block a protein called Jak2	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	mTOR	mTOR	2475	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3CA	5290	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3CB	5291	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3CG	5294	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3CD	5293	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3R1	5295	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3R2	5296	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3R3	8503	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3R4	30849	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3R5	23533	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	PI3K	PIK3R6	146850	BEZ235	dactolisib	11977753	N/A	NCT01756118	Purpose: To assess pre-treatment phosphatidylinositol 3-kinase (PI3K) pathway-related genes. %Official title: Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235	inhibitor
Chronic Myeloid Leukemia	BCR-ABL1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01787487	Inclusion criteria: BCR-ABL1 negative	inhibitor
Colorectal cancer	AKT1	Akt	Akt1	207	Perifosine	Perifosine	148177	N/A	NCT00776867	Purpose: perifosine- a drug that inhibits the protein AKT	inhibitor
Colorectal cancer	AKT1	Hsp90	HSP90AA1	3320	AUY922A	N/A	N/A	N/A	NCT01024283	Official title: Administration of the Heat Shock Protein 90 Inhibitor AUY922A	inhibitor
Colorectal cancer	AKT1	Hsp90	HSP90AB1	3326	AUY922A	N/A	N/A	N/A	NCT01024283	Official title: Administration of the Heat Shock Protein 90 Inhibitor AUY922A	inhibitor
Colorectal cancer	AKT1	Etar	EDNRA	1909	zibotentan	ZD4054	9910224	N/A	NCT01205711	Official title: Addition of an Endothelin Receptor Antagonist	inhibitor
Colorectal cancer	AKT1	PDGFR	PDGFRA	5156	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	PDGFR	PDGFRB	5159	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	RAF	BRAF	673	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	RAF	RAF1	5894	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	VEGFR	FLT4	2324	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	VEGFR-1	FLT1	2321	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	VEGFR-3	FLT4	2324	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	MEK	MAP2k1	5604	AZD6244	AZD6244	10127622	N/A	NCT01333475	Purpose: MK-2206 and AZD6244 are experimental cancer treatment drugs that block the effect of certain proteins that cancer cells need to grow and survive. %Official title:  MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor	inhibitor
Colorectal cancer	AKT1	MEK	MAP2k2	5605	AZD6244	AZD6244	10127622	N/A	NCT01333475	Purpose: MK-2206 and AZD6244 are experimental cancer treatment drugs that block the effect of certain proteins that cancer cells need to grow and survive. %Official title:  MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor	inhibitor
Colorectal cancer	AKT1	MEK	MAP2K3	5606	AZD6244	AZD6244	10127622	N/A	NCT01333475	Purpose: MK-2206 and AZD6244 are experimental cancer treatment drugs that block the effect of certain proteins that cancer cells need to grow and survive. %Official title:  MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor	inhibitor
Colorectal cancer	AKT1	MEK	MAP2K4	6416	AZD6244	AZD6244	10127622	N/A	NCT01333475	Purpose: MK-2206 and AZD6244 are experimental cancer treatment drugs that block the effect of certain proteins that cancer cells need to grow and survive. %Official title:  MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor	inhibitor
Colorectal cancer	AKT1	MEK	MAP2K5	5607	AZD6244	AZD6244	10127622	N/A	NCT01333475	Purpose: MK-2206 and AZD6244 are experimental cancer treatment drugs that block the effect of certain proteins that cancer cells need to grow and survive. %Official title:  MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor	inhibitor
Colorectal cancer	AKT1	MEK	MAP2k6	5608	AZD6244	AZD6244	10127622	N/A	NCT01333475	Purpose: MK-2206 and AZD6244 are experimental cancer treatment drugs that block the effect of certain proteins that cancer cells need to grow and survive. %Official title:  MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor	inhibitor
Colorectal cancer	AKT1	MEK	MAP2k7	5609	AZD6244	AZD6244	10127622	N/A	NCT01333475	Purpose: MK-2206 and AZD6244 are experimental cancer treatment drugs that block the effect of certain proteins that cancer cells need to grow and survive. %Official title:  MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor	inhibitor
Colorectal cancer	AKT1	Akt	Akt1	207	MK-2206	MK2206	46930998	N/A	NCT01333475	Purpose: MK-2206 and AZD6244 are experimental cancer treatment drugs that block the effect of certain proteins that cancer cells need to grow and survive. %Official title:  MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor	inhibitor
Colorectal cancer	AKT1	EGFR	EGFR	1956	Avastin	N/A	N/A	bevacizumab	NCT01383707	Inclusion criteria: No previous chemotherapy for metastatic disease or treatment with drugs targeting VEGF or EGFR	inhibitor
Colorectal cancer	AKT1	VEGF	VEGFA	7422	Avastin	N/A	N/A	bevacizumab	NCT01383707	Inclusion criteria: No previous chemotherapy for metastatic disease or treatment with drugs targeting VEGF or EGFR	inhibitor
Colorectal cancer	AKT1	VEGF	VEGFB	7423	Avastin	N/A	N/A	bevacizumab	NCT01383707	Inclusion criteria: No previous chemotherapy for metastatic disease or treatment with drugs targeting VEGF or EGFR	inhibitor
Colorectal cancer	AKT1	VEGF	VEGFC	7424	Avastin	N/A	N/A	bevacizumab	NCT01383707	Inclusion criteria: No previous chemotherapy for metastatic disease or treatment with drugs targeting VEGF or EGFR	inhibitor
Colorectal cancer	AKT1	CD137	TNFRSF9	3604	Urelumab	N/A	N/A	BMS-663513	NCT01471210	Exclusion criteria: Prior treatment with anti-programmed death 1 (anti-PD-1)/Programmed cell death 1 ligand 1 (PD-L1) or anti-CD137	inhibitor
Colorectal cancer	AKT1	Akt	Akt1	207	GSK2110183	N/A	N/A	N/A	NCT01531894	Purpose: GSK2110183 is an orally administered, pan-AKT kinase inhibitor. %Official title: Oral AKT Inhibitor GSK2110183	inhibitor
Colorectal cancer	AKT1	Ang1	ANGPT1	284	trebananib	N/A	N/A	AMG386	NCT01548482	Purpose: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	Ang2	ANGPT2	285	trebananib	N/A	N/A	AMG386	NCT01548482	Purpose: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Colorectal cancer	AKT1	PADI1	PADI1	29943	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Colorectal cancer	AKT1	PADI2	PADI2	11240	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Colorectal cancer	AKT1	PADI3	PADI3	51702	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Colorectal cancer	AKT1	PADI4	PADI4	23569	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Colorectal cancer	AKT1	PADI6	PADI6	353238	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Colorectal cancer	AKT1	Mek	MAP2k1	5604	trametinib	trametinib	11707110	GSK1120212	NCT01740648	Purpose: Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Official title: MEK Inhibitor Trametinib	inhibitor
Colorectal cancer	AKT1	Mek	MAP2k2	5605	trametinib	trametinib	11707110	GSK1120212	NCT01740648	Purpose: Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Official title: MEK Inhibitor Trametinib	inhibitor
Colorectal cancer	AKT1	Mek	MAP2K3	5606	trametinib	trametinib	11707110	GSK1120212	NCT01740648	Purpose: Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Official title: MEK Inhibitor Trametinib	inhibitor
Colorectal cancer	AKT1	Mek	MAP2K4	6416	trametinib	trametinib	11707110	GSK1120212	NCT01740648	Purpose: Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Official title: MEK Inhibitor Trametinib	inhibitor
Colorectal cancer	AKT1	Mek	MAP2K5	5607	trametinib	trametinib	11707110	GSK1120212	NCT01740648	Purpose: Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Official title: MEK Inhibitor Trametinib	inhibitor
Colorectal cancer	AKT1	Mek	MAP2k6	5608	trametinib	trametinib	11707110	GSK1120212	NCT01740648	Purpose: Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Official title: MEK Inhibitor Trametinib	inhibitor
Colorectal cancer	AKT1	Mek	MAP2k7	5609	trametinib	trametinib	11707110	GSK1120212	NCT01740648	Purpose: Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Official title: MEK Inhibitor Trametinib	inhibitor
Colorectal cancer	AKT1	Notch1	Notch1	4851	OMP-52M51	N/A	N/A	N/A	NCT01778439	Exclusion criteria: Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors	inhibitor
Colorectal cancer	AKT1	Mct1	SLC16A1	6566	AZD3965	N/A	N/A	N/A	NCT01791595	Purpose: AZD3965 is a type of drug called a monocarboxylate transporter 1 inhibitor. %Official title:  AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1)	inhibitor
Colorectal cancer	AKT1	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01802320	Purpose:  Akt inhibitor MK2206	inhibitor
Colorectal cancer	BRAF	PKC	PRRT2	112476	bryostatin 	bryostatin 	25235992	B705008K112	NCT00112476	N/A	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	PLX3603	N/A	N/A	RO5212054	NCT01143753	Purpose: efficacy of RO5212054 [PLX3603] in patients with BRAF V600-mutated advanced solid tumours. %Official title:  BRAF Inhibitor RO5212054 (PLX3603)	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01231594	Purpose: provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors. %Official title: Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.	inhibitor
Colorectal cancer	BRAF	Abl	Abl	45821	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	DDR2	DDR2	4921	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	Eph2A	EphA2	1969	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	FGFR1	FGFR1	2260	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	FGFR2	FGFR2	2263	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	KIT	KIT	3815	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	PDGFR-alpha	PDGFRA	5156	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	PDGFR-beta	PDGFRB	5159	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	PTK5	FRK	2444	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	RAF-1	RAF-1	5894	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	RET	RET	5979	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	SAPK2	MAPk11	5600	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	TIE2	TEK	7010	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	TrkA	NTRK1	4914	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	VEGFR1	FLT1	2321	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	VEGFR2	KDR	3791	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	VEGFR3	FLT4	2324	regorafenib	Regorafenib	11167602	N/A	NCT01298570	N/A	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01436656	Purpose: LGX818 (daily, twice daily and/or every-other-day), a RAF kinase inhibitor. %Inclusion criteria: documentation of BRAF V600E mutation, or any other BRAF V600 mutation	inhibitor
Colorectal cancer	BRAF	KRAS	KRAS	3845	GS-6624	N/A	N/A	N/A	NCT01479465	Official title: GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma. %Inclusion criteria: Metastatic Colorectal Carcinoma with KRAS mutation.	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01524978	Official title: Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers. %Inclusion criteria: Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01531361	Official title: Vemurafenib (BRAF Inhibitor). %Inclusion criteria: Patients with advanced or metastatic cancers and BRAF mutations 	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3CA	5290	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3CB	5291	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3CG	5294	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3CD	5293	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R1	5295	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R2	5296	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R3	8503	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R4	30849	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R5	23533	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R6	146850	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	PLX4032	NCT01636622	Purpose: Vemurafenib is designed to block a protein (called mutated BRAF). %Inclusion criteria: Patient must have histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma harboring a BRAF mutation	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01677741	Purpose: dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. %Official title: Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation. %Inclusion criteria: BRAF V600 mutation-positive tumor.	inhibitor
Colorectal cancer	BRAF	EGFR	EGFR	1956	Panitumumab	N/A	N/A	N/A	NCT01704703	N/A	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	GSK2118436	NCT01713972	Purpose: Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Assigned intervention: BRAF inhibitor GSK2118436. %Inclusion criteria: Tumors must carry the BRAF mutation	inhibitor
Colorectal cancer	BRAF	EGFR	EGFR	1956	cetuximab	N/A	N/A	N/A	NCT01718808	N/A	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3CB	5291	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3CG	5294	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3CD	5293	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R1	5295	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R2	5296	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R3	8503	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R4	30849	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R5	23533	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	PI3K	PIK3R6	146850	BYL719	BYL719	56649450	N/A	NCT01719380	Keywords: PI3K inhibitor	inhibitor
Colorectal cancer	BRAF	EGFR	EGFR	1956	cetuximab	N/A	N/A	N/A	NCT01719380	Keywords: EGFR; cetuximab	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01719380	keywords: BRAF inhibitor	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	dabrafenib	Dabrafenib mesylate	44516822	GSK2118436	NCT01750918	Official title: BRAF Inhibitor. %Detailed description: subjects with BRAF-mutation	inhibitor
Colorectal cancer	BRAF	EGFR	EGFR	1956	Panitumumab	N/A	N/A	N/A	NCT01750918	Purpose: anti-EGFR antibody panitumumab. %Official title: Anti-EGFR Antibody Panitumumab. %Detailed description: anti-EGFR antibody panitumumab	inhibitor
Colorectal cancer	BRAF	MEK	MAP2k1	5604	trametinib	trametinib	11707110	GSK1120212	NCT01750918	Official title: MEK Inhibitor GSK1120212	inhibitor
Colorectal cancer	BRAF	MEK	MAP2k2	5605	trametinib	trametinib	11707110	GSK1120212	NCT01750918	Official title: MEK Inhibitor GSK1120212	inhibitor
Colorectal cancer	BRAF	MEK	MAP2K3	5606	trametinib	trametinib	11707110	GSK1120212	NCT01750918	Official title: MEK Inhibitor GSK1120212	inhibitor
Colorectal cancer	BRAF	MEK	MAP2K4	6416	trametinib	trametinib	11707110	GSK1120212	NCT01750918	Official title: MEK Inhibitor GSK1120212	inhibitor
Colorectal cancer	BRAF	MEK	MAP2K5	5607	trametinib	trametinib	11707110	GSK1120212	NCT01750918	Official title: MEK Inhibitor GSK1120212	inhibitor
Colorectal cancer	BRAF	MEK	MAP2k6	5608	trametinib	trametinib	11707110	GSK1120212	NCT01750918	Official title: MEK Inhibitor GSK1120212	inhibitor
Colorectal cancer	BRAF	MEK	MAP2k7	5609	trametinib	trametinib	11707110	GSK1120212	NCT01750918	Official title: MEK Inhibitor GSK1120212	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01765543	Purpose: in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Inclusion criteria: positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01767623	Purpose:  vemurafenib in patients with BRAF V600 mutation positive cancer. %Official title: Vemurafenib in BRAF V600 Mutation Positive Cancer Patients. %Inclusion criteria: confirmed BRAF V600 mutation	inhibitor
Colorectal cancer	BRAF	ERK1	MAPK3	5595	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Colorectal cancer	BRAF	ERK2	MAPK1	5594	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Colorectal cancer	BRAF	EGFR	EGFR	1956	Cetuximab	N/A	N/A	Erbitux	NCT01791309	Purpose: Vemurafenib is designed to block BRAFV600. %Official title: Patients With BRAF V600 Mutant Advanced Solid Malignancies. %Inclusion criteria: Cancers with positive BRAF V600 mutation	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01791309	Purpose: treatment is being tested in a subgroup of patients with colorectal cancer whose tumors have changes in the BRAF gene that may make them more likely to respond to this new drug combination. %Inclusion criteria: Patient must have metastatic colorectal cancer with a V600E BRAF mutation. %Keywords: V600E BRAF mutation	inhibitor
Colorectal cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	PLX4032, PLX4032	NCT01791309	Purpose: Vemurafenib is designed to block BRAFV600. %Official title: Patients With BRAF V600 Mutant Advanced Solid Malignancies. %Inclusion criteria: Cancers with positive BRAF V600 mutation	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	cetuximab	N/A	N/A	N/A	NCT00326495	Purpose: Therapies targeting EGFR, like cetuximab, have shown activity in the treatment of solid tumors like CRC. %Inclusion criteria: Tumor should express EGFR	inhibitor
Colorectal cancer	KRAS	RAF	BRAF	673	Sorafenib	Sorafenib	406563	Bay 43-9006	NCT00326495	Purpose: BAY 43-9006 is both a Raf kinase inhibitor and an inhibitor of VEGF receptor (VEGFR2) tyrosine kinase. Therapies targeting EGFR, like cetuximab, have shown activity in the treatment of solid tumors like CRC. %Inclusion criteria: Tumor should express EGFR	inhibitor
Colorectal cancer	KRAS	RAF	RAF1	5894	Sorafenib	Sorafenib	406563	Bay 43-9006	NCT00326495	Purpose: BAY 43-9006 is both a Raf kinase inhibitor and an inhibitor of VEGF receptor (VEGFR2) tyrosine kinase. Therapies targeting EGFR, like cetuximab, have shown activity in the treatment of solid tumors like CRC. %Inclusion criteria: Tumor should express EGFR	inhibitor
Colorectal cancer	KRAS	VEGFR	FLT1	2321	Sorafenib	Sorafenib	406563	Bay 43-9006	NCT00326495	Purpose: BAY 43-9006 is both a Raf kinase inhibitor and an inhibitor of VEGF receptor (VEGFR2) tyrosine kinase. Therapies targeting EGFR, like cetuximab, have shown activity in the treatment of solid tumors like CRC. %Inclusion criteria: Tumor should express EGFR	inhibitor
Colorectal cancer	KRAS	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	Bay 43-9006	NCT00326495	Purpose: BAY 43-9006 is both a Raf kinase inhibitor and an inhibitor of VEGF receptor (VEGFR2) tyrosine kinase. Therapies targeting EGFR, like cetuximab, have shown activity in the treatment of solid tumors like CRC. %Inclusion criteria: Tumor should express EGFR	inhibitor
Colorectal cancer	KRAS	VEGFR	FLT4	2324	Sorafenib	Sorafenib	406563	Bay 43-9006	NCT00326495	Purpose: BAY 43-9006 is both a Raf kinase inhibitor and an inhibitor of VEGF receptor (VEGFR2) tyrosine kinase. Therapies targeting EGFR, like cetuximab, have shown activity in the treatment of solid tumors like CRC. %Inclusion criteria: Tumor should express EGFR	inhibitor
Colorectal cancer	KRAS	top1	Top1	7150	irinotecan	Irinotecan	60838	N/A	NCT00856375	N/A	inhibitor
Colorectal cancer	KRAS	top1	Top1	7150	NKTR-102	NKTR-102	71300727	N/A	NCT00856375	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	erlotinib hydrochloride	erlotinib hydrochloride	176871	erlotinib hydrochloride	NCT00940316	Purpose: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Detailed description: Determine the effect of these regimens on downstream targets of EGFR in skin rash associated with pharmacologic EGFR inhibition. 	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	panitumumab	N/A	N/A	N/A	NCT00940316	Purpose: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Detailed description: Determine the effect of these regimens on downstream targets of EGFR in skin rash associated with pharmacologic EGFR inhibition. 	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	Sym004	N/A	N/A	N/A	NCT01117428	Inclusion criteria: Documented disease progression during or within 6 months after cessation of anti-EGFR Ab treatment.	inhibitor
Colorectal cancer	KRAS	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	Everolimus	NCT01139138	N/A	inhibitor
Colorectal cancer	KRAS	top1	Top1	7150	Irinotecan	Irinotecan	60838	N/A	NCT01139138	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	Panitumumab	N/A	N/A	N/A	NCT01139138	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	Panitumumab	N/A	N/A	N/A	NCT01257360	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	Panitumumab	N/A	N/A	N/A	NCT01260415	Detailed description: Emerging data suggests that KRAS mutation is a strong predictor for resistance to EGFR antagonist therapy. In the KRAS wild-type cohort, the addition of EGFR antagonists to chemotherapy has been shown to improve RR and PFS.	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	Cetuximab	N/A	N/A	N/A	NCT01276379	N/A	inhibitor
Colorectal cancer	KRAS	Hsp90	HSP90AA1	3320	AUY922	AUY922	10096043	N/A	NCT01294826	N/A	inhibitor
Colorectal cancer	KRAS	Hsp90	HSP90AB1	3326	AUY922	AUY922	10096043	N/A	NCT01294826	N/A	inhibitor
Colorectal cancer	KRAS	KRAS	KRAS	3845	Regorafenib	Regorafenib	11167602	BAY 73-4506	NCT01298570	Purpose:  in patients with mCRC and KRAS or BRAF mutant disease. 	inhibitor
Colorectal cancer	KRAS	BRAF	BRAF	673	Regorafenib	Regorafenib	11167602	BAY 73-4520	NCT01298584	Purpose:  in patients with mCRC and KRAS or BRAF mutant disease. 	inhibitor
Colorectal cancer	KRAS	VEGFR-1	FLT1	2321	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Colorectal cancer	KRAS	VEGFR-2	KDR	3791	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Colorectal cancer	KRAS	VEGFR-3	FLT4	2324	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Colorectal cancer	KRAS	mTOR	mTOR	2475	everolimus	Everolimus	6442177	Everolimus	NCT01334073	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	Panitumumab	N/A	N/A	N/A	NCT01504477	Purpose: Panitumumab is a drug that targets a protein important for the growth of cancer cells known as EGFR. %Official title: Anti-EGFR Monoclonal Antibody, Panitumumab. 	inhibitor
Colorectal cancer	KRAS	IGF-1R	IGF1R	3480	Ganitumab	N/A	N/A	AMG 479	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	IGF-1R	IGF1R	5609	MEK163	N/A	N/A	N/A	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	MEK	MAP2k1	5604	MEK163	N/A	N/A	N/A	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	MEK	MAP2k2	5605	MEK163	N/A	N/A	N/A	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	MEK	MAP2K3	5606	MEK163	N/A	N/A	N/A	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	MEK	MAP2K4	6416	MEK163	N/A	N/A	N/A	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	MEK	MAP2K5	5607	MEK163	N/A	N/A	N/A	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	MEK	MAP2k6	5608	MEK163	N/A	N/A	N/A	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	MEK	MAP2k7	5609	MEK163	N/A	N/A	N/A	NCT01562899	Exclusion criteria: Prior therapy with MEK- or IGF-1R- inhibitor	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	Cetuximab	N/A	N/A	N/A	NCT01564810	Inclusion criteria: With evidence of tumor EGFR expression and KRAS gene wild-type status.	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	Necitumumab	N/A	N/A	IMC-11F8	NCT01606748	N/A	inhibitor
Colorectal cancer	KRAS	N/A	N/A	N/A	TAS-114	N/A	N/A	N/A	NCT01610479	N/A	inhibitor
Colorectal cancer	KRAS	EWS-FLI1	N/A	N/A	Mithramycin	Plicamycin	163659	N/A	NCT01610570	Purpose:  Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript. %Inclusion criteria: Ewing sarcoma with EWS-FLI1 fusion transcript.	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	cetuximab	N/A	N/A	N/A	NCT01652482	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	MEHD7945A	N/A	N/A	N/A	NCT01652482	N/A	inhibitor
Colorectal cancer	KRAS	HER3	ERBB3	2065	MEHD7945A	N/A	N/A	N/A	NCT01652482	N/A	inhibitor
Colorectal cancer	KRAS	elF4e	ELF4	2000	ISIS 183750	N/A	N/A	N/A	NCT01675128	Detailed description: ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the human eukaryotic translation initiation factor 4E (eIF4E) protein. 	inhibitor
Colorectal cancer	KRAS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01703910	Inclusion criteria: Patients should have received at least two lines of standard treatment, including therapies antiEGFR in cases of tumors with Kras oncogene B-Raf and native	inhibitor
Colorectal cancer	KRAS	COX-2	PTGS2	5743	Celecoxib	Celecoxib	2662	N/A	NCT01729923	Purpose: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Colorectal cancer	KRAS	microtubules	N/A	N/A	Eribulin Mesylate	Eribulin	17755248	N/A	NCT01744340	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	panitumumab	N/A	N/A	N/A	NCT01801904	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	cetuximab	N/A	N/A	N/A	NCT01832467	N/A	inhibitor
Colorectal cancer	KRAS	EGFR	EGFR	1956	cetuximab	N/A	N/A	N/A	NCT01836653	Inclusion criteria: EGFR positive	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	NRAS	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Colorectal cancer	PIK3CA	Alk	ALK	238	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. %Inclusion criteria: No prior ALK inhibitor therapy. 	inhibitor
Colorectal cancer	PIK3CA	EGFR	EGFR	1956	Cetuximab	N/A	N/A	N/A	NCT01522612	Exclusion criteria: Previous exposure to EGFR or VEGF/VEGFR targeted therapy	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Colorectal cancer	PIK3CA	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PIK3CA	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Colorectal cancer	PTEN	Akt	Akt1	207	Mk2206	MK2206	46930998	N/A	NCT01263145	Purpose: Akt inhibitor MK2206.	inhibitor
Colorectal cancer	PTEN	EGFR	EGFR	1956	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. 	inhibitor
Colorectal cancer	PTEN	PTEN	PTEN	5728	GSK2636771	1372540-25-4	56949517	N/A	NCT01458067	Inclusion criteria: Subjects must have tumors with a documented PTEN deficiency. 	inhibitor
Colorectal cancer	PTEN	NY-ESO-1	CTAG1-B	255753	DEC-205-NY-ESO-1 fusion protein vaccine	N/A	N/A	N/A	NCT01522820	Purpose: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. 	inhibitor
Colorectal cancer	PTEN	CDK	CDK6	1021	PD-0332991	PD-0332991	5330286	N/A	NCT01522989	Purpose: PD-0332991 stops cells from dividing by blocking an enzyme called cyclin-dependent kinase (CDK), which cancer cells need to grow and divide. 	inhibitor
Colorectal cancer	PTEN	CDK	CDK4	1019	PD-0332991	PD-0332991	5330286	N/A	NCT01522989	Purpose: PD-0332991 stops cells from dividing by blocking an enzyme called cyclin-dependent kinase (CDK), which cancer cells need to grow and divide. 	inhibitor
Gastric cancer	Her2	PARP1	PARP1	142	ABT-888	Veliparib	11960529	N/A	NCT00740805	Purpose: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.	inhibitor
Gastric cancer	Her2	PARP2	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT00740805	Purpose: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01118975	Purpose: Lapatinib is an anti-cancer drug that is approved by the Food and Drug Administration (FDA) for the treatment of metastatic HER2-positive breast cancer. 	inhibitor
Gastric cancer	Her2	histone deacetylase	N/A	N/A	Vorinostat	Vorinostat	5311	N/A	NCT01118975	Exclusion criteria: Prior exposure to lapatinib, vorinostat, or other Histone deacetylase (HDAC) inhibitors	inhibitor
Gastric cancer	Her2	EGFR	EGFR	1956	Cetuximab	N/A	N/A	N/A	NCT01190462	N/A	inhibitor
Gastric cancer	Her2	HMG-CoA reductase	N/A	N/A	Simvastin	Simvastin	54454	N/A	NCT01190462	Purpose: Simvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	MM-111	N/A	N/A	N/A	NCT01304784	Official title: MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors.	inhibitor
Gastric cancer	Her2	N/A	N/A	N/A	TRC105	N/A	N/A	N/A	NCT01326481	N/A	inhibitor
Gastric cancer	Her2	mTOR1	mTOR	2475	MLN0128	N/A	N/A	N/A	NCT01351350	Keywords: mTORC1/2 inhibitors	inhibitor
Gastric cancer	Her2	mTOR2	N/A	N/A	MLN0128	N/A	N/A	N/A	NCT01351350	Keywords: mTORC1/2 inhibitors	inhibitor
Gastric cancer	Her2	Akt	Akt1	207	GDC-0068	GDC-0068	24788740	N/A	NCT01362374	N/A	inhibitor
Gastric cancer	Her2	Akt	Akt2	208	GDC-0068	GDC-0068	24788740	N/A	NCT01362374	N/A	inhibitor
Gastric cancer	Her2	Akt	Akt3	10000	GDC-0068	GDC-0068	24788740	N/A	NCT01362374	N/A	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	HER-2 vaccine	N/A	N/A	N/A	NCT01376505	Purpose: Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine. 	inhibitor
Gastric cancer	Her2	c-Kit	KIT	3815	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Gastric cancer	Her2	PDGFR-a	PDGFRA	5156	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Gastric cancer	Her2	PDGFR-_	PDGFRB	5159	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Gastric cancer	Her2	VEFGR2	VEGFR2	3791	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Gastric cancer	Her2	VEGFR1	FLT1	2321	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Gastric cancer	Her2	VEGFR3	FLT4	2324	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Gastric cancer	Her2	PDGFR-_	PDGFRB	5159	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Gastric cancer	Her2	Raf	BRAF	673	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Gastric cancer	Her2	Raf	Raf1	5894	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Gastric cancer	Her2	VEGFR-1	FLT1	2321	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Gastric cancer	Her2	VEGFR-2	KDR	3791	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Gastric cancer	Her2	VEGFR-3	FLT4	2324	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	Trastuzumab	N/A	N/A	Herceptin	NCT01450696	Exclusion criteria: Prior therapy with an anti-HER2 agent	inhibitor
Gastric cancer	Her2	ERBB3	ERBB3	2065	MM121	N/A	N/A	N/A	NCT01451632	N/A	inhibitor
Gastric cancer	Her2	cMet	MET	4233	ABT-700	N/A	N/A	N/A	NCT01472016	Purpose: ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody. 	inhibitor
Gastric cancer	Her2	HER1	EGFR	1956	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01497626	Purpose: Lapatinib is a drug that targets two proteins important for the growth of cancer cells known as HER1 (EGFR) and HER2. 	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01497626	Purpose: Lapatinib is a drug that targets two proteins important for the growth of cancer cells known as HER1 (EGFR) and HER2. 	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	Afatinib	Afatinib	10184653	BIBW 2992	NCT01522768	Purpose:  investigational (experimental) drug afatinib (BIBW 2992) that targets HER2. 	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	AVX901	N/A	N/A	N/A	NCT01526473	Purpose: has been changed so it tells the immune system to attack cancer cells which make HER2. %Detailed description: When VRP are used for immunization, the VRP infect individual cells and the replicon expresses HER2 which then induces an immune response. %Inclusion criteria: subgroups of patients with HER2 overexpression	inhibitor
Gastric cancer	Her2	Akt	Akt1	207	Akt Inhibitor MK2206	MK2206	46930998	MK2206	NCT01705340	Purpose: Akt inhibitor MK2206 and lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth.  %Official tititle: AKT inhibitor MK2206	inhibitor
Gastric cancer	Her2	Akt	Akt2	208	Akt Inhibitor MK2206	MK2206	46930998	MK2206	NCT01705340	Purpose: Akt inhibitor MK2206 and lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth.  %Official tititle: AKT inhibitor MK2206	inhibitor
Gastric cancer	Her2	Akt	Akt3	10000	Akt Inhibitor MK2206	MK2206	46930998	MK2206	NCT01705340	Purpose: Akt inhibitor MK2206 and lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth.  %Official tititle: AKT inhibitor MK2206	inhibitor
Gastric cancer	Her2	EGFR	EGFR	1956	lapatinib ditosylate	lapatinib ditosylate	9941095	Lapatinib	NCT01705340	Purpose: Akt inhibitor MK2206 and lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth.	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	lapatinib ditosylate	lapatinib ditosylate	9941095	Lapatinib	NCT01705340	Purpose: Akt inhibitor MK2206 and lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth.	inhibitor
Gastric cancer	Her2	Her2	ERBB2	2064	trastuzumab	N/A	N/A	N/A	NCT01705340	N/A	inhibitor
GIST	BRAF	N/A	N/A	N/A	Everolimus	Everolimus	6442177	N/A	NCT00770263	N/A	inhibitor
GIST	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01231594	Purpose: provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors. %Official title: Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.	inhibitor
GIST	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01231594	Purpose: provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors. %Official title: Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.	inhibitor
GIST	BRAF	tubulin	N/A	N/A	Crolibulin	Crolibulin	23649181	N/A	NCT01240590	Purpose: Crolibulin (EPC2407) is a microtubulin inhibitor.	inhibitor
GIST	BRAF	N/A	N/A	N/A	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01325441	N/A	inhibitor
GIST	BRAF	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
GIST	BRAF	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
GIST	BRAF	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
GIST	BRAF	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
GIST	BRAF	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
GIST	BRAF	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
GIST	BRAF	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
GIST	BRAF	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
GIST	BRAF	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
GIST	BRAF	MEK1/2	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
GIST	BRAF	MEK1/2	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
GIST	BRAF	PI3K	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3CB	5291	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3CG	5294	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3CD	5293	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3R1	5295	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3R2	5296	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3R3	8503	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3R4	30849	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3R5	23533	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	PI3K	PIK3R6	146850	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	Mek	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	Mek	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	Mek	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	Mek	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	Mek	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	Mek	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	Mek	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
GIST	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01524978	Official title: Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers. %Inclusion criteria: Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation	inhibitor
GIST	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01524978	Official title: Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers. %Inclusion criteria: Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation	inhibitor
GIST	BRAF	mTor	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
GIST	BRAF	mTor	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
GIST	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01531361	Official title: Vemurafenib (BRAF Inhibitor). %Inclusion criteria: Patients with advanced or metastatic cancers and BRAF mutations 	inhibitor
GIST	BRAF	EGFR	EGFR	1956	BIBW 2992	BIBW 2992	10184653	N/A	NCT01542437	Purpose: BIBW 2992, an irreversible inhibitor of receptor Epidermal growth factor type 1/2 (EGFR/HER2). %Official title: BIBW 2992, Irreversible Inhibitor of EGFR and HER-2. %Exclusion criteria: Pre-treatment with systemic anti-tumor therapy with EGFR inhibitors	inhibitor
GIST	BRAF	Her2	ERBB2	2064	BIBW 2992	BIBW 2992	10184653	N/A	NCT01542437	Purpose: BIBW 2992, an irreversible inhibitor of receptor Epidermal growth factor type 1/2 (EGFR/HER2). %Official title: BIBW 2992, Irreversible Inhibitor of EGFR and HER-2. %Exclusion criteria: Pre-treatment with systemic anti-tumor therapy with EGFR inhibitors	inhibitor
GIST	BRAF	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
GIST	BRAF	PI3K	PIK3CA	5290	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3CB	5291	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3CG	5294	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3CD	5293	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3R1	5295	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3R2	5296	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3R3	8503	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3R4	30849	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3R5	23533	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	PI3K	PIK3R6	146850	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
GIST	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	PLX4032	NCT01636622	Purpose: Vemurafenib is designed to block a protein (called mutated BRAF). %Inclusion criteria: Patient must have histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma harboring a BRAF mutation	inhibitor
GIST	BRAF	N/A	N/A	N/A	SAR260301	N/A	N/A	N/A	NCT01673737	N/A	inhibitor
GIST	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01677741	Purpose: dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. %Official title: Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation. %Inclusion criteria: BRAF V600 mutation-positive tumor.	inhibitor
GIST	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	GSK2118436	NCT01713972	Purpose: Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Assigned intervention: BRAF inhibitor GSK2118436. %Inclusion criteria: Tumors must carry the BRAF mutation	inhibitor
GIST	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01738451	N/A	inhibitor
GIST	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01739764	Purpose: This open-label, multicenter, non-randomized study will provide continued access to vemurafenib for eligible patients with BRAF V600 mutation-positive malignancy. %Official title: A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies. %Inclusion criteria: BRAF V600 mutation-positive malignancy. 	inhibitor
GIST	BRAF	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
GIST	BRAF	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
GIST	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01765543	Purpose: in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Inclusion criteria: positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF	inhibitor
GIST	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01767623	Purpose:  vemurafenib in patients with BRAF V600 mutation positive cancer. %Official title: Vemurafenib in BRAF V600 Mutation Positive Cancer Patients. %Inclusion criteria: confirmed BRAF V600 mutation	inhibitor
GIST	BRAF	ERK1	MAPK3	5595	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
GIST	BRAF	ERK2	MAPK1	5594	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
GIST	BRAF	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
GIST	BRAF	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
GIST	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
GIST	KIT	Fms	CSF1R	1436	PLX3397	N/A	N/A	N/A	NCT01004861	Purpose: PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.	inhibitor
GIST	KIT	kit	KIT	3815	PLX3398	N/A	N/A	N/A	NCT01004862	Purpose: PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.	inhibitor
GIST	KIT	Flt3	FLT3	2322	PLX3399	N/A	N/A	N/A	NCT01004863	Purpose: PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.	inhibitor
GIST	KIT	VEGFR	FLT1	2321	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	VEGFR	KDR	3791	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	VEGFR	FLT4	2324	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	PDGF	PDGFA	5154	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	PDGF	PDGFB	5155	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	PDGF	PDGFC	56034	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	PDGF	PDGFD	80310	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	Flt-3	FLT3	2322	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	PDGFR-A	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
GIST	KIT	Abl	Abl	45821	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
GIST	KIT	c-Kit	Kit	16590	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
GIST	KIT	EPHA2	EPHA2	1696	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
GIST	KIT	PDGFRb	PDGFRB	5159	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
GIST	KIT	VEGF	VEGFA	7422	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
GIST	KIT	VEGF	VEGFB	7423	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
GIST	KIT	VEGF	VEGFC	7424	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
GIST	KIT	CD30	TNFRSF8	943	brentuximab	N/A	N/A	N/A	NCT01461538	Purpose: brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies. %Official title: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies. %Inclusion criteria: Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy.	inhibitor
GIST	KIT	MDM2	MDM2	4193	RO5503781	N/A	N/A	N/A	NCT01462175	Official title: RO5503781, a Small Molecule MDM2 Antagonist. 	inhibitor
GIST	KIT	mTor	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
GIST	KIT	mTor	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
GIST	KIT	VEGFR1	FLT1	2321	Pazopanib	pazopanib	10113978	N/A	NCT01543763	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
GIST	KIT	HDAC	N/A	N/A	PCI-24781	PCI-24781	11749858	N/A	NCT01543763	Purpose: PCI-24781 is a pan HDAC inhibitor.	inhibitor
GIST	KIT	VEGFR2	KDR	3791	Pazopanib	pazopanib	10113978	N/A	NCT01529593	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
GIST	KIT	VEGFR3	FLT4	2324	Pazopanib	pazopanib	10113978	N/A	NCT01529593	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
GIST	KIT	PDGFR-a	PDGFRA	5156	Pazopanib	pazopanib	10113978	N/A	NCT01543763	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
GIST	KIT	PDGFR-b	PDGFRB	5159	Pazopanib	pazopanib	10113978	N/A	NCT01543763	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
GIST	KIT	c-kit	KIT	3815	Pazopanib	pazopanib	10113978	N/A	NCT01529593	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Alk	ALK	238	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	c-Met	MET	4234	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00790816	N/A	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01283516	Purpose: assess the safety and efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK). %Official title:  LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK). %Keywords: LDK378	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90AA1	3320	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90B1	7184	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01358331	N/A	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Alk	ALK	238	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. %Inclusion criteria: No prior ALK inhibitor therapy. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	EGFR	EGFR	1956	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	ALK	ALK	238	Crizotinib 	crenolanib 	10366136	N/A	NCT01524926	Purpose: assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways. The targeted patient population will include patients with tumors harboring specific alterations leading to ALK and/or MET activation. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Met	MET	4233	Crizotinib 	crenolanib 	10366136	N/A	NCT01524926	Purpose: assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways. The targeted patient population will include patients with tumors harboring specific alterations leading to ALK and/or MET activation. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	mTor	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	mTor	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	ALK	ALK	238	Crizotinib	crenolanib 	10366136	N/A	NCT01548144	Purpose: Crizotinib is designed to block a protein called ALK. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	ALK	ALK	238	X-396	N/A	N/A	N/A	NCT01625234	Brief_title: Alk inhibitor. %Intervention: X-396, Oral ALK inhibitor	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01634763	Purpose: LDK378 as a single agent when administered orally to Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK). %Inclusion criteria: Only patients with tumors characterized by genetic alterations in ALK.	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01742286	Official title: Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK). %Purpose: LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose pharmacokinetics when administered orally to pediatric patients with ALK-activated tumors. %Detailed description: LDK378 is a novel inhibitor of ALK	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	N/A	N/A	N/A	GS-5745	N/A	N/A	N/A	NCT01803282	N/A	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00313599	N/A	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	nelfinavir mesylate	nelfinavir mesylate	64142	N/A	NCT00589056	N/A	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	everolimus	Everolimus	6442177	N/A	NCT00610948	N/A	inhibitor
Lung cancer	Akt1	Akt	Akt1	207	Perifosine	Perifosine	148177	N/A	NCT00776867	Purpose: perifosine- a drug that inhibits the protein AKT	inhibitor
Lung cancer	Akt1	EGFR	EGFR	1956	erlotinib hydrochloride	erlotinib hydrochloride	176871	N/A	NCT00801385	Secondary objectives: To analyze biomarkers, including evaluation of EGFR expression, mutational analysis of EGFR and K-ras, and immunohistochemical analysis of EGFR downstream pathway.	inhibitor
Lung cancer	Akt1	Hsp90	HSP90AB1	3326	AUY922A	N/A	N/A	N/A	NCT01024283	Official title: Administration of the Heat Shock Protein 90 Inhibitor AUY922A	inhibitor
Lung cancer	Akt1	Akt	Akt1	207	Hocena	N/A	N/A	Antroquinonol	NCT01134016	Detailed description: The pharmacological effects of antroquinonol were postulated to exert its antitumorigenesis effects through interactions to primary targets of epidermal growth factor receptor (EGFR)/Akt/mitogen-activated protein kinase (MAPK).	inhibitor
Lung cancer	Akt1	Akt	Akt2	208	Hocena	N/A	N/A	Antroquinonol	NCT01134016	Detailed description: The pharmacological effects of antroquinonol were postulated to exert its antitumorigenesis effects through interactions to primary targets of epidermal growth factor receptor (EGFR)/Akt/mitogen-activated protein kinase (MAPK).	inhibitor
Lung cancer	Akt1	Akt	Akt3	10000	Hocena	N/A	N/A	Antroquinonol	NCT01134016	Detailed description: The pharmacological effects of antroquinonol were postulated to exert its antitumorigenesis effects through interactions to primary targets of epidermal growth factor receptor (EGFR)/Akt/mitogen-activated protein kinase (MAPK).	inhibitor
Lung cancer	Akt1	MEK	MAP2k1	5604	GSK1120212	Trametinib	11707110	N/A	NCT01138085	Purpose: orally administered MEK inhibitor GSK1120212	inhibitor
Lung cancer	Akt1	MEK	MAP2k2	5605	GSK1120212	Trametinib	11707110	N/A	NCT01138085	Purpose: orally administered MEK inhibitor GSK1120212	inhibitor
Lung cancer	Akt1	MEK	MAP2K3	5606	GSK1120212	Trametinib	11707110	N/A	NCT01138085	Purpose: orally administered MEK inhibitor GSK1120212	inhibitor
Lung cancer	Akt1	MEK	MAP2K4	6416	GSK1120212	Trametinib	11707110	N/A	NCT01138085	Purpose: orally administered MEK inhibitor GSK1120212	inhibitor
Lung cancer	Akt1	MEK	MAP2K5	5607	GSK1120212	Trametinib	11707110	N/A	NCT01138085	Purpose: orally administered MEK inhibitor GSK1120212	inhibitor
Lung cancer	Akt1	MEK	MAP2k6	5608	GSK1120212	Trametinib	11707110	N/A	NCT01138085	Purpose: orally administered MEK inhibitor GSK1120212	inhibitor
Lung cancer	Akt1	MEK	MAP2k7	5609	GSK1120212	Trametinib	11707110	N/A	NCT01138085	Purpose: orally administered MEK inhibitor GSK1120212	inhibitor
Lung cancer	Akt1	AKT	Akt1	207	GSK2141795	GSK2126458	25167777	N/A	NCT01138085	Purpose: AKT kinase inhibitor GSK2141795	inhibitor
Lung cancer	Akt1	AKT	Akt2	208	GSK2141795	GSK2126458	25167777	N/A	NCT01138085	Purpose: AKT kinase inhibitor GSK2141795	inhibitor
Lung cancer	Akt1	AKT	Akt3	10000	GSK2141795	GSK2126458	25167777	N/A	NCT01138085	Purpose: AKT kinase inhibitor GSK2141795	inhibitor
Lung cancer	Akt1	EGFR	EGFR	1956	BIBW2992	BIBW 2992	10184653	N/A	NCT01156545	Purpose: BIBW2992, an irreversible EGFR-TKI	inhibitor
Lung cancer	Akt1	Ras	KRAS	3845	Simvastin	Simvastin	54454	N/A	NCT01156545	Detailed description: statins inhibit activation of RAS and downstream signaling cascades, including the RAF/MEK/ERK and PI3K/AKT	inhibitor
Lung cancer	Akt1	Akt	Akt1	207	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Lung cancer	Akt1	Akt	Akt2	208	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Lung cancer	Akt1	Akt	Akt3	10000	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Lung cancer	Akt1	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	Sativex	tetrahydrocannabinol-cannabidiol combination	44148067	N/A	NCT01262651	N/A	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	Pazopanib	pazopanib	10113978	N/A	NCT01262820	N/A	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	BMS-906024	UNII-DRL23N424R	66550890	N/A	NCT01292655	N/A	inhibitor
Lung cancer	Akt1	PDGFR	PDGFRA	5156	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	PDGFR	PDGFRB	5159	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	RAF	BRAF	673	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	RAF	RAF1	5894	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	VEGFR	FLT4	2324	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	VEGFR-1	FLT1	2321	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	VEGFR-3	FLT4	2324	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	MEK	MAP2k1	5604	AZD6244	AZD6244	10127622	N/A	NCT01306045	Purpose: AZD6244, which inhibits a protein called MEK that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	MEK	MAP2k2	5605	AZD6244	AZD6244	10127622	N/A	NCT01306045	Purpose: AZD6244, which inhibits a protein called MEK that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	MEK	MAP2K3	5606	AZD6244	AZD6244	10127622	N/A	NCT01306045	Purpose: AZD6244, which inhibits a protein called MEK that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	MEK	MAP2K4	6416	AZD6244	AZD6244	10127622	N/A	NCT01306045	Purpose: AZD6244, which inhibits a protein called MEK that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	MEK	MAP2K5	5607	AZD6244	AZD6244	10127622	N/A	NCT01306045	Purpose: AZD6244, which inhibits a protein called MEK that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	MEK	MAP2k6	5608	AZD6244	AZD6244	10127622	N/A	NCT01306045	Purpose: AZD6244, which inhibits a protein called MEK that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	MEK	MAP2k7	5609	AZD6244	AZD6244	10127622	N/A	NCT01306045	Purpose: AZD6244, which inhibits a protein called MEK that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01306045	Purpose: Participants with EGFR gene mutation will receive a drug called erlotinib, which inhibits a protein called EGFR.	inhibitor
Lung cancer	Akt1	ERBB2	ERBB2	2064	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01306045	Purpose: ERBB2 gene mutation or amplification will receive a drug called lapatinib	inhibitor
Lung cancer	Akt1	AKT	Akt1	207	MK-2206	MK2206	46930998	N/A	NCT01306045	Purpose: MK-2206, which inhibits a protein called AKT that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	AKT	Akt2	208	MK-2206	MK2206	46930998	N/A	NCT01306045	Purpose: MK-2206, which inhibits a protein called AKT that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	AKT	Akt3	10000	MK-2206	MK2206	46930998	N/A	NCT01306045	Purpose: MK-2206, which inhibits a protein called AKT that is thought to be a key factor in the development and progression of some cancers.	inhibitor
Lung cancer	Akt1	PDGFRA	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	Akt1	Kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	Endostar	N/A	N/A	N/A	NCT01327235	N/A	inhibitor
Lung cancer	Akt1	IL2	IL2	3558	TG4010	N/A	N/A	N/A	NCT01383148	Purpose: TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). 	inhibitor
Lung cancer	Akt1	CD137	TNFRSF9	3604	Urelumab	N/A	N/A	BMS-663513	NCT01471210	Exclusion criteria: Prior treatment with anti-programmed death 1 (anti-PD-1)/Programmed cell death 1 ligand 1 (PD-L1) or anti-CD137	inhibitor
Lung cancer	Akt1	CD137	TNFRSF9	3604	Urelumab	N/A	N/A	BMS-663513	NCT01471210	Exclusion criteria: Prior treatment with anti-programmed death 1 (anti-PD-1)/Programmed cell death 1 ligand 1 (PD-L1) or anti-CD137	inhibitor
Lung cancer	Akt1	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01480154	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01480154	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01480154	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	Akt	Akt1	207	GSK2110183	N/A	N/A	N/A	NCT01531894	Purpose: GSK2110183 is an orally administered, pan-AKT kinase inhibitor. %Official title: Oral AKT Inhibitor GSK2110183	inhibitor
Lung cancer	Akt1	Ang1	ANGPT1	284	trebananib	N/A	N/A	AMG386	NCT01548482	Purpose: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	Akt1	Akt1	207	Mk2206	MK2206	46930998	N/A	NCT01604772	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	PADI1	PADI1	29943	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Lung cancer	Akt2	PADI2	PADI2	11240	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Lung cancer	Akt3	PADI3	PADI3	51702	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Lung cancer	Akt4	PADI4	PADI4	23569	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Lung cancer	Akt5	PADI6	PADI6	353238	ADI-PEG 20	N/A	N/A	N/A	NCT01665183	Purpose: Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers that require arginine.	inhibitor
Lung cancer	Akt1	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01665417	Inclusion criteria: Patients must have lung cancer with a documented EGFR activating mutation. %Official title: Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients	inhibitor
Lung cancer	Akt1	VEGF	VEGFA	7422	Bevacizumab	N/A	N/A	N/A	NCT01700400	Detailed description: antiangiogenic activity that appears to have different targets than direct VEGF inhibiting strategies and therefore may augment the activity of targeted VEGF inhibitors	inhibitor
Lung cancer	Akt1	VEGF	VEGFB	7423	Bevacizumab	N/A	N/A	N/A	NCT01700400	Detailed description: antiangiogenic activity that appears to have different targets than direct VEGF inhibiting strategies and therefore may augment the activity of targeted VEGF inhibitors	inhibitor
Lung cancer	Akt1	VEGF	VEGFC	7424	Bevacizumab	N/A	N/A	N/A	NCT01700400	Detailed description: antiangiogenic activity that appears to have different targets than direct VEGF inhibiting strategies and therefore may augment the activity of targeted VEGF inhibitors	inhibitor
Lung cancer	Akt1	Akt	Akt1	207	Everolimus	Everolimus	6442177	N/A	NCT01700400	Detailed description: The AKT/mTOR pathway is a relevant target in NSCLC based on preclinical data showing aberrant pathway activation in human NSCLC tumors. Everolimus as a single agent has produced some responses as well as prolonged stable disease in both chemonaive and pre-treated NSCLC (Gridelli et al, 2008). There is interest in augmenting tumor responses to chemotherapy by the addition of mTOR inhibition. 	inhibitor
Lung cancer	Akt1	Akt	Akt2	208	Everolimus	Everolimus	6442177	N/A	NCT01700400	Detailed description: The AKT/mTOR pathway is a relevant target in NSCLC based on preclinical data showing aberrant pathway activation in human NSCLC tumors. Everolimus as a single agent has produced some responses as well as prolonged stable disease in both chemonaive and pre-treated NSCLC (Gridelli et al, 2008). There is interest in augmenting tumor responses to chemotherapy by the addition of mTOR inhibition. 	inhibitor
Lung cancer	Akt1	Akt	Akt3	10000	Everolimus	Everolimus	6442177	N/A	NCT01700400	Detailed description: The AKT/mTOR pathway is a relevant target in NSCLC based on preclinical data showing aberrant pathway activation in human NSCLC tumors. Everolimus as a single agent has produced some responses as well as prolonged stable disease in both chemonaive and pre-treated NSCLC (Gridelli et al, 2008). There is interest in augmenting tumor responses to chemotherapy by the addition of mTOR inhibition. 	inhibitor
Lung cancer	Akt1	mTor	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01700400	Detailed description: The AKT/mTOR pathway is a relevant target in NSCLC based on preclinical data showing aberrant pathway activation in human NSCLC tumors. Everolimus as a single agent has produced some responses as well as prolonged stable disease in both chemonaive and pre-treated NSCLC (Gridelli et al, 2008). There is interest in augmenting tumor responses to chemotherapy by the addition of mTOR inhibition. 	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	ASP9853	N/A	N/A	N/A	NCT01705483	N/A	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	SPI-1620	N/A	N/A	N/A	NCT01741155	N/A	inhibitor
Lung cancer	Akt1	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01752023	N/A	inhibitor
Lung cancer	Akt1	Notch1	Notch1	4851	OMP-52M51	N/A	N/A	N/A	NCT01778439	Exclusion criteria: Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors	inhibitor
Lung cancer	Akt1	kras	KRAS	3845	Selumetinib	Selumetinib	10127622	N/A	NCT01783197	Inclusion criteria: Patients planned for the pemetrexed single agent cohort, as well as those accrued to the RP2D expansion cohorts must have a documented KRAS mutation.	inhibitor
Lung cancer	Akt1	Mct1	SLC16A1	6566	AZD3965	N/A	N/A	N/A	NCT01791595	Purpose: AZD3965 is a type of drug called a monocarboxylate transporter 1 inhibitor. %Official title:  AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1)	inhibitor
Lung cancer	Akt2	Ang2	ANGPT2	285	trebananib	N/A	N/A	AMG386	NCT01548482	Purpose: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Alk	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Lung cancer	Alk	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00790816	N/A	inhibitor
Lung cancer	Alk	Alk	ALK	238	PF-02341066	Crizotinib	11626560	N/A	NCT00932451	Purpose: PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. %Official title: PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene. %Inclusion criteria: positive for the ALK fusion gene.	inhibitor
Lung cancer	Alk	Alk	ALK	238	PF-02341066	Crizotinib	11626560	N/A	NCT00932451	Purpose: PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. %Official title: PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene. %Inclusion criteria: positive for the ALK fusion gene.	inhibitor
Lung cancer	Alk	HDAC	N/A	N/A	Vorinostat	Vorinostat	5311	N/A	NCT01059552	Purpose: HDAC Inhibitor Vorinostat	inhibitor
Lung cancer	Alk	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01283516	Purpose: assess the safety and efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK). %Official title:  LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK). %Keywords: LDK378	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90AA1	3320	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90B1	7184	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01358331	N/A	inhibitor
Lung cancer	Alk	Alk	ALK	238	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. %Inclusion criteria: No prior ALK inhibitor therapy. 	inhibitor
Lung cancer	Alk	EGFR	EGFR	1956	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. 	inhibitor
Lung cancer	Alk	mTor	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	Alk	mTor	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	Alk	ALK	ALK	239	Crizotinib	crenolanib 	10366137	N/A	NCT01548144	Purpose: Crizotinib is designed to block a protein called ALK. 	inhibitor
Lung cancer	Alk	Alk	ALK	238	Ganetespib	Ganetespib	23624255	N/A	NCT01562015	Purpose: The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC.	inhibitor
Lung cancer	Alk	Alk	ALK	238	Ganetespib	Ganetespib	23624255	N/A	NCT01562015	Purpose: The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC.	inhibitor
Lung cancer	Alk	Alk	ALK	238	crizotinib	crenolanib 	10366136	N/A	NCT01579994	Inclusion criteria: Positive for translocation or inversion events involving the ALK gene locus as determined standard methods. %Official title: Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers.	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	Ganetespib	Ganetespib	23624255	N/A	NCT01579994	N/A	inhibitor
Lung cancer	Alk	ALK	ALK	238	X-396	N/A	N/A	N/A	NCT01625234	Brief_title: Alk inhibitor. %Intervention: X-396, Oral ALK inhibitor	inhibitor
Lung cancer	Alk	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01634763	Purpose: LDK378 as a single agent when administered orally to Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK). %Inclusion criteria: Only patients with tumors characterized by genetic alterations in ALK.	inhibitor
Lung cancer	Alk	Alk	ALK	238	Crizotinib	crenolanib 	10366136	N/A	NCT01637597	Purpose: Patients who are eligible to apply for Extended Access Program of crizotinib must have ALK translocation detected by RT-PCR, IHC or FISH analyses methods. %Inclusion criteria: Patient must have locally advanced or metastatic NSCLC (Stage IIIb or Stage IV by AJCC 7th.) with positive ALK. 	inhibitor
Lung cancer	Alk	Alk	ALK	238	Crizotinib	crenolanib 	10366136	N/A	NCT01639001	Purpose: The objective of the study is to demonstrate that Crizotinib is superior to first-line chemotherapy pemetrexed/cisplatin or pemetrexed/carboplatin in prolonging Progression Free Survival (PFS) in East Asian patients with advanced Non-Squamous NSCLC whose tumors harbor a translocation or inversion event involving the ALK (Anaplastic Lymphoma Kinase) gene locus. %Official title:  Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated East Asian Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus. %Inclusion criteria: Positive for translocation or inversion events involving the ALK gene locus.	inhibitor
Lung cancer	Alk	ISG15	ISG15	9636	Irinotecan	Irinotecan	60838	N/A	NCT01654081	Purpose: clinical benefit of irinotecan chemotherapy in patients with a specific NSCLC phenotype, ISG15-positive. %Inclusion criteria: All participants must have the appropriate phenotype on pretreatment screening of tumor tissue or sputa, consisting of ISG15-positive cells by immunohistochemistry.	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	BIBF 1120	N/A	N/A	N/A	NCT01683682	N/A	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	BIBF 1120	N/A	N/A	N/A	NCT01684111	N/A	inhibitor
Lung cancer	Alk	Alk	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01685138	Purpose: Patients will be pre-screened for ALK positive status. %Official title: Oral LDK378 in Crizotinib nave Adult Patients With ALK-activated Non-small Cell Lung Cancer. %inclusion criteria: Histologically or cytologically confirmed diagnosis of stage IIIb or IV NSCLC that carries an ALK rearrangement.	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	AT13387	AT13387	11955716	N/A	NCT01712217	N/A	inhibitor
Lung cancer	Alk	Alk	ALK	238	crizotinib	crenolanib 	10366136	N/A	NCT01712217	Detailed description:  patients with anaplastic lymphoma kinase (ALK) + or other potentially crizotinib-sensitive NSCLC. %Inclusion criteria: Must have Non-small Cell Lung Cancer with ALK+ mutation or other mutations or rearrangements potentially sensitive to crizotinib	inhibitor
Lung cancer	Alk	PI3k	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	PI3k	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	Alk	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01742286	Official title: Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK). %Purpose: LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose pharmacokinetics when administered orally to pediatric patients with ALK-activated tumors. %Detailed description: LDK378 is a novel inhibitor of ALK	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Lung cancer	Alk	Hsp90	HSP90AB2	3327.2	AUY922	AUY922	10096043	N/A	NCT01752400	Exclusion criteria: Prior anti-neoplastic treatment with any HSP90 or HDAC inhibitor compound.	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	Bevacizumab	N/A	N/A	N/A	NCT01763671	N/A	inhibitor
Lung cancer	Alk	Hsp90	HSP90AA2	3326	AUY922	AUY922	10096043	N/A	NCT01772797	Exclusion criteria: prior treatment with a HSP90 inhibitor	inhibitor
Lung cancer	Alk	Alk	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01772797	Purpose: This study will assess the safety, tolerability, pharmacokinetics and preliminary evidence of anti-tumor activity of the combination of LDK378 and AUY922 in ALK-rearranged non-small cell lung cancer. %Inclusion criteria: tumor must carry an ALK rearrangement in 15% or more of tumor cells as measured by FISH.	inhibitor
Lung cancer	Alk	Alk	ALK	238	RO5424802	N/A	N/A	N/A	NCT01801111	Purpose: evaluate the safety and efficacy of RO5424802 in patients with non-small cell lung cancer who have ALK mutation	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	GS-5745	N/A	N/A	N/A	NCT01803282	N/A	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	GSE	N/A	N/A	N/A	NCT01820299	N/A	inhibitor
Lung cancer	Alk	N/A	N/A	N/A	Sunitinib	Sunitinib	5329102	N/A	NCT01829217	N/A	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT00770263	N/A	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01231594	Purpose: provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors. %Official title: Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.	inhibitor
Lung cancer	BRAF	tubulin	N/A	N/A	Crolibulin	Crolibulin	23649181	N/A	NCT01240590	Purpose: Crolibulin (EPC2407) is a microtubulin inhibitor.	inhibitor
Lung cancer	Akt1	PDGFRA	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	BRAF	Kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01336634	Purpose: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity. %Inclusion criteria: Presence of a V600E BRAF mutation in lung cancer tissue.	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01336634	Purpose: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity. %Inclusion criteria: Presence of a V600E BRAF mutation in lung cancer tissue.	inhibitor
Lung cancer	BRAF	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	BRAF	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	BRAF	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	BRAF	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	BRAF	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	BRAF	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	BRAF	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	BRAF	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	BRAF	MEK1/2	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	BRAF	MEK1/2	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	BRAF	PI3K	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CB	5291	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CG	5294	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CD	5293	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R1	5295	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R2	5296	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R3	8503	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R4	30849	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R5	23533	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R6	146850	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CB	5291	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CG	5294	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3CD	5293	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R1	5295	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R2	5296	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R3	8503	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R4	30849	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R5	23533	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	PI3K	PIK3R6	146850	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	Mek	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	CDX-1127	N/A	N/A	N/A	NCT01524978	N/A	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	CDX-1127	N/A	N/A	N/A	NCT01524978	N/A	inhibitor
Lung cancer	BRAF	mTor	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	BRAF	mTor	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01531361	Official title: Vemurafenib (BRAF Inhibitor). %Inclusion criteria: Patients with advanced or metastatic cancers and BRAF mutations 	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Lung cancer	BRAF	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	BRAF	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Lung cancer	BRAF	PI3K	PIK3CA	5290	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3CB	5291	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3CG	5294	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3CD	5293	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3R1	5295	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3R2	5296	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3R3	8503	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3R4	30849	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3R5	23533	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	PI3K	PIK3R6	146850	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	PLX4032	NCT01636622	Purpose: Vemurafenib is designed to block a protein (called mutated BRAF). %Inclusion criteria: Patient must have histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma harboring a BRAF mutation	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	SAR260301	N/A	N/A	N/A	NCT01673737	N/A	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01673737	Purpose: standard dosage of vemurafenib to patients with unresectable / metastatic v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutated melanoma. %Inclusion criteria: Unresectable / metastatic BRAF-mutated melanomas.	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01677741	Purpose: dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. %Official title: Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation. %Inclusion criteria: BRAF V600 mutation-positive tumor.	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	GSK2118436	NCT01713972	Purpose: Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Assigned intervention: BRAF inhibitor GSK2118436. %Inclusion criteria: Tumors must carry the BRAF mutation	inhibitor
Lung cancer	BRAF	HSP90	HSP90AA2	3328.4	Debio 0932	N/A	N/A	N/A	NCT01714037	Official title: HSP90 Inhibitor Debio 0932	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01738451	N/A	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01739764	Purpose: This open-label, multicenter, non-randomized study will provide continued access to vemurafenib for eligible patients with BRAF V600 mutation-positive malignancy. %Official title: A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies. %Inclusion criteria: BRAF V600 mutation-positive malignancy. 	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	SPI-1620	N/A	N/A	N/A	NCT01741155	N/A	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01765543	Purpose: in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Inclusion criteria: positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01767623	Purpose:  vemurafenib in patients with BRAF V600 mutation positive cancer. %Official title: Vemurafenib in BRAF V600 Mutation Positive Cancer Patients. %Inclusion criteria: confirmed BRAF V600 mutation	inhibitor
Lung cancer	BRAF	ERK1	MAPK3	5595	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Lung cancer	BRAF	ERK2	MAPK1	5594	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Lung cancer	BRAF	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Lung cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Lung cancer	DDR2	BRAF	BRAF	673	Dasatinib	Dasatinib	3062316	N/A	NCT01514864	Purpose: patients with malignancy harboring a Discoidin Domain Receptor 2 (DDR2) mutation or an inactivating B-RAF mutation will respond to Dasatinib. %Official title: Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation. %Inclusion criteria: Malignancy of other histology with DDR2 mutation or inactivating B-RAF mutation.	inhibitor
Lung cancer	DDR2	DDR2	DDR2	4921	Dasatinib	Dasatinib	3062316	N/A	NCT01514864	Purpose: patients with malignancy harboring a Discoidin Domain Receptor 2 (DDR2) mutation or an inactivating B-RAF mutation will respond to Dasatinib. %Official title: Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation. %Inclusion criteria: Malignancy of other histology with DDR2 mutation or inactivating B-RAF mutation.	inhibitor
Lung cancer	DDR2	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Lung cancer	DDR3	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	bortezomib	Bortezomib	387447	N/A	NCT00118144	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT00339586	Official title: EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene. %Exclusion criteria: Prior therapy with systemic anti-tumour therapy with HER1/EGFR inhibitors.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	Tarceva	NCT00452075	Secondary outcome measures: Correlation of EGFR expression rate and FISH potentially predictive for response.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	gefitinib	Gefitinib	123631	Iressa	NCT00497250	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	CETUXIMAB	N/A	N/A	N/A	NCT00561054	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	N/A	NCT00563784	Detailed description: Erlotinib is designed to block the activity of a protein called epidermal growth factor (EGFR). 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	gefitinib	Gefitinib	123631	N/A	NCT00616499	Detailed description: To assess the response rate to gefitinib treatment as preoperative induction therapy in patients with biopsy-proven stage IIIA (pN2) non-squamous non-small cell lung cancer accompanied by epidermal growth factor receptor (EGFR) mutations. %Criteria: EGFR mutations.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT00637910	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Panitumumab	N/A	N/A	N/A	NCT00658658	Exclusion criteria: Prior use of any monoclonal antibodies directly targeting the EGFr.	inhibitor
Lung cancer	EGFR	PARP2	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT00740805	Purpose: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib hydrochloride	erlotinib hydrochloride	176871	N/A	NCT00801385	Secondary objectives: To analyze biomarkers, including evaluation of EGFR expression, mutational analysis of EGFR and K-ras, and immunohistochemical analysis of EGFR downstream pathway.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	gefitinib	Gefitinib	123631	Iressa	NCT00809237	Purpose: gefitinib (Iressa , formerly known as ZD1839) and erlotinib (Tarceva , formerly known as OSI-774). Both are small molecule orally-bioavailable tyrosine kinase inhibitors (TKIs) of the EGFR TK domain.	inhibitor
Lung cancer	EGFR	Her2	ERBB2	2064	TGFBeta resistant HER2/EBV-CTLs	N/A	N/A	N/A	NCT00889954	Purpose: The antibody used in this study is called anti-HER2 (Human Epidermal Growth Factor Receptor 2). %Inclusion criteria: Diagnosis of advanced stage* or metastatic HER2-positive cancer.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	veliparib	Veliparib	11960529	N/A	NCT00892736	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT00940381	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Sirolimus	rapamycin	5284616	N/A	NCT00940381	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	cetuximab	N/A	N/A	N/A	NCT00946712	Purpose: To prospectively test EGFR FISH as a predictive marker for the selection of patients for treatment with cetuximab.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT00950365	Purpose:  Erlotinib may stop the growth of tumor cells, and even shrink the tumors in some patients, by blocking some of the enzymes such as epidermal growth factor receptor (EGFR) needed for cell growth and spread.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	BAY80-6946	 BAY80-6946	24989044	N/A	NCT00962611	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT00966472	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Rosuvastatin	Rosuvastatin calcium	5282455	N/A	NCT00966472	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	erlotinib	erlotinib hydrochloride	176871	N/A	NCT00973310	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	panitumumab	N/A	N/A	N/A	NCT00979212	Exclusion criteria: No prior therapy that specifically and directly targets the EGFR pathway.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Nimotuzumab	N/A	N/A	N/A	NCT00983047	Purpose: Nimotuzumab is a humanized monoclonal anti-body targeting the epidermal growth factor receptor (EGFR). %Inclusion criteria: EGFR expression is positive.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00984425	Purpose:  Lapatinib is an oral selective and reversible inhibitor of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER-2). 	inhibitor
Lung cancer	EGFR	Her2	ERBB2	2064	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00984425	Purpose:  Lapatinib is an oral selective and reversible inhibitor of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER-2). 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Nimotuzumab 	N/A	N/A	hR3	NCT00985998	Purpose: Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). %Detailed description: Nimotuzumab (hR3) is a humanized monoclonal antibody (mAb) that binds to the EGFR. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	BIBW 2992	BIBW 2992	10184653	Afatinib	NCT00993499	Official title: BIBW 2992 Plus Sirolimus in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01024413	Inclusion criteria: Gene analyses of tumor tissue confirmed exon21 EGFR mutation.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	gefitinib	Gefitinib	123631	N/A	NCT01024413	Inclusion criteria: Gene analyses of tumor tissue confirmed exon21 EGFR mutation.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01047059	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Pazopanib 	pazopanib	10113978	GW786034	NCT01049776	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01061788	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01091376	Inclusion criteria: Tumor EGFR mutation. 	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	bevacizumab	N/A	N/A	N/A	NCT01107626	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	bevacizumab	N/A	N/A	N/A	NCT01116219	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01116219	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Sym004	N/A	N/A	N/A	NCT01117428	Inclusion criteria: Documented disease progression during or within 6 months after cessation of anti-EGFR Ab treatment.	inhibitor
Lung cancer	EGFR	histone deacetylase	N/A	N/A	Vorinostat	Vorinostat	5311	N/A	NCT01118975	Exclusion criteria: Prior exposure to lapatinib, vorinostat, or other Histone deacetylase (HDAC) inhibitors	inhibitor
Lung cancer	EGFR	Her	EGFR	1956	PF- 00299804	Dacomitinib	11511120	N/A	NCT01121575	Official title: PAN-HER Inhibitor (PF- 00299804).	inhibitor
Lung cancer	EGFR	Her	ERBB2	2064	PF- 00299804	Dacomitinib	11511121	N/A	NCT01121575	Official title: PAN-HER Inhibitor (PF- 00299804).	inhibitor
Lung cancer	EGFR	Her	ERBB3	2065	PF- 00299804	Dacomitinib	11511122	N/A	NCT01121575	Official title: PAN-HER Inhibitor (PF- 00299804).	inhibitor
Lung cancer	EGFR	Her	ERBB4	2066	PF- 00299804	Dacomitinib	11511123	N/A	NCT01121575	Official title: PAN-HER Inhibitor (PF- 00299804).	inhibitor
Lung cancer	EGFR	ALK	ALK	238	PF- 02341066	Crizotinib	11626560	N/A	NCT01121575	Official title: C- MET/ALK Inhibitor (PF- 02341066). 	inhibitor
Lung cancer	EGFR	c-MET	MET	4235	PF- 02341066	Crizotinib	11626560	N/A	NCT01121575	Official title: C- MET/ALK Inhibitor (PF- 02341066). 	inhibitor
Lung cancer	EGFR	c-MET	MET	4235	PF- 02341066	Crizotinib	11626560	N/A	NCT01121575	Official title: C- MET/ALK Inhibitor (PF- 02341066). 	inhibitor
Lung cancer	EGFR	Akt	Akt1	207	Hocena	N/A	N/A	Antroquinonol	NCT01134016	Detailed description: The pharmacological effects of antroquinonol were postulated to exert its antitumorigenesis effects through interactions to primary targets of epidermal growth factor receptor (EGFR)/Akt/mitogen-activated protein kinase (MAPK).	inhibitor
Lung cancer	EGFR	Akt	Akt2	208	Hocena	N/A	N/A	Antroquinonol	NCT01134016	Detailed description: The pharmacological effects of antroquinonol were postulated to exert its antitumorigenesis effects through interactions to primary targets of epidermal growth factor receptor (EGFR)/Akt/mitogen-activated protein kinase (MAPK).	inhibitor
Lung cancer	EGFR	Akt	Akt3	10000	Hocena	N/A	N/A	Antroquinonol	NCT01134016	Detailed description: The pharmacological effects of antroquinonol were postulated to exert its antitumorigenesis effects through interactions to primary targets of epidermal growth factor receptor (EGFR)/Akt/mitogen-activated protein kinase (MAPK).	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	BIBW2992	BIBW 2992	10184653	N/A	NCT01156545	Purpose: BIBW2992, an irreversible EGFR-TKI	inhibitor
Lung cancer	EGFR	Ras	KRAS	3845	Simvastin	Simvastin	54454	N/A	NCT01156545	Detailed description: statins inhibit activation of RAS and downstream signaling cascades, including the RAF/MEK/ERK and PI3K/AKT	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01158170	Detailed description:  EGFR-TKI(Erlotinib or Gefitinib)	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	gefitinib	Gefitinib	123631	N/A	NCT01158170	Detailed description:  EGFR-TKI(Erlotinib or Gefitinib)	inhibitor
Lung cancer	EGFR	CTLA-4	N/A	N/A	Lenalidomide	N/A	N/A	N/A	NCT01166035	Detailed description: IMiDs are able to mitigate the negative effects of CTLA-4 signalling.	inhibitor
Lung cancer	EGFR	VEGF	VEGFA	7422	Bevacizumab	N/A	N/A	N/A	NCT01171170	Detailed description: Bevacizumab interacts with this pathway by blocking VEGF. 	inhibitor
Lung cancer	EGFR	VEGF	VEGFB	7423	Bevacizumab	N/A	N/A	N/A	NCT01171170	Detailed description: Bevacizumab interacts with this pathway by blocking VEGF. 	inhibitor
Lung cancer	EGFR	VEGF	VEGFC	7424	Bevacizumab	N/A	N/A	N/A	NCT01171170	Detailed description: Bevacizumab interacts with this pathway by blocking VEGF. 	inhibitor
Lung cancer	EGFR	HIF1-a	HIF1A	3091	Nitroglycerin	Nitroglycerin	4510	N/A	NCT01171170	Detailed description: Nitroglycerin (NTG) is a NO donating drug. NTG increases tumor blood flow and thereby augments antitumor drug delivery to the tumor and inhibits HIF-1_.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	erlotinib	erlotinib hydrochloride	176871	Tarceva	NCT01174563	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	OPB-51602	N/A	N/A	N/A	NCT01184807	N/A	inhibitor
Lung cancer	EGFR	VEGF	VEGFA	7422	Endostatins	Endostatin (84-114)-NH2 (JKC367)	71581480	N/A	NCT01192230	Exclusion criteria: Patients who have previously received Docetaxel or anti-VEGF inhibitors.	inhibitor
Lung cancer	EGFR	VEGF	VEGFB	7423	Endostatins	Endostatin (84-114)-NH2 (JKC367)	71581480	N/A	NCT01192230	Exclusion criteria: Patients who have previously received Docetaxel or anti-VEGF inhibitors.	inhibitor
Lung cancer	EGFR	VEGF	VEGFC	7424	Endostatins	Endostatin (84-114)-NH2 (JKC367)	71581480	N/A	NCT01192230	Exclusion criteria: Patients who have previously received Docetaxel or anti-VEGF inhibitors.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	RO4929097. 	RO4929097	49867930	N/A	NCT01193868	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01204307	Detailed description: Erlotinib, an orally-available epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI).	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01217619	Purpose: erlotinib as neoadjuvent treatment in patients with EBUS confirmed stage _A N2 NSCLC with activating EGFR mutation. %Official title:  Erlotinib as Neoadjuvent Treatment in Patients With Endobronchial Ultrasound Confirmed Stage _A N2 NSCLC With EGFR Mutation. %Detailed description: patients with EGFR mutation in exon 19 or 21 will be enrolled in this study. %Inclusion criteria: The biopsy specimen shows EGFR mutation in exon 19 or 21 by DNA sequencing.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01218529	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01233687	Inclusion criteria: Prior erlotinib, other epidermal growth factor receptor (EGFR) TKIs or monoclonal antibodies targeting EGFR are not allowed. %Exclusion criteria: Prior treatment of NSCLC with EGFR TKIs or monoclonal antibodies targeting EGFR.	inhibitor
Lung cancer	EGFR	tubulin	N/A	N/A	Crolibulin	Crolibulin	23649181	N/A	NCT01240590	Purpose: Crolibulin (EPC2407) is a microtubulin inhibitor.	inhibitor
Lung cancer	EGFR	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	EGFR	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	EGFR	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	EGFR	MEK1/2	MAP2k1	5604	AZD6244	Selumetinib	10127622	N/A	NCT01248247	Exclusion criteria: from the MEK inhibitor arm if they have received prior MEK inhibitor therapy.	inhibitor
Lung cancer	EGFR	MEK1/2	MAP2k2	5605	AZD6244	Selumetinib	10127622	N/A	NCT01248247	Exclusion criteria: from the MEK inhibitor arm if they have received prior MEK inhibitor therapy.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01248247	Exclusion criteria: Subjects are excluded from the erlotinib monotherapy arm if they have progressed on prior EGFR TKI therapy.	inhibitor
Lung cancer	EGFR	Akt	Akt1	207	Mk2206	MK2206	46930998	N/A	NCT01248247	Exclusion criteria: from the AKT inhibitor arm(s) if they have received prior AKT inhibitor therapy.	inhibitor
Lung cancer	EGFR	Akt	Akt2	208	Mk2206	MK2206	46930998	N/A	NCT01248247	Exclusion criteria: from the AKT inhibitor arm(s) if they have received prior AKT inhibitor therapy.	inhibitor
Lung cancer	EGFR	Akt	Akt3	10000	Mk2206	MK2206	46930998	N/A	NCT01248247	Exclusion criteria: from the AKT inhibitor arm(s) if they have received prior AKT inhibitor therapy.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Sativex	tetrahydrocannabinol-cannabidiol combination	44148067	N/A	NCT01262651	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Sativex	tetrahydrocannabinol-cannabidiol combination	44148067	N/A	NCT01262651	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Sativex	tetrahydrocannabinol-cannabidiol combination	44148067	N/A	NCT01262651	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Pazopanib	pazopanib	10113978	N/A	NCT01262820	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01263782	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	cilengitide	cilengitide	176873	N/A	NCT01276496	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	LY2875358	N/A	N/A	N/A	NCT01287546	N/A	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90AA1	3320	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90B1	7184	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Lung cancer	EGFR	Her2	ERBB2	2064	MM-111	N/A	N/A	N/A	NCT01304784	Official title: MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors.	inhibitor
Lung cancer	Akt1	PDGFRA	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	EGFR	Kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	gefitinib	Gefitinib	123631	Iressa	NCT01312337	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01320501	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	Tarceva	NCT01328951	Purpose: evaluate the benefit of first-line maintenance Tarceva (erlotinib) versus Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following 4 cycles of platinum based-chemotherapy and whose tumour does not harbor an EGFR activating mutation.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Pemetrexed	Pemetrexed	446556	N/A	NCT01344824	N/A	inhibitor
Lung cancer	EGFR	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	EGFR	MEK1/2	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	EGFR	MEK1/2	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	LY2157299	LY-2157299	10090485	N/A	NCT01373164	N/A	inhibitor
Lung cancer	EGFR	IL2	IL2	3558	TG4010	N/A	N/A	N/A	NCT01383148	Purpose: TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	Iressa	NCT01391260	Purpose: access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations. %Official title: Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Nimotuzumab	N/A	N/A	N/A	NCT01393080	Purpose: Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). %Inclusion criteria: EGFR mRNA from peripheral bloods is positive.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01401192	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01405079	Purpose: studying gefitinib to see how well it works compared to cisplatin-based chemotherapy in treating patients who have undergone surgery for stage II-IIIA(N1-N2) NSCLC with EGFR activating mutation. %Official title: Gefitinib Versus Combination of Vinorelbine Plus Platinum as Adjuvant Treatment in Pathological Stage II-IIIA(N1-N2) Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutation. %Inclusion criteria: EGFR exon 19 deletions and exon 21 L858R activating mutation.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01407822	Purpose: EGFR tyrosine kinase inhibitor (TKI) may provide a dramatic response in pts with pulmonary adenocarcinoma carrying EGFR activating mutations. %Official title: Erlotinib Versus Combination of Gemcitabine Plus Cisplatin as (Neo)Adjuvant Treatment in Stage IIIA-N2 Non-small-cell Lung Cancer With Sensitizing EGFR Mutation. %Detailed description: Tarceva may provide an important treatment alternative for local advanced pts with EGFR mutation. %Inclusion criteria: EGFR activating mutation. %Exclusion criteria: EGFR mutation (exon 19 or 21) negative or unknown.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01410214	Official title: Erlotinib Versus Combination of Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage IIIA Non-small-cell Lung Cancer After Complete Resection With Sensitizing EGFR Mutation. %Purpose: erlotinib versus NVB plus cisplatin (NP) as adjuvant treatment in patients with stage IIIA NSCLC after complete resection with EGFR activating mutations. %Inlcusion criteria: EGFR activating mutation.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	BIBW 2992	BIBW 2992	10184653	N/A	NCT01415011	Purpose: BIBW 2992 to treat patients with non-small cell lung cancer and suspected Epidermal Growth Factor Receptor (EGFR) mutation. %Detailed description: irreversible EGFR inhibitor drug BIBW 2992. %Exclusion criteria: Previous treatment with BIBW 2992, or any EGFR-directed inhibitor.	inhibitor
Lung cancer	EGFR	Alk	ALK	238	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. %Inclusion criteria: No prior ALK inhibitor therapy. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. 	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Nivolumab	N/A	N/A	N/A	NCT01454102	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	Tarceva	NCT01456325	Purpose: Results of EGFR-activating mutation testing.	inhibitor
Lung cancer	EGFR	Met	MET	4233	onartuzumab	N/A	N/A	MetMAb	NCT01456325	Purpose: identified to be Met diagnostic-positive.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01465243	Detailed description: Icotinib is a novel EGFR-TKI. %Exclusion criteria: Previous usage of EGFR-TKI or antibody to EGFR.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Dacomitinib	Dacomitinib	11511120	PF-00299804	NCT01465802	Purpose: To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation. %Exclusion criteria: rior treatment with an EGFR-targeted or HER-targeted agent.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01470716	Purpose: Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations. %Official title: Erlotinib for Operable Stage IIB or IIIA Non-small Cell Lunc Cancer With Epidermal Growth Factor Receptor Activation Mutations. %Detailed description: Erlotinib is an orally administered tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR).	inhibitor
Lung cancer	EGFR	cMet	MET	4233	ABT-700	N/A	N/A	N/A	NCT01472016	Purpose: ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody. 	inhibitor
Lung cancer	EGFR	Her3	ERBB3	2065	RO5479599	N/A	N/A	N/A	NCT01482377	Purpose: RO5479599, alone or in combination with cetuximab or Erlotinib, in patients with metastatic and/or locally advanced malignant HER3-positive solid tumors. %Official title: RO5479599, a Glycoengineered Antibody Against HER3.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	Iressa	NCT01485809	Purpose: Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). %Inclusion criteria: an activating sensitizing EGFR mutation.	inhibitor
Lung cancer	EGFR	HER1	EGFR	1956	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01497626	Purpose: Lapatinib is a drug that targets two proteins important for the growth of cancer cells known as HER1 (EGFR) and HER2. 	inhibitor
Lung cancer	EGFR	Her2	ERBB2	2064	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01497626	Purpose: Lapatinib is a drug that targets two proteins important for the growth of cancer cells known as HER1 (EGFR) and HER2. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01498562	Official title: Gefitinib Plus Nimotuzumab Versus Gefitinib in Patients With Advanced Non-small Cell Lung Cancer: Dual-agent Molecular Targeting of EGFR. %Detailed description: Reversible EGFR tyrosine kinase inhibitors (TKI), such as gefitinib.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Nimotuzumab	N/A	N/A	N/A	NCT01498562	Official title: Gefitinib Plus Nimotuzumab Versus Gefitinib in Patients With Advanced Non-small Cell Lung Cancer: Dual-agent Molecular Targeting of EGFR. %Detailed description: Nimotuzumab is a humanized monoclonal antibody targeting the EGFR.	inhibitor
Lung cancer	EGFR	Her	EGFR	1956	gefitinib	Gefitinib	123631	Iressa	NCT01502202	Exclusion criteria: Patients with prior exposure to agents directed at the HER	inhibitor
Lung cancer	EGFR	Her	ERBB2	2064	gefitinib	Gefitinib	123631	Iressa	NCT01502202	Exclusion criteria: Patients with prior exposure to agents directed at the HER	inhibitor
Lung cancer	EGFR	Her	ERBB3	2065	gefitinib	Gefitinib	123631	Iressa	NCT01502202	Exclusion criteria: Patients with prior exposure to agents directed at the HER	inhibitor
Lung cancer	EGFR	Her	ERBB4	2066	gefitinib	Gefitinib	123631	Iressa	NCT01502202	Exclusion criteria: Patients with prior exposure to agents directed at the HER	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01510990	Purpose: gefitinib treatment for NSCLC, the investigators need epidermal growth factor receptor (EGFR) mutational status of the tumor. %Detailed description: Gefitinib has anti-tumor activity as a result of EGFR tyrosine kinase inhibition. %Inclusion criteria: Patients with tissue for the detection of EGFR mutation.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01513174	Purpose: gefitinib in combination with olaparib (AZD2281) versus gefitinib alone, in patients with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced non-small-cell lung cancer.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	olaparib 	AZD 2281	23725625	AZD2281	NCT01513174	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01514877	Purpose: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC. %Inclusion criteria: patients with EGFR mutation.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	icotinib	Icotinib	22024915	N/A	NCT01516983	Purpose: Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation. %Inclusion criteria: Positive EGFR mutation.	inhibitor
Lung cancer	EGFR	Met	MET	4233	onartuzumab	N/A	N/A	N/A	NCT01519804	Purpose: Adequate tissue for central IHC assay of Met receptor	inhibitor
Lung cancer	EGFR	Her2	ERBB2	2064	AVX901	N/A	N/A	N/A	NCT01526473	Purpose: has been changed so it tells the immune system to attack cancer cells which make HER2. %Detailed description: When VRP are used for immunization, the VRP infect individual cells and the replicon expresses HER2 which then induces an immune response. %Inclusion criteria: subgroups of patients with HER2 overexpression	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	CO-1686	N/A	N/A	N/A	NCT01526928	Purpose: Study of Oral CO-1686 in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC). %Detailed description: CO-1686 inhibits T790M. Evaluation of the recommended phase 2 dose in patients with the T790M EGFR mutation. %Inclusion criteria: Documented evidence of any activating mutation in the EGFR.	inhibitor
Lung cancer	EGFR	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	EGFR	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	Iressa	NCT01530334	Purpose: Gefitinib 250 mg (IRESSA) as 3rd Line Treatment Re-challenge in Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation. %Inclusion criteria: Histologically or cytologically confirmed NSCLC with an activating sensitising EGFR TK mutation. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01532011	Inclusion criteria: patients will be eligible if they meet one of the following criteria: I. Have an EGFR-sensitive mutation (as G719C in exon 18, E746-A750 in exon 90, L858R in exon 21) and have been previously treated with EGFR inhibitor therapy but have subsequently developed resistance, OR II. Have an EGFR-resistant mutation (as T790M in exon 20), OR III. Do not have an EGFR mutation, but have benefited from EGFR inhibitor therapy.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Bevacizumab	N/A	N/A	N/A	NCT01532089	Purpose: erlotinib (Tarceva) with or without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. %Detailed description: To prospectively evaluate the predictive value of plasma vascular endothelial growth factor A (VEGF-A) levels on progression free survival in patients treated with erlotinib alone or in combination with bevacizumab. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01532089	Purpose: erlotinib (Tarceva) with or without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. %Detailed description: To prospectively evaluate the predictive value of plasma vascular endothelial growth factor A (VEGF-A) levels on progression free survival in patients treated with erlotinib alone or in combination with bevacizumab. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	BIBW 2992	BIBW 2992	10184653	N/A	NCT01542437	Purpose: BIBW 2992, an irreversible inhibitor of receptor Epidermal growth factor type 1/2 (EGFR/HER2). %Official title: BIBW 2992, Irreversible Inhibitor of EGFR and HER-2. %Exclusion criteria: Pre-treatment with systemic anti-tumor therapy with EGFR inhibitors	inhibitor
Lung cancer	EGFR	Her2	ERBB2	2064	BIBW 2992	BIBW 2992	10184653	N/A	NCT01542437	Purpose: BIBW 2992, an irreversible inhibitor of receptor Epidermal growth factor type 1/2 (EGFR/HER2). %Official title: BIBW 2992, Irreversible Inhibitor of EGFR and HER-2. %Exclusion criteria: Pre-treatment with systemic anti-tumor therapy with EGFR inhibitors	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01544179	Purpose: Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR). %Inclusion criteria: Cytological or histological confirmation of NSCLC other than predominantly squamous cell histology with an activating EGFR TK mutation as determined locally.	inhibitor
Lung cancer	EGFR	mTOR1	mTOR	2475	cc-223	N/A	N/A	N/A	NCT01545947	Purpose: dual mTOR inhibitor, CC-223.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Cetuximab	N/A	N/A	N/A	NCT01552434	Purpose: Cetuximab is designed to block a certain protein, called EGFR.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Afatinib	Afatinib	10184653	N/A	NCT01553942	Purpose: Afatinib is a tyrosine kinase inhibitor. It has been studied in a previous research study in participants with more advanced NSCLC. Results from that study indicate it may be helpful in treating NSCLC with EGFR mutations. %Inclusion criteria: Have lung cancer harboring an EGFR mutation. %Exclusion criteria: Prior EGFR TKI therapy	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Fulvestrant	Fulvestrant	104741	N/A	NCT01556191	Purpose: anti-estrogen (fulvestrant)	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Bevacizumab	N/A	N/A	N/A	NCT01562028	Official title: Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations. %Inclusion criteria: Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01562028	Official title: Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations. %Inclusion criteria: Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)	inhibitor
Lung cancer	EGFR	PARP	PARP1	142	Olaparib	AZD 2281	23725625	N/A	NCT01562210	Detailed description: PARP inhibitors increase radiation and chemotherapy (Cisplatin) response in preclinical studies including lung cancer models. 	inhibitor
Lung cancer	EGFR	PARP	PARP2	10038	Olaparib	AZD 2281	23725625	N/A	NCT01562210	Detailed description: PARP inhibitors increase radiation and chemotherapy (Cisplatin) response in preclinical studies including lung cancer models. 	inhibitor
Lung cancer	EGFR	Akt	Akt1	207	GDC-0068	GDC-0068	24788740	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another PI3K or Akt pathway or mTOR inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	Akt	Akt2	208	GDC-0068	GDC-0068	24788740	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another PI3K or Akt pathway or mTOR inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	Akt	Akt3	10000	GDC-0068	GDC-0068	24788740	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another PI3K or Akt pathway or mTOR inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	MEK	MAP2k1	5604	GDC-0973	GDC-0973	16222096	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	MEK	MAP2k2	5605	GDC-0973	GDC-0973	16222096	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	MEK	MAP2K3	5606	GDC-0973	GDC-0973	16222096	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	MEK	MAP2K4	6416	GDC-0973	GDC-0973	16222096	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	MEK	MAP2K5	5607	GDC-0973	GDC-0973	16222096	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	MEK	MAP2k6	5608	GDC-0973	GDC-0973	16222096	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	MEK	MAP2k7	5609	GDC-0973	GDC-0973	16222096	N/A	NCT01562275	Exclusion criteria: History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01570296	Purpose: Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa). %Inclusion criteria: Patients with histologically or cytologically proven NSCLC who meet the clinical definition of EGFR TKI resistance, and are progressing on existing treatment or have previously progressed on EGFR TKI	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01573702	Official title: Erlotinib for Patients With Epidermal Growth Factor Receptor(EGFR) Mutation. %Inclusion criteria: Histologically or cytologically confirmed stge IV EGFR-mutant NSCLC.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Pemetrexed	Pemetrexed	446556	N/A	NCT01579630	N/A	inhibitor
Lung cancer	EGFR	MEK	MAP2k1	5604	Selumetinib 	Selumetinib	10127622	AZD6244	NCT01586624	Official title: Oral MEK Inhibitor, Selumetinib. %Detailed description: selumetinib a MEK (Mitogen Activated Kinase)inhibitor.	inhibitor
Lung cancer	EGFR	MEK	MAP2k2	5605	Selumetinib 	Selumetinib	10127622	AZD6244	NCT01586624	Official title: Oral MEK Inhibitor, Selumetinib. %Detailed description: selumetinib a MEK (Mitogen Activated Kinase)inhibitor.	inhibitor
Lung cancer	EGFR	MEK	MAP2K3	5606	Selumetinib 	Selumetinib	10127622	AZD6244	NCT01586624	Official title: Oral MEK Inhibitor, Selumetinib. %Detailed description: selumetinib a MEK (Mitogen Activated Kinase)inhibitor.	inhibitor
Lung cancer	EGFR	MEK	MAP2K4	6416	Selumetinib 	Selumetinib	10127622	AZD6244	NCT01586624	Official title: Oral MEK Inhibitor, Selumetinib. %Detailed description: selumetinib a MEK (Mitogen Activated Kinase)inhibitor.	inhibitor
Lung cancer	EGFR	MEK	MAP2K5	5607	Selumetinib 	Selumetinib	10127622	AZD6244	NCT01586624	Official title: Oral MEK Inhibitor, Selumetinib. %Detailed description: selumetinib a MEK (Mitogen Activated Kinase)inhibitor.	inhibitor
Lung cancer	EGFR	MEK	MAP2k6	5608	Selumetinib 	Selumetinib	10127622	AZD6244	NCT01586624	Official title: Oral MEK Inhibitor, Selumetinib. %Detailed description: selumetinib a MEK (Mitogen Activated Kinase)inhibitor.	inhibitor
Lung cancer	EGFR	MEK	MAP2k7	5609	Selumetinib 	Selumetinib	10127622	AZD6244	NCT01586624	Official title: Oral MEK Inhibitor, Selumetinib. %Detailed description: selumetinib a MEK (Mitogen Activated Kinase)inhibitor.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Vandetanib 	Vandetanib	3081361	ZD6474	NCT01586624	Official title: VEGFR and EGFR Inhibitor, Vandetanib	inhibitor
Lung cancer	EGFR	VEGFR	FLT1	2321	Vandetanib 	Vandetanib	3081361	ZD6474	NCT01586624	Official title: VEGFR and EGFR Inhibitor, Vandetanib. %Detailed description: vandetanib, a VEGFR (Vascular Endothelial Growth Factor Receptor) and EGFR (Epidermal Growth Factor Receptor) inhibitor.	inhibitor
Lung cancer	EGFR	VEGFR	KDR	3791	Vandetanib 	Vandetanib	3081361	ZD6474	NCT01586624	Official title: VEGFR and EGFR Inhibitor, Vandetanib. %Detailed description: vandetanib, a VEGFR (Vascular Endothelial Growth Factor Receptor) and EGFR (Epidermal Growth Factor Receptor) inhibitor.	inhibitor
Lung cancer	EGFR	VEGFR	FLT4	2324	Vandetanib 	Vandetanib	3081361	ZD6474	NCT01586624	Official title: VEGFR and EGFR Inhibitor, Vandetanib. %Detailed description: vandetanib, a VEGFR (Vascular Endothelial Growth Factor Receptor) and EGFR (Epidermal Growth Factor Receptor) inhibitor.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	HM61713	N/A	N/A	N/A	NCT01588145	Official title: HM61713 Tablet in NSCLC Patients With EGFR Mutation. %Inclusion criteria: Patients with EGFR mutation-positive tumor. 	inhibitor
Lung cancer	EGFR	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	EGFR	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	EGFR	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Lung cancer	EGFR	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Lung cancer	EGFR	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	EGFR	Met	MET	4233	LY2875358	N/A	N/A	N/A	NCT01602289	Exclusion criteria: Previous treatment with any extracellular domain of mesenchymal-epithelial transition factor (c-MET) targeting experimental therapeutic.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01609543	Purpose: Tarceva (erlotinib) as single-agent first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer who show epidermal growth factor receptor (EGFR) activating mutations. %Official title: Erlotinib (Tarceva) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations. %Inclusion criteria: EGFR activating mutation.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01610336	Official title: INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer. %Inclusion criteria: Documented EGFR  amplification.	inhibitor
Lung cancer	EGFR	Met	MET	4233	INC280	N/A	N/A	N/A	NCT01610336	Purpose: INC280 when added to gefitinib in patients with lung cancer that are known to have dysregulation of the c-MET pathway. %Official title: INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer. %Inclusion criteria: Documented c-MET amplification.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Bevacizumab	N/A	N/A	N/A	NCT01623102	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Nivestim	N/A	N/A	N/A	NCT01627990	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Decitabine	Decitabine	451668	N/A	NCT01628471	N/A	inhibitor
Lung cancer	EGFR	PD-1	PDCD1	5133	BMS-936558	N/A	N/A	N/A	NCT01629758	Official title: BMS-936558 (Anti-PD-1)	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01630733	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Cisplatin	N/A	N/A	N/A	NCT01631136	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01646125	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01646450	Purpose: icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and IV) NSCLC and mutated EGFR. %Official title: Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation. %Inclusion criteria: Positive EGFR Mutation.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Afatinib	Afatinib	10184653	N/A	NCT01647711	Official title: Irreversible EGFR Inhibitor Afatinib. %Inclusion criteria: Documented Epidermal Growth Factor Receptor (EGFR) T790M mutation. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01652469	Purpose: EGFR-TK inhibitor (erlotinib). 	inhibitor
Lung cancer	EGFR	ISG15	ISG15	9636	Irinotecan	Irinotecan	60838	N/A	NCT01654081	Purpose: clinical benefit of irinotecan chemotherapy in patients with a specific NSCLC phenotype, ISG15-positive. %Inclusion criteria: All participants must have the appropriate phenotype on pretreatment screening of tumor tissue or sputa, consisting of ISG15-positive cells by immunohistochemistry.	inhibitor
Lung cancer	EGFR	Met	MET	4233	SAR125844	N/A	N/A	N/A	NCT01657214	Purpose: To explore the relationship of MET gene amplification status with anti-tumor effects. %Inclusion criteria: At the recommended dose (expansion cohort): only patients with measurable disease and MET gene amplification.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Veliparib	Veliparib	11960529	N/A	NCT01657799	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01661972	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01665417	Inclusion criteria: Patients must have lung cancer with a documented EGFR activating mutation. %Official title: Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	erlotinib	erlotinib hydrochloride	176871	Tarceva	NCT01667562	Purpose: Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). %Official title: Erlotinib (Tarceva) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor. %Inclusion criteria: mutations in the tyrosine kinase domain of the epidermal growth factor receptor. %Exclusion criteria: Previous chemotherapy or treatment against EGFR for metastatic disease.	inhibitor
Lung cancer	EGFR	elF4e	ELF4	2000	ISIS 183750	N/A	N/A	N/A	NCT01675128	Detailed description: ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the human eukaryotic translation initiation factor 4E (eIF4E) protein. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01683175	Purpose:  patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib. %Exclusion criteria: Having treated by Her-Target therapy.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01688713	Purpose: Icotinib is one agent of EGFR-TKIs. %Inclusion criteria: Patients with EGFR mutation. 	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01702844	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Ramucirumab	N/A	N/A	N/A	NCT01703091	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Bevacizumab	N/A	N/A	N/A	NCT01705184	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Cisplatin	N/A	N/A	N/A	NCT01705184	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Pemetrexed	Pemetrexed	446556	N/A	NCT01705184	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	ASP9853	N/A	N/A	N/A	NCT01705483	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01708954	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Reolysin	N/A	N/A	N/A	NCT01708993	N/A	inhibitor
Lung cancer	EGFR	HSP90	HSP90AA2	3328.4	Debio 0932	N/A	N/A	N/A	NCT01714037	Official title: HSP90 Inhibitor Debio 0932	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01719536	Purpose: icotinib with induction and maintenance chemotherapy in the first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation. %Inclusion criteria: Positive EGFR Mutation.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	MUC1	N/A	N/A	N/A	NCT01720836	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	ASLAN002	N/A	N/A	BMS 777607	NCT01721148	N/A	inhibitor
Lung cancer	EGFR	PI3k	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	PI3k	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	PI3k	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	PI3k	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	PI3k	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	PI3k	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	PI3k	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	PI3k	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	PI3k	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01724801	Official title: Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer. %Inclusion criteria: Patient who was confirmed stage IV NSCLC with EGFR activating mutation.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Afatinib	Afatinib	10184653	N/A	NCT01746251	Official title: Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation. %Inclusion criteria: Pathologically confirmed diagnosis of non-small cell lung cancer with EGFR mutation.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Gefitinib	Gefitinib	123631	Iressa	NCT01746277	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01749072	N/A	inhibitor
Lung cancer	EGFR	CTLA4	CTLA-4	1493	Ipilimumab	N/A	N/A	N/A	NCT01750580	Official title: Ipilimumab, an Anti-CTLA4 Monoclonal Antibody.	inhibitor
Lung cancer	EGFR	Kir	N/A	N/A	Lirilumab	N/A	N/A	BMS-986015	NCT01750580	Official title: BMS-986015, an Anti-KIR Monoclonal Antibody.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01755923	Purpose: EGFR mutations predicted benefit form gefitinib treatment. 	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01763385	Inclusion criteria: Patients in initial treatment should be detected EGFR mutation;	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Simotinib Hydrochloride	N/A	N/A	N/A	NCT01772732	Exclusion criteria: Patients who were previously treated by EGFR inhibitor.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Dacomitinib	Dacomitinib	11511120	PF-00299804	NCT01774721	Purpose: Dacomitinib (PF-00299804) to treatment with gefitinib in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal growth factor receptor (EGFR) activating mutation. %Official title: Dacomitinib (PF-00299804) Vs. Gefitinib For The First-Line Treatment Of Locally Advanced or Metastatic NSCLC In Subjects With EGFR Activating Mutations. %Inclusion criteria: presence of EGFR activating mutation. 	inhibitor
Lung cancer	EGFR	Notch1	Notch1	4851	OMP-52M51	N/A	N/A	N/A	NCT01778439	Exclusion criteria: Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors	inhibitor
Lung cancer	EGFR	kras	KRAS	3845	Selumetinib	Selumetinib	10127622	N/A	NCT01783197	Inclusion criteria: Patients planned for the pemetrexed single agent cohort, as well as those accrued to the RP2D expansion cohorts must have a documented KRAS mutation.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01784549	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Lung cancer	EGFR	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01796288	Inclusion criteria: Have never received other targeted drug treatments for EGFR inhibition.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01801111	repeat	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	AZD9291	N/A	N/A	N/A	NCT01802632	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	GS-5745	N/A	N/A	N/A	NCT01803282	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Poziotinib	Poziotinib	25127713	NOV120101	NCT01819428	Purpose:  to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib). %Inclusion criteria: Documented EGFR mutation.	inhibitor
Lung cancer	EGFR	Her2	ERBB2	2064	Poziotinib	Poziotinib	25127713	NOV120101	NCT01819428	Purpose:  to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib). 	inhibitor
Lung cancer	EGFR	Her3	ERBB3	2065	Poziotinib	Poziotinib	25127713	NOV120101	NCT01819428	Purpose:  to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib). 	inhibitor
Lung cancer	EGFR	Her4	ERBB4	2066	Poziotinib	Poziotinib	25127713	NOV120101	NCT01819428	Purpose:  to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib). 	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	GSE	N/A	N/A	N/A	NCT01820299	N/A	inhibitor
Lung cancer	EGFR	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01820325	Inclusion criteria: Patient has archival or fresh tumor tissue for the exploratory analysis of biomarkers related to sensitivity to PI3K inhibitors.	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	ruxolitinib	Ruxolitinib	25126798	N/A	NCT01822756	N/A	inhibitor
Lung cancer	EGFR	N/A	N/A	N/A	Sunitinib	Sunitinib	5329102	N/A	NCT01829217	N/A	inhibitor
Lung cancer	EGFR	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01833572	Purpose: EGFR-TKI, like gefitinib. %Inclusion criteria: Pathologically confirmed non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858 mutation. 	inhibitor
Lung cancer	FGFR1	N/A	N/A	N/A	bortezomib	Bortezomib	387447	N/A	NCT00118144	N/A	inhibitor
Lung cancer	FGFR1	N/A	N/A	N/A	dasatinib	Dasatinib	3062316	N/A	NCT00608361	N/A	inhibitor
Lung cancer	FGFR1	FGFR1	FGFR1	2260	AZD4547	AZD4547	51039095	N/A	NCT00979134	Inclusion criteria: Solid tumours,FGFR1 and/or FGFR2 gene amplified.	inhibitor
Lung cancer	FGFR1	FGFR2	FGFR2	2263	AZD4547	AZD4547	51039095	N/A	NCT00979134	Inclusion criteria: Solid tumours,FGFR1 and/or FGFR2 gene amplified.	inhibitor
Lung cancer	FGFR1	FGFR1	FGFR1	2260	BGJ398	BGJ398	53235510	N/A	NCT01004224	Official title: Oral BGJ398, a Pan FGF-R Kinase Inhibitor. %Inclusion criteria: Patients with histologically/cytologically confirmed advanced solid tumors with FGFR1 or FGFR2 amplification or FGFR3 mutation.	inhibitor
Lung cancer	FGFR1	FGFR2	FGFR2	2263	BGJ398	BGJ398	53235510	N/A	NCT01004224	Official title: Oral BGJ398, a Pan FGF-R Kinase Inhibitor. %Inclusion criteria: Patients with histologically/cytologically confirmed advanced solid tumors with FGFR1 or FGFR2 amplification or FGFR3 mutation.	inhibitor
Lung cancer	FGFR1	FGFR3	FGFR3	2261	BGJ398	BGJ398	53235510	N/A	NCT01004224	Official title: Oral BGJ398, a Pan FGF-R Kinase Inhibitor. %Inclusion criteria: Patients with histologically/cytologically confirmed advanced solid tumors with FGFR1 or FGFR2 amplification or FGFR3 mutation.	inhibitor
Lung cancer	FGFR1	FGFR1	FGFR1	2260	Lucitanib	1058137-23-7	25031915	E-3810	NCT01283945	Purpose: Lucitanib is a novel dual-targeted small molecule inhibitor of VEGFR1, 2, 3 and FGFR1. %Official title: Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810.	inhibitor
Lung cancer	FGFR1	VEGFR	FLT1	2321	Lucitanib	1058137-23-7	25031915	E-3810	NCT01283945	Purpose: Lucitanib is a novel dual-targeted small molecule inhibitor of VEGFR1, 2, 3 and FGFR1. %Official title: Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810.	inhibitor
Lung cancer	FGFR1	VEGFR	KDR	3791	Lucitanib	1058137-23-7	25031915	E-3810	NCT01283945	Purpose: Lucitanib is a novel dual-targeted small molecule inhibitor of VEGFR1, 2, 3 and FGFR1. %Official title: Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810.	inhibitor
Lung cancer	FGFR1	VEGFR	FLT4	2324	Lucitanib	1058137-23-7	25031915	E-3810	NCT01283945	Purpose: Lucitanib is a novel dual-targeted small molecule inhibitor of VEGFR1, 2, 3 and FGFR1. %Official title: Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810.	inhibitor
Lung cancer	FGFR1	B7-h3	N/A	N/A	MGA271	N/A	N/A	N/A	NCT01391143	Detailed description: study will be conducted to define the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics (PK), immunogenicity, and potential antitumor activity of MGA271 in patients with refractory cancer that expresses B7-H3.	inhibitor
Lung cancer	FGFR1	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	FGFR1	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	FGFR1	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Lung cancer	FGFR1	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Lung cancer	FGFR1	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	FGFR1	FGFR1	FGFR1	2260	JNJ-42756493	N/A	N/A	N/A	NCT01703481	Purpose: JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. %Official title: JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor.%Inclusion criteria: participants must have tumors that are K-ras wild-type and also express FGFR 1, 2, or 4 gene amplifications.	inhibitor
Lung cancer	FGFR1	FGFR2	FGFR2	2263	JNJ-42756493	N/A	N/A	N/A	NCT01703481	Purpose: JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. %Official title: JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor.%Inclusion criteria: participants must have tumors that are K-ras wild-type and also express FGFR 1, 2, or 4 gene amplifications.	inhibitor
Lung cancer	FGFR1	FGFR3	FGFR3	2261	JNJ-42756493	N/A	N/A	N/A	NCT01703481	Purpose: JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. %Official title: JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor.%Inclusion criteria: participants must have tumors that are K-ras wild-type and also express FGFR 1, 2, or 4 gene amplifications.	inhibitor
Lung cancer	FGFR1	FGFR4	FGFR4	2264	JNJ-42756493	N/A	N/A	N/A	NCT01703481	Purpose: JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. %Official title: JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor.%Inclusion criteria: participants must have tumors that are K-ras wild-type and also express FGFR 1, 2, or 4 gene amplifications.	inhibitor
Lung cancer	FGFR1	FGFR1	FGFR1	2260	AZD4547	AZD4547	51039095	N/A	NCT01795768	Purpose: FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2 amplified breast, squamous lung and stomach cancer. %Official title: AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours. %Inclusion criteria: confirmation of FGFR gene amplification.	inhibitor
Lung cancer	FGFR1	FGFR2	FGFR2	2263	AZD4547	AZD4547	51039095	N/A	NCT01795768	Purpose: FGFR inhibitor AZD4547 in patients with FGFR1 or FGFR2 amplified breast, squamous lung and stomach cancer. %Official title: AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours. %Inclusion criteria: confirmation of FGFR gene amplification.	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	bortezomib	Bortezomib	387447	N/A	NCT00118144	N/A	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00313599	N/A	inhibitor
Lung cancer	Her2	COX	N/A	N/A	celecoxib	Celecoxib	2662	N/A	NCT00520845	Detailed description: determine the efficacy of celecoxib when administered with standard chemotherapy comprising docetaxel or pemetrexed disodium in patients with advanced, recurrent non-small cell lung cancer (NSCLC) exhibiting cyclooxygenase (COX) dependence. %Eligibility criteria: Cytologically or histologically confirmed COX dependent non-small cell lung cancer.	inhibitor
Lung cancer	Her2	PARP2	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT00740805	Purpose: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	TGFBeta resistant HER2/EBV-CTLs	N/A	N/A	N/A	NCT00889954	Purpose: The antibody used in this study is called anti-HER2 (Human Epidermal Growth Factor Receptor 2). %Inclusion criteria: Diagnosis of advanced stage* or metastatic HER2-positive cancer.	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	veliparib	Veliparib	11960529	N/A	NCT00892736	N/A	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00984425	Purpose:  Lapatinib is an oral selective and reversible inhibitor of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER-2). 	inhibitor
Lung cancer	Her2	Hsp90	HSP90AB1	3326	AUY922A	N/A	N/A	N/A	NCT01024283	Official title: Administration of the Heat Shock Protein 90 Inhibitor AUY922A	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	Pazopanib 	pazopanib	10113978	GW786034	NCT01049776	N/A	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01087983	N/A	inhibitor
Lung cancer	Her2	histone deacetylase	N/A	N/A	Vorinostat	Vorinostat	5311	N/A	NCT01118975	Exclusion criteria: Prior exposure to lapatinib, vorinostat, or other Histone deacetylase (HDAC) inhibitors	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	F16IL2	N/A	N/A	N/A	NCT01134250	N/A	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	MGAH22	N/A	N/A	N/A	NCT01148849	Purpose:  to determine if MGAH22 is safe when given by intravenous (IV) infusion to patients with HER2-positive cancer. %Official title: Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas. %Detailed description: potential antitumor activity of MGAH22 in patients with refractory HER2 positive breast cancer and patients with other carcinomas that overexpress HER2. %Inclusion criteria: Histologically or cytologically confirmed carcinoma that overexpresses HER2.	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01165385	N/A	inhibitor
Lung cancer	Her2	gamma secretase	N/A	N/A	RO4929097	RO4929097	49867930	N/A	NCT01217411	Purpose: gamma-secretase/Notch signalling pathway inhibitor RO4929097. 	inhibitor
Lung cancer	Her2	PIK3CA	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01219699	Purpose: Advanced Solid Tumors With an Alteration of the PIK3CA Gene. 	inhibitor
Lung cancer	Her2	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Her2	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Her2	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	cilengitide	cilengitide	176873	N/A	NCT01276496	N/A	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	veliparib	Veliparib	11960529	N/A	NCT01281150	N/A	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	MM-111	N/A	N/A	N/A	NCT01304784	Official title: MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors.	inhibitor
Lung cancer	Akt1	PDGFRA	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	Her2	Kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	TRC105	N/A	N/A	N/A	NCT01326481	N/A	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	Endostar	N/A	N/A	N/A	NCT01327235	N/A	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	Endostar	N/A	N/A	N/A	NCT01328054	N/A	inhibitor
Lung cancer	Her2	Akt	Akt1	207	GDC-0068	GDC-0068	24788740	N/A	NCT01362374	N/A	inhibitor
Lung cancer	Her2	Akt	Akt2	208	GDC-0068	GDC-0068	24788740	N/A	NCT01362374	N/A	inhibitor
Lung cancer	Her2	Akt	Akt3	10000	GDC-0068	GDC-0068	24788740	N/A	NCT01362374	N/A	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	HER-2 vaccine	N/A	N/A	N/A	NCT01376505	Purpose: Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine. 	inhibitor
Lung cancer	Her2	IL2	IL2	3558	TG4010	N/A	N/A	N/A	NCT01383148	Purpose: TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). 	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	2B3-101	N/A	N/A	N/A	NCT01386580	Purpose: study will explore the preliminary antitumor activity of 2B3-101 as single agent in patients with with solid tumors and brain metastases or recurrent malignant glioma as well as in patients with various forms of breast cancer with and in combination with trastuzumab in HER2+ breast cancer patients with brain metastases. %Inclusion criteria: Patients with histologically-confirmed HER2-positive.	inhibitor
Lung cancer	Her2	c-Kit	KIT	3815	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	TrasGEX	N/A	N/A	N/A	NCT01409343	Purpose:  study evaluating the safety, tolerability and pharmacokinetics of TrasGEX after intravenous administration in patients with HER-2 positive cancers. %Official title: Study of TrasGEX in Patients With Locally Advanced or Metastatic HER-2-positive Cancer. %Criteria: ERBB2 (HER-2) gene amplification or ERBB2 overexpression. 	inhibitor
Lung cancer	Her2	PTEN	PTEN	5728	GSK2636771	1372540-25-4	56949517	N/A	NCT01458067	Inclusion criteria: Subjects must have tumors with a documented PTEN deficiency. 	inhibitor
Lung cancer	Her2	EGFR	EGFR	1956	Dacomitinib	Dacomitinib	11511120	PF-00299804	NCT01465802	Purpose: To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation. %Exclusion criteria: rior treatment with an EGFR-targeted or HER-targeted agent.	inhibitor
Lung cancer	Her2	EGFR	EGFR	1956	Dacomitinib	Dacomitinib	11511120	PF-00299804	NCT01465802	Purpose: To assess the impact of an interrupted dacomitinib dosing schedule in Cycle 1 on the incidence of adverse events in first-line advanced NSCLC patients with an EGFR mutation. %Exclusion criteria: rior treatment with an EGFR-targeted or HER-targeted agent.	inhibitor
Lung cancer	Her2	cMet	MET	4233	ABT-700	N/A	N/A	N/A	NCT01472016	Purpose: ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody. 	inhibitor
Lung cancer	Her2	HER1	EGFR	1956	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01497626	Purpose: Lapatinib is a drug that targets two proteins important for the growth of cancer cells known as HER1 (EGFR) and HER2. 	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT01497626	Purpose: Lapatinib is a drug that targets two proteins important for the growth of cancer cells known as HER1 (EGFR) and HER2. 	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	AVX901	N/A	N/A	N/A	NCT01526473	Purpose: has been changed so it tells the immune system to attack cancer cells which make HER2. %Detailed description: When VRP are used for immunization, the VRP infect individual cells and the replicon expresses HER2 which then induces an immune response. %Inclusion criteria: subgroups of patients with HER2 overexpression	inhibitor
Lung cancer	Her2	EGFR	EGFR	1956	CO-1686	N/A	N/A	N/A	NCT01526928	Purpose: Study of Oral CO-1686 in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC). %Detailed description: CO-1686 inhibits T790M. Evaluation of the recommended phase 2 dose in patients with the T790M EGFR mutation. %Inclusion criteria: Documented evidence of any activating mutation in the EGFR.	inhibitor
Lung cancer	Her2	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	Her2	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	Her2	EGFR	EGFR	1956	BIBW 2992	BIBW 2992	10184653	N/A	NCT01542437	Purpose: BIBW 2992, an irreversible inhibitor of receptor Epidermal growth factor type 1/2 (EGFR/HER2). %Official title: BIBW 2992, Irreversible Inhibitor of EGFR and HER-2. %Exclusion criteria: Pre-treatment with systemic anti-tumor therapy with EGFR inhibitors	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	BIBW 2992	BIBW 2992	10184653	N/A	NCT01542437	Purpose: BIBW 2992, an irreversible inhibitor of receptor Epidermal growth factor type 1/2 (EGFR/HER2). %Official title: BIBW 2992, Irreversible Inhibitor of EGFR and HER-2. %Exclusion criteria: Pre-treatment with systemic anti-tumor therapy with EGFR inhibitors	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	Fulvestrant	Fulvestrant	104741	N/A	NCT01556191	Purpose: anti-estrogen (fulvestrant)	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	Ertumaxomab	N/A	N/A	N/A	NCT01569412	Purpose: Patients with HER2/neu expressing solid tumors progressing after standard therapy will be treated with a so called trifunctional antibody (Ertumaxomab). %Official title: Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab. %Inclusion criteria: Solid HER2/neu positive tumors.	inhibitor
Lung cancer	Her2	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	Her2	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	Her2	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Lung cancer	Her2	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Lung cancer	Her2	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	afatinib	Afatinib	10184653	N/A	NCT01649271	Purpose: assess the efficacy of afatinib given at the MTD dosage, with 3-weekly trastuzumab in HER2 overexpressing metastatic breast cancer. %Official title: Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. %Inclusion criteria: Patients with cancers overexpressing HER2.	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	trastuzumab	N/A	N/A	N/A	NCT01649271	Purpose: assess the efficacy of afatinib given at the MTD dosage, with 3-weekly trastuzumab in HER2 overexpressing metastatic breast cancer. %Official title: Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. %Inclusion criteria: Patients with cancers overexpressing HER2.	inhibitor
Lung cancer	Her2	Met	MET	4233	SAR125844	N/A	N/A	N/A	NCT01657214	Purpose: To explore the relationship of MET gene amplification status with anti-tumor effects. %Inclusion criteria: At the recommended dose (expansion cohort): only patients with measurable disease and MET gene amplification.	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	Veliparib	Veliparib	11960529	N/A	NCT01657799	N/A	inhibitor
Lung cancer	Her2	CDK1	CDK1	983	Dinaciclib	dinaciclib	46926350	N/A	NCT01676753	Official title: Cyclin-dependent Kinase Inhibitor Dinaciclib. 	inhibitor
Lung cancer	Her2	CDK2	CDK2	1017	Dinaciclib	dinaciclib	46926350	N/A	NCT01676753	Official title: Cyclin-dependent Kinase Inhibitor Dinaciclib. 	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	ASP9853	N/A	N/A	N/A	NCT01705483	N/A	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01720836	repeat	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01721148	repeat	inhibitor
Lung cancer	EGFR	CTLA4	CTLA-4	1493	Ipilimumab	N/A	N/A	N/A	NCT01750580	Official title: Ipilimumab, an Anti-CTLA4 Monoclonal Antibody.	inhibitor
Lung cancer	EGFR	Kir	N/A	N/A	Lirilumab	N/A	N/A	BMS-986015	NCT01750580	Official title: BMS-986015, an Anti-KIR Monoclonal Antibody.	inhibitor
Lung cancer	Her2	Notch1	Notch1	4851	OMP-52M51	N/A	N/A	N/A	NCT01778439	Exclusion criteria: Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01795768	repeat	inhibitor
Lung cancer	Her2	N/A	N/A	N/A	GS-5745	N/A	N/A	N/A	NCT01803282	N/A	inhibitor
Lung cancer	Her2	Her2	ERBB2	2064	neratinib	neratinib	9915743	N/A	NCT01827267	Purpose: evaluating neratinib monotherapy and neratinib plus temsirolimus combination therapy in patients with non-small cell lung cancer (NSCLC) who have documented somatic HER2 mutations. %Official title: Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations. %Inclusion criteria: Documented somatic ErbB2 (HER2) activating mutation.	inhibitor
Lung cancer	Her3	PDGFR-a	PDGFRA	5156	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Lung cancer	Her4	PDGFR-_	PDGFRB	5159	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Lung cancer	Her5	VEFGR2	VEGFR2	3791	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Lung cancer	Her6	VEGFR1	FLT1	2321	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Lung cancer	Her7	VEGFR3	FLT4	2324	pazopanib	pazopanib	10113978	N/A	NCT01407562	N/A	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Sirolimus	rapamycin	5284616	N/A	NCT00940381	N/A	inhibitor
Lung cancer	KRAS	EGFR	EGFR	1956	cetuximab	N/A	N/A	N/A	NCT00946712	Purpose: To prospectively test EGFR FISH as a predictive marker for the selection of patients for treatment with cetuximab.	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT00980239	N/A	inhibitor
Lung cancer	KRAS	EGFR	EGFR	1956	Sym004	N/A	N/A	N/A	NCT01117428	Inclusion criteria: Documented disease progression during or within 6 months after cessation of anti-EGFR Ab treatment.	inhibitor
Lung cancer	KRAS	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	KRAS	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	KRAS	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	PDGFRA	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	KRAS	Kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	KRAS	VEGFR-1	FLT1	2321	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Lung cancer	KRAS	VEGFR-2	KDR	3791	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Lung cancer	KRAS	VEGFR-3	FLT4	2324	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Lung cancer	KRAS	mTOR	mTOR	2475	everolimus	Everolimus	6442177	N/A	NCT01334073	N/A	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Pemetrexed	Pemetrexed	446556	N/A	NCT01344824	N/A	inhibitor
Lung cancer	KRAS	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	KRAS	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	KRAS	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	KRAS	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	KRAS	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	KRAS	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	KRAS	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	KRAS	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	KRAS	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	KRAS	MEK1/2	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	KRAS	MEK1/2	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	KRAS	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01427946	Exclusion criteria: Prior treatment with everolimus, other rapamycin analogs, AP23573(Ridaforolimus), rapamycin, or other mTOR inhibitors.	inhibitor
Lung cancer	KRAS	Hsp90	HSP90AB2	3329.6	IPI-504	retaspimycin hydrochloride	11685945	N/A	NCT01427946	Exclusion criteria: Prior treatment with IPI-504 or other Hsp90 inhibitors.	inhibitor
Lung cancer	KRAS	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	KRAS	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	KRAS	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Lung cancer	KRAS	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01610336	Official title: INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer. %Inclusion criteria: Documented EGFR  amplification.	inhibitor
Lung cancer	KRAS	Met	MET	4233	INC280	N/A	N/A	N/A	NCT01610336	Purpose: INC280 when added to gefitinib in patients with lung cancer that are known to have dysregulation of the c-MET pathway. %Official title: INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer. %Inclusion criteria: Documented c-MET amplification.	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	TAS-115	N/A	N/A	N/A	NCT01610479	N/A	inhibitor
Lung cancer	KRAS	EWS-FLI2	N/A	N/A	Mithramycin	Plicamycin	163660	N/A	NCT01610570	Purpose:  Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript. %Inclusion criteria: Ewing sarcoma with EWS-FLI1 fusion transcript.	inhibitor
Lung cancer	KRAS	EGFR	EGFR	1956	necitumumab	N/A	N/A	N/A	NCT01624467	Exclusion criteria: Have received necitumumab or any other monoclonal antibody targeting the EGFR as the most recent prior treatment	inhibitor
Lung cancer	KRAS	elF4e	ELF4	2000	ISIS 183750	N/A	N/A	N/A	NCT01675128	Detailed description: ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the human eukaryotic translation initiation factor 4E (eIF4E) protein. 	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01708954	N/A	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	SPI-1620	N/A	N/A	N/A	NCT01741155	N/A	inhibitor
Lung cancer	KRAS	kras	KRAS	3845	Selumetinib	Selumetinib	10127622	N/A	NCT01783197	Inclusion criteria: Patients planned for the pemetrexed single agent cohort, as well as those accrued to the RP2D expansion cohorts must have a documented KRAS mutation.	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Lung cancer	KRAS	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Sunitinib	Sunitinib	5329102	N/A	NCT01829217	N/A	inhibitor
Lung cancer	KRAS	N/A	N/A	N/A	Bortezomib	Bortezomib	387447	N/A	NCT01833143	N/A	inhibitor
Lung cancer	Mek1	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	MEK1	Mek1	MAP2k1	5604	GSK1120212	Trametinib	11707110	N/A	NCT01658553	Detailed description: GSK1120212 is an orally administered, potent and highly selective small molecule inhibitor of MEK1. %Exclusion criteria: History of prior exposure to a MEK(activated extracellular signal-regulated kinase) inhibitor.	inhibitor
Lung cancer	Mek10	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Mek11	MEK1/2	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	Mek12	MEK1/2	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	Mek2	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Mek3	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Mek4	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Mek5	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Mek6	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Mek7	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Mek8	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Mek9	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	Met	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Lung cancer	Met	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00790816	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Sunitinib	Sunitinib	5329102	N/A	NCT00884676	N/A	inhibitor
Lung cancer	Met	Flt3	FLT3	2322	PLX3399	N/A	N/A	N/A	NCT01014936	Purpose: PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.	inhibitor
Lung cancer	Met	N/A	N/A	N/A	DM-CHOC-PEN	N/A	N/A	N/A	NCT01048008	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	KML-001	N/A	N/A	N/A	NCT01110226	N/A	inhibitor
Lung cancer	Met	c-MET	MET	4235	PF- 02341066	Crizotinib	11626560	N/A	NCT01121575	Official title: C- MET/ALK Inhibitor (PF- 02341066). 	inhibitor
Lung cancer	Met	c-MET	MET	4235	PF- 02341066	Crizotinib	11626560	N/A	NCT01121575	Official title: C- MET/ALK Inhibitor (PF- 02341066). 	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Cabazitaxel	Cabazitaxel	9854073	XRP6258	NCT01140607	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	SCB01A	N/A	N/A	N/A	NCT01159522	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Marqibo	vincristine	5978	N/A	NCT01222780	N/A	inhibitor
Lung cancer	Met	Wnt	wnt16	51384	PRI-724	N/A	N/A	N/A	NCT01302405	Purpose: PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread. 	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT01324479	N/A	inhibitor
Lung cancer	Met	histone deacetylase	N/A	N/A	LBH589B	N/A	N/A	N/A	NCT01341834	Purpose: This study will also be exploring the hypothesis that HDACi and mTOR inhibitors abrogate the effects of key viral proteins. %Official title: LBH589B (Histone Deacetylase Inhibitor).	inhibitor
Lung cancer	Met	mTOR	mTOR	2475	RAD001	Everolimus	6442177	N/A	NCT01341834	Purpose: This study will also be exploring the hypothesis that HDACi and mTOR inhibitors abrogate the effects of key viral proteins. %Official title: RAD001 (mTOR Inhibitor). 	inhibitor
Lung cancer	Met	Her2	ERBB2	2064	HER-2 vaccine	N/A	N/A	N/A	NCT01376505	Purpose: Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine. 	inhibitor
Lung cancer	Met	Met	MET	4233	SAR125844	N/A	N/A	N/A	NCT01391533	Purpose: To evaluate the preliminary anti- tumoral effect of SAR125844 in patients with MET-gene amplified tumors and in patients with Phospho-MET positive tumors without MET-gene amplification. %Inclusion criteria: in the first cohort, patients with diagnosed MET- gene amplified and measurable tumors will be eligible. In the second cohort, patients with P-MET positive measurable solid tumor without MET-gene amplification will be eligible. %Exclusion criteria: Prior treatment with any MET inhibitor compound.	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Asp3026	ASP-3026	25134326	N/A	NCT01401504	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Gefitinib	Gefitinib	123631	N/A	NCT01405846	N/A	inhibitor
Lung cancer	Met	Nectin-4	N/A	N/A	AGS-22M6E	N/A	N/A	N/A	NCT01409135	Detailed description: AGS-22M6E and ASG-22CE are fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting Nectin-4. %Inclusion criteria: Subjects must have a tumor positive for Nectin-4 expression.	inhibitor
Lung cancer	Met	Nectin-4	N/A	N/A	ASG-22CE	N/A	N/A	N/A	NCT01409135	Detailed description: AGS-22M6E and ASG-22CE are fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting Nectin-4. %Inclusion criteria: Subjects must have a tumor positive for Nectin-4 expression.	inhibitor
Lung cancer	Met	Met	MET	4233	onartuzumab	N/A	N/A	MetMAb	NCT01456325	Purpose: identified to be Met diagnostic-positive.	inhibitor
Lung cancer	Met	c-Met	MET	4237	ARQ 197	ARQ 197	11494412	N/A	NCT01468922	Purpose: ARQ 197 is an experimental drug that blocks a protein called c-MET, which cancer cells need to grow.	inhibitor
Lung cancer	Met	cMet	MET	4233	ABT-700	N/A	N/A	N/A	NCT01472016	Purpose: ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody. 	inhibitor
Lung cancer	Met	Met	MET	4233	onartuzumab	N/A	N/A	N/A	NCT01519804	Purpose: Adequate tissue for central IHC assay of Met receptor	inhibitor
Lung cancer	Met	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	Met	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	Met	ALK	ALK	240	Crizotinib	crenolanib 	10366138	N/A	NCT01548144	Purpose: Crizotinib is designed to block a protein called ALK. 	inhibitor
Lung cancer	Met	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	Met	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	Met	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Lung cancer	Met	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Lung cancer	Met	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	Met	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01610336	Official title: INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer. %Inclusion criteria: Documented EGFR  amplification.	inhibitor
Lung cancer	Met	Met	MET	4233	INC280	N/A	N/A	N/A	NCT01610336	Purpose: INC280 when added to gefitinib in patients with lung cancer that are known to have dysregulation of the c-MET pathway. %Official title: INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer. %Inclusion criteria: Documented c-MET amplification.	inhibitor
Lung cancer	Met	N/A	N/A	N/A	TAS-116	N/A	N/A	N/A	NCT01610479	N/A	inhibitor
Lung cancer	Met	EWS-FLI3	N/A	N/A	Mithramycin	Plicamycin	163661	N/A	NCT01610570	Purpose:  Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript. %Inclusion criteria: Ewing sarcoma with EWS-FLI1 fusion transcript.	inhibitor
Lung cancer	Met	mTOR	mTOR	2475	temsirolimus	Temsirolimus	23724530	N/A	NCT01625156	Detailed description: To assess for pharmacodynamic evidence of c-Met and mammalian target of rapamycin (mTOR) inhibition.	inhibitor
Lung cancer	Met	c-Met	MET	4236	tivantinib	ARQ 197	11494412	ARQ197	NCT01625156	Detailed description: To correlate archived tumor tissue expression of c-Met with objective response to ARQ 197 and temsirolimus therapy.	inhibitor
Lung cancer	Met	ALK	ALK	238	X-396	N/A	N/A	N/A	NCT01625234	Brief_title: Alk inhibitor. %Intervention: X-396, Oral ALK inhibitor	inhibitor
Lung cancer	Met	N/A	N/A	N/A	tivantinib	ARQ 197	11494412	N/A	NCT01654965	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	topotecan hydrochloride	topotecan hydrochloride	60699	N/A	NCT01654965	N/A	inhibitor
Lung cancer	Met	mTOR	mTOR	2475	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3CA	5290	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3CB	5291	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3CG	5294	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3CD	5293	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3R1	5295	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3R2	5296	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3R3	8503	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3R4	30849	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3R5	23533	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	PI3K	PIK3R6	146850	LY3023414	N/A	N/A	N/A	NCT01655225	Exclusion criteria: no previous treatment with any PI3K and/or mTOR inhibitor is allowed.	inhibitor
Lung cancer	Met	Met	MET	4233	SAR125844	N/A	N/A	N/A	NCT01657214	Purpose: To explore the relationship of MET gene amplification status with anti-tumor effects. %Inclusion criteria: At the recommended dose (expansion cohort): only patients with measurable disease and MET gene amplification.	inhibitor
Lung cancer	Met	N/A	N/A	N/A	erlotinib	erlotinib hydrochloride	176871	N/A	NCT01708954	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Reolysin	N/A	N/A	N/A	NCT01708993	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	metformin	Metformin	4091	N/A	NCT01717482	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01721148	repeat	inhibitor
Lung cancer	Met	c-Met	MET	4240	tivantinib	ARQ 197	11494412	ARQ 197	NCT01725191	Official title: c-Met Inhibitor, Tivantinib	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Lung cancer	Met	c-Met	MET	4239	Volitinib	N/A	N/A	N/A	NCT01773018	Purpose: Volitinib (HMPL-504) is a novel, highly potent and selective small molecule inhibitor of c-Met kinase. 	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Rilotumumab	N/A	N/A	N/A	NCT01791374	N/A	inhibitor
Lung cancer	Met	N/A	N/A	N/A	Sunitinib	Sunitinib	5329102	N/A	NCT01829217	N/A	inhibitor
Lung cancer	Met	c-Met	MET	4238	MSC2156119J	N/A	N/A	N/A	NCT01832506	Official title: c-Met Inhibitor MSC2156119J. 	inhibitor
Lung cancer	NRAS	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	NRAS	MEK1/2	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	NRAS	MEK1/2	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	NRAS	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	NRAS	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	NRAS	N/A	N/A	N/A	SPI-1620	N/A	N/A	N/A	NCT01741155	N/A	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Lung cancer	PIK3CA	EGFR	EGFR	1956	BIBW2992	BIBW 2992	10184653	N/A	NCT01156545	Purpose: BIBW2992, an irreversible EGFR-TKI	inhibitor
Lung cancer	PIK3CA	Ras	KRAS	3845	Simvastin	Simvastin	54454	N/A	NCT01156545	Detailed description: statins inhibit activation of RAS and downstream signaling cascades, including the RAF/MEK/ERK and PI3K/AKT	inhibitor
Lung cancer	PIK3CA	PIK3CA	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01219699	Purpose: Advanced Solid Tumors With an Alteration of the PIK3CA Gene. 	inhibitor
Lung cancer	PIK3CA	Akt	Akt1	207	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Lung cancer	PIK3CA	Akt	Akt2	208	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Lung cancer	PIK3CA	Akt	Akt3	10000	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Lung cancer	PIK3CA	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	PIK3CA	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	PIK3CA	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k1	5604	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k2	5605	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K3	5606	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K4	6416	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K5	5607	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k6	5608	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k7	5609	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	BMS-906024	UNII-DRL23N424R	66550890	N/A	NCT01292655	N/A	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01297491	Purpose: assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. %Official title: BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway. %Inclusion criteria: Histologically confirmed NSCLC with activated PI3K pathway. %Exclusion criteria: Patient has received previous treatment with PI3K inhibitors.	inhibitor
Lung cancer	PIK3CA	BRAF	BRAF	673	Regorafenib	Regorafenib	11167602	BAY 73-4520	NCT01300299	Purpose:  in patients with mCRC and KRAS or BRAF mutant disease. 	inhibitor
Lung cancer	PIK3CA	PDGFR	PDGFRA	5156	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	PDGFR	PDGFRB	5159	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	RAF	BRAF	673	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	RAF	RAF1	5894	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	VEGFR	FLT4	2324	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	VEGFR-1	FLT1	2321	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	VEGFR-3	FLT4	2324	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	Akt1	PDGFRA	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	PIK3CA	Kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	PIK3CA	PARP1	PARP1	142	ABT-767	N/A	N/A	N/A	NCT01339650	Purpose: ABT-767 is a potent oral inhibitor of the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2). %Exclusion criteria: Subject has previously received a poly (ADP-ribose) polymerase (PARP) inhibitor.	inhibitor
Lung cancer	PIK3CA	PARP2	PARP2	10038	ABT-767	N/A	N/A	N/A	NCT01339650	Purpose: ABT-767 is a potent oral inhibitor of the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2). %Exclusion criteria: Subject has previously received a poly (ADP-ribose) polymerase (PARP) inhibitor.	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01363232	Purpose: phosphatidylinositol 3'-kinase (PI3K) inhibitor BKM120	inhibitor
Lung cancer	PIK3CA	MEK1/2	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	PIK3CA	MEK1/2	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01363232	Purpose: MEK1/2 inhibitor MEK162	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k1	5604	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k2	5605	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K3	5606	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K4	6416	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Lung cancer	PIK3CA	MEK	MAP2K5	5607	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k6	5608	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Lung cancer	PIK3CA	MEK	MAP2k7	5609	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Lung cancer	PIK3CA	PIK3CA	PIK3CA	5290	MLN1117	N/A	N/A	N/A	NCT01449370	Inclusion criteria: Subjects have had their PIK3CA gene mutation status assessed prior to enrolling into the study. %Exclusion criteria: Have received a selective PI3K-alpha inhibitor.	inhibitor
Lung cancer	PIK3CA	Alk	ALK	238	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. %Inclusion criteria: No prior ALK inhibitor therapy. 	inhibitor
Lung cancer	PIK3CA	EGFR	EGFR	1956	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. 	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01508104	Purpose: Everolimus is an agent that also targets mTOR. 	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Lung cancer	PIK3CA	Ang1	ANGPT1	284	trebananib	N/A	N/A	AMG386	NCT01548482	Purpose: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	Ang2	ANGPT2	285	trebananib	N/A	N/A	AMG386	NCT01548482	Purpose: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PIK3CA	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01570296	Purpose: Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa). %Inclusion criteria: Patients with histologically or cytologically proven NSCLC who meet the clinical definition of EGFR TKI resistance, and are progressing on existing treatment or have previously progressed on EGFR TKI	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	PIK3CA	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Lung cancer	PIK3CA	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PIK3CA	Akt1	Akt1	207	Mk2206	MK2206	46930998	N/A	NCT01604772	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01626209	N/A	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01637597	repeat	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	ASP9853	N/A	N/A	N/A	NCT01705483	N/A	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	AMG 479	N/A	N/A	N/A	NCT01708161	N/A	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	BYL719	BYL719	56649450	N/A	NCT01708161	N/A	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	PI3k	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01723800	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. %Secondary objectives: To evaluate downstream inhibition of the phosphatidylinositol 3 kinase (PI3K) pathway. 	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	SPI-1620	N/A	N/A	N/A	NCT01741155	N/A	inhibitor
Lung cancer	PIK3CA	Notch1	Notch1	4851	OMP-52M51	N/A	N/A	N/A	NCT01778439	Exclusion criteria: Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors	inhibitor
Lung cancer	PIK3CA	Mct1	SLC16A1	6566	AZD3965	N/A	N/A	N/A	NCT01791595	Purpose: AZD3965 is a type of drug called a monocarboxylate transporter 1 inhibitor. %Official title:  AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1)	inhibitor
Lung cancer	PIK3CA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01820325	repeat	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	AMG479	N/A	N/A	N/A	NCT01122199	N/A	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	RAD001	Everolimus	6442177	N/A	NCT01122199	N/A	inhibitor
Lung cancer	PTEN	EGFR	EGFR	1956	BIBW2992	BIBW 2992	10184653	N/A	NCT01156545	Purpose: BIBW2992, an irreversible EGFR-TKI	inhibitor
Lung cancer	PTEN	Ras	KRAS	3845	Simvastin	Simvastin	54454	N/A	NCT01156545	Detailed description: statins inhibit activation of RAS and downstream signaling cascades, including the RAF/MEK/ERK and PI3K/AKT	inhibitor
Lung cancer	PTEN	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	PTEN	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	PTEN	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Lung cancer	Akt1	PDGFRA	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	PTEN	Kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	Endostar	N/A	N/A	N/A	NCT01327235	N/A	inhibitor
Lung cancer	PTEN	PDGFR-_	PDGFRB	5159	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Lung cancer	PTEN	Raf	BRAF	673	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Lung cancer	PTEN	Raf	Raf1	5894	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Lung cancer	PTEN	VEGFR-1	FLT1	2321	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Lung cancer	PTEN	VEGFR-2	KDR	3791	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Lung cancer	PTEN	VEGFR-3	FLT4	2324	Sorafenib Tosylate	Sorafenib Tosylate	406563	BAY 43-9006	NCT01450384	Purpose: Pemetrexed disodium and sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. 	inhibitor
Lung cancer	PTEN	PTEN	PTEN	5728	GSK2636771	1372540-25-4	56949517	N/A	NCT01458067	Inclusion criteria: Subjects must have tumors with a documented PTEN deficiency. 	inhibitor
Lung cancer	PTEN	NY-ESO-1	CTAG1-B	255753	DEC-205-NY-ESO-1 fusion protein vaccine	N/A	N/A	N/A	NCT01522820	Purpose: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. 	inhibitor
Lung cancer	PTEN	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	PTEN	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	PTEN	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Lung cancer	PTEN	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01570296	Purpose: Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa). %Inclusion criteria: Patients with histologically or cytologically proven NSCLC who meet the clinical definition of EGFR TKI resistance, and are progressing on existing treatment or have previously progressed on EGFR TKI	inhibitor
Lung cancer	PTEN	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	PTEN	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	PTEN	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Lung cancer	PTEN	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Lung cancer	PTEN	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01639001	Repeat	inhibitor
Lung cancer	PTEN	RET	RET	5979	Cabozantinib	Cabozantinib	25102847	XL184	NCT01639508	Purpose: The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors have a gene called KIF5B/RET. KIF5B/RET is an abnormal gene that leads to lung cancer cell growth. Cabozantinib is an oral medicine that inhibits the effects of this gene. %Inclusion criteria: Documented presence of KIF5B/RET or related variant RET fusions. 	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	ASP9853	N/A	N/A	N/A	NCT01705483	N/A	inhibitor
Lung cancer	PTEN	Mct1	SLC16A1	6566	AZD3965	N/A	N/A	N/A	NCT01791595	Purpose: AZD3965 is a type of drug called a monocarboxylate transporter 1 inhibitor. %Official title:  AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1)	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01819428	Repeat	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	GSE	N/A	N/A	N/A	NCT01820299	N/A	inhibitor
Lung cancer	PTEN	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01820325	Repeat	inhibitor
Lung cancer	RET	EGFR	EGFR	1956	Erlotinib	erlotinib hydrochloride	176871	N/A	NCT00339586	Official title: EGFR-1 Tyrosine Kinase Inhibition as a First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring a Mutant EGFR Gene. %Exclusion criteria: Prior therapy with systemic anti-tumour therapy with HER1/EGFR inhibitors.	inhibitor
Lung cancer	RET	N/A	N/A	N/A	gefitinib	Gefitinib	123631	Iressa	NCT00497250	N/A	inhibitor
Lung cancer	RET	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Lung cancer	RET	N/A	N/A	N/A	Pazopanib 	pazopanib	10113978	GW786034	NCT01049776	N/A	inhibitor
Lung cancer	RET	VEGF	VEGFA	7422	Bevacizumab	N/A	N/A	N/A	NCT01171170	Detailed description: Bevacizumab interacts with this pathway by blocking VEGF. 	inhibitor
Lung cancer	RET	VEGFR	FLT1	2321	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Lung cancer	RET	VEGFR	KDR	3791	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Lung cancer	RET	VEGFR	FLT4	2324	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90AA1	3320	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90B1	7184	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Lung cancer	RET	N/A	N/A	N/A	dinaciclib	dinaciclib	46926350	SCH727965	NCT01434316	N/A	inhibitor
Lung cancer	RET	N/A	N/A	N/A	veliparib	Veliparib	11960529	ABT-888	NCT01434316	N/A	inhibitor
Lung cancer	RET	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	Iressa	NCT01485809	Purpose: Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). %Inclusion criteria: an activating sensitizing EGFR mutation.	inhibitor
Lung cancer	RET	EGFR	EGFR	1956	Icotinib	Icotinib	22024915	N/A	NCT01514877	Purpose: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the blood-brain barrier and show promising antitumor activity against brain metastases from NSCLC. %Inclusion criteria: patients with EGFR mutation.	inhibitor
Lung cancer	RET	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Lung cancer	RET	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Lung cancer	RET	EGFR	EGFR	1956	HM61713	N/A	N/A	N/A	NCT01588145	Official title: HM61713 Tablet in NSCLC Patients With EGFR Mutation. %Inclusion criteria: Patients with EGFR mutation-positive tumor. 	inhibitor
Lung cancer	RET	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	RET	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Lung cancer	RET	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Lung cancer	RET	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Lung cancer	RET	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Lung cancer	RET	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01639508	repeat	inhibitor
Lung cancer	RET	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01677741	Purpose: dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. %Official title: Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation. %Inclusion criteria: BRAF V600 mutation-positive tumor.	inhibitor
Lung cancer	RET	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01688713	repeat	inhibitor
Lung cancer	RET	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01724801	repeat	inhibitor
Lung cancer	RET	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01746277	repeat	inhibitor
Lung cancer	RET	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01749072	repeat	inhibitor
Lung cancer	RET	RET	RET	5979	Vandetanib	Vandetanib	3081361	N/A	NCT01823068	Purpose: Vandetanib, a multi-kinase inhibitors with anti-RET activity. %Inclusion criteria: Presence of a RET fusion. %Detailed description: Patients will be screened so as to confirm RET fusion in their tumor tissue.	inhibitor
Lung cancer	RET	N/A	N/A	N/A	Sunitinib	Sunitinib	5329102	N/A	NCT01829217	N/A	inhibitor
Lung cancer	ROS	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Lung cancer	ROS	ALK	ALK	241	Crizotinib	crenolanib 	10366139	N/A	NCT01548144	Purpose: Crizotinib is designed to block a protein called ALK. 	inhibitor
Lung cancer	ROS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01702844	repeat	inhibitor
Medulloblastoma	SMO	SMO	SMO	6608	LY2940680	LY2940680	49848070	N/A	NCT01226485	Detailed Description: Participants may include those who have previously received treatment with another hedgehog smoothened (Hh/Smo) inhibitor	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Melanoma	BRAF	c-KIT	KIT	3815	Nilotinib	Nilotinib	644241	N/A	NCT01168050	Official title:  Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification. 	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01231594	Purpose: provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors. %Official title: Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.	inhibitor
Melanoma	BRAF	tubulin	N/A	N/A	Crolibulin	Crolibulin	23649181	N/A	NCT01240590	Purpose: Crolibulin (EPC2407) is a microtubulin inhibitor.	inhibitor
Melanoma	BRAF	Aurora A kinase	AURKA	6790	MLN8237	Alisertib	24771867	N/A	NCT01316692	Purpose: Aurora A kinase inhibitor MLN8237. %Official title: MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor. 	inhibitor
Melanoma	BRAF	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	BRAF	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	BRAF	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	BRAF	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	BRAF	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	BRAF	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	BRAF	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Melanoma	BRAF	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Melanoma	BRAF	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Melanoma	BRAF	CD20	MS4A1	931	Ofatumumab	N/A	N/A	N/A	NCT01376713	Official title: CD20-Immunotargeting	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT01377025	Purpose: sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR).	inhibitor
Melanoma	BRAF	PDGFR	PDGFRA	5156	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT01377025	Purpose: sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR).	inhibitor
Melanoma	BRAF	PDGFR	PDGFRB	5159	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT01377025	Purpose: sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR).	inhibitor
Melanoma	BRAF	Raf-1	RAF-1	5894	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT01377025	Purpose: sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR).	inhibitor
Melanoma	BRAF	VEGFR	FLT1	2321	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT01377025	Purpose: sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR).	inhibitor
Melanoma	BRAF	VEGFR	KDR	3791	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT01377025	Purpose: sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR).	inhibitor
Melanoma	BRAF	VEGFR	FLT4	2324	Sorafenib	Sorafenib Tosylate	406563	N/A	NCT01377025	Purpose: sorafenib as inhibitor of b-Raf and Raf-1 (c-Raf or c-Raf-1), pro-angiogenic vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR).	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01436656	Purpose: LGX818 (daily, twice daily and/or every-other-day), a RAF kinase inhibitor. %Inclusion criteria: documentation of BRAF V600E mutation, or any other BRAF V600 mutation	inhibitor
Melanoma	BRAF	PI3K	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3CB	5291	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3CG	5294	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3CD	5293	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3R1	5295	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3R2	5296	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3R3	8503	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3R4	30849	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3R5	23533	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3R6	146850	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	Mek	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	Mek	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	Mek	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	Mek	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	Mek	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	Mek	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	Mek	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Melanoma	BRAF	CD27	CD27	939	CDX-1127	N/A	N/A	N/A	NCT01460134	Detailed description: CDX-1127 is a fully human monoclonal antibody that binds to a molecule called CD27. 	inhibitor
Melanoma	BRAF	VEGF	VEGFA	7422	Bevacizumab	N/A	N/A	N/A	NCT01495988	Purpose: Bevacizumab is a humanized monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer) directed against vascular endothelial growth factor (VEGF).	inhibitor
Melanoma	BRAF	VEGF	VEGFB	7423	Bevacizumab	N/A	N/A	N/A	NCT01495988	Purpose: Bevacizumab is a humanized monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer) directed against vascular endothelial growth factor (VEGF).	inhibitor
Melanoma	BRAF	VEGF	VEGFC	7424	Bevacizumab	N/A	N/A	N/A	NCT01495988	Purpose: Bevacizumab is a humanized monoclonal antibody (a type of protein that is normally made by the immune system to help defend the body from infection and cancer) directed against vascular endothelial growth factor (VEGF).	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01495988	Purpose: Vemurafenib works by blocking a protein called B-RAF.	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Sylatron	N/A	N/A	PEG-Intron	NCT01496807	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Yervoy	N/A	N/A	Ipilimumab	NCT01496807	N/A	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	RO5185426	NCT01519323	Purpose: vemurafenib (RO5185426) in pediatric patients (aged 12 through 17) with newly diagnosed or recurrent surgically incurable and unresectable Stage IIIC or Stage IV melanoma harboring BRAFV600 mutations. %Official title: RO5185426 in Pediatric Patients With Surgically Incurable and Unresectable Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations Mutations. %Inclusion criteria: Positive BRAF mutation result. %Exclusion criteria: Previous treatment with selective/specific BRAF or MEK inhibitor.	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	CDX-1127	N/A	N/A	N/A	NCT01524978	N/A	inhibitor
Melanoma	BRAF	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Melanoma	BRAF	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01531361	Official title: Vemurafenib (BRAF Inhibitor). %Inclusion criteria: Patients with advanced or metastatic cancers and BRAF mutations 	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Melanoma	BRAF	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Melanoma	BRAF	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Melanoma	BRAF	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Melanoma	BRAF	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Melanoma	BRAF	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Melanoma	BRAF	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Melanoma	BRAF	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01585415	Purpose: Vemurafenib targets melanoma cells that have a mutation in the B-raf gene. %Inclusion criteria: Measurable metastatic melanoma that expresses the VtoE BRAF mutation. 	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01586195	Official title: Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations. %Inclusion criteria: activating BRAF mutation. 	inhibitor
Melanoma	BRAF	iNOS	NOS2	4843	Doxycycline	Doxycycline	54671203	N/A	NCT01590082	Purpose: Doxycycline is designed to treat bacterial infection. It also blocks a protein called iNOS that is important in tumor cell growth. 	inhibitor
Melanoma	BRAF	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Melanoma	BRAF	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	temsirolimus	Temsirolimus	23724530	N/A	NCT01614301	Exclusion criteria: Prior immunotherapy with ipilimumab, vaccination, B-raf inhibitor.	inhibitor
Melanoma	BRAF	PI3K	PIK3CA	5290	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3CB	5291	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3CG	5294	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3CD	5293	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3R1	5295	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3R2	5296	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3R3	8503	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3R4	30849	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3R5	23533	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	PI3K	PIK3R6	146850	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	dabrafenib	Dabrafenib mesylate	44516822	GSK2118436	NCT01619774	Purpose: Dabrafenib is designed to block the mutated BRAF protein.	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Trametinib	trametinib	11707110	GSK1120212	NCT01619774	N/A	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	PLX4032	NCT01636622	Purpose: Vemurafenib is designed to block a protein (called mutated BRAF). %Inclusion criteria: Patient must have histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma harboring a BRAF mutation	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Pasireotide	Pasireotide	9941444	N/A	NCT01652547	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	MPDL3280A	N/A	N/A	N/A	NCT01656642	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Vemurafenib 	Vemurafenib	42611257	Zelboraf	NCT01656642	N/A	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01657591	Official title: Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma.	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90AA1	3320	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90B1	7184	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01667419	Purpose: evaluate the efficacy and safety of vemurafenib in patients with completely resected, cutaneous BRAF-mutation positive melanoma. %Official title: Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma.	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	SAR260301	N/A	N/A	N/A	NCT01673737	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Ipilimumab	N/A	N/A	N/A	NCT01673854	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	vemurafenib	Vemurafenib	42611257	N/A	NCT01673854	N/A	inhibitor
Melanoma	BRAF	CTLA4	CTLA4	1493	Ipilimumab	N/A	N/A	N/A	NCT01676649	Exclusion criteria: A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA 4 inhibitor or agonist.	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01677741	Purpose: dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. %Official title: Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation. %Inclusion criteria: BRAF V600 mutation-positive tumor.	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01682083	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Trametinib	trametinib	11707110	N/A	NCT01682083	N/A	inhibitor
Melanoma	BRAF	IL-2	IL2	3558	HD IL-2	N/A	N/A	Proleukin	NCT01683188	Purpose: High Dose Interleukin-2 (abbreviated as HD IL-2 and known as Proleukin). 	activator
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01683188	Official title: Vemurafenib Therapy in Patients With BRAFV600 Mutation. 	activator
Melanoma	BRAF	MEK1	MAP2k1	5604	cobimetinib	GDC-0973	N/A	N/A	NCT01689519	Purpose: GDC-0973 (cobimetinib), a MEK inhibitor	inhibitor
Melanoma	BRAF	MEK2	MAP2k2	5605	cobimetinib	GDC-0973	N/A	N/A	NCT01689519	Purpose: GDC-0973 (cobimetinib), a MEK inhibitor	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Ipilimumab	N/A	N/A	N/A	NCT01689974	N/A	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01701037	Official title: B-RAF and MEK Targeted Therapy. %Inclusion criteria: B-RAF V-600 mutation positive. 	inhibitor
Melanoma	BRAF	MEK	MAP2k1	5604	dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01701037	Official title: B-RAF and MEK Targeted Therapy.	inhibitor
Melanoma	BRAF	MEK	MAP2k2	5605	dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01701037	Official title: B-RAF and MEK Targeted Therapy.	inhibitor
Melanoma	BRAF	MEK	MAP2K3	5606	dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01701037	Official title: B-RAF and MEK Targeted Therapy.	inhibitor
Melanoma	BRAF	MEK	MAP2K4	6416	dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01701037	Official title: B-RAF and MEK Targeted Therapy.	inhibitor
Melanoma	BRAF	MEK	MAP2K5	5607	dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01701037	Official title: B-RAF and MEK Targeted Therapy.	inhibitor
Melanoma	BRAF	MEK	MAP2k6	5608	dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01701037	Official title: B-RAF and MEK Targeted Therapy.	inhibitor
Melanoma	BRAF	MEK	MAP2k7	5609	dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01701037	Official title: B-RAF and MEK Targeted Therapy.	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Ipilimumab	N/A	N/A	N/A	NCT01701674	N/A	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	GSK2118436	NCT01713972	Purpose: Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Assigned intervention: BRAF inhibitor GSK2118436. %Inclusion criteria: Tumors must carry the BRAF mutation	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01721603	Purpose: dabrafenib (a BRAF inhibitor). 	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Nivolumab	N/A	N/A	BMS-936558	NCT01721772	N/A	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01726738	Purpose: BRAF inhibitor (dabrafenib) %Exclusion criteria: Prior treatment with a BRAF inhibitor (including but not limited to dabrafenib (GSK2118436), vemurafenib, and LX281/BMS-908662)	inhibitor
Melanoma	BRAF	MEK1	MAP2k1	5604	trametinib	trametinib	11707110	N/A	NCT01726738	Purpose: MEK inhibitor (trametinib) %Exclusion criteria: prior treatment with MEK inhibitor (including but not limited to trametinib (GSK1120212), AZD6244, and RDEA119)	inhibitor
Melanoma	BRAF	MEK2	MAP2k2	5605	trametinib	trametinib	11707110	N/A	NCT01726738	Purpose: MEK inhibitor (trametinib) %Exclusion criteria: prior treatment with MEK inhibitor (including but not limited to trametinib (GSK1120212), AZD6244, and RDEA119)	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01738451	N/A	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01739764	Purpose: This open-label, multicenter, non-randomized study will provide continued access to vemurafenib for eligible patients with BRAF V600 mutation-positive malignancy. %Official title: A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies. %Inclusion criteria: BRAF V600 mutation-positive malignancy. 	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Melanoma	BRAF	IL-2	IL2	3558	Aldesleukin	N/A	N/A	N/A	NCT01754376	Purpose: Aldesleukin, also referred to as IL-2. 	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01754376	Purpose: Researchers have found that a large number of melanoma cells have mutations in the BRAF gene. It has been shown that vemurafenib blocks the effects of these mutations in the BRAF gene. 	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01765543	Purpose: in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Inclusion criteria: positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01767623	Purpose:  vemurafenib in patients with BRAF V600 mutation positive cancer. %Official title: Vemurafenib in BRAF V600 Mutation Positive Cancer Patients. %Inclusion criteria: confirmed BRAF V600 mutation	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01765569	Purpose: effect of vemurafenib on the pharmacokinetics of digoxin in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Exclusion criteria: Prior treatment with vemurafenib or other BRAF inhibitor.	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01767454	Official title: BRAF Inhibitor Dabrafenib	inhibitor
Melanoma	BRAF	MEK	MAP2k1	5604	Trametinib	trametinib	11707110	N/A	NCT01767454	Official title: MEK Inhibitor Trametinib	inhibitor
Melanoma	BRAF	MEK	MAP2k2	5605	Trametinib	trametinib	11707110	N/A	NCT01767454	Official title: MEK Inhibitor Trametinib	inhibitor
Melanoma	BRAF	MEK	MAP2K3	5606	Trametinib	trametinib	11707110	N/A	NCT01767454	Official title: MEK Inhibitor Trametinib	inhibitor
Melanoma	BRAF	MEK	MAP2K4	6416	Trametinib	trametinib	11707110	N/A	NCT01767454	Official title: MEK Inhibitor Trametinib	inhibitor
Melanoma	BRAF	MEK	MAP2K5	5607	Trametinib	trametinib	11707110	N/A	NCT01767454	Official title: MEK Inhibitor Trametinib	inhibitor
Melanoma	BRAF	MEK	MAP2k6	5608	Trametinib	trametinib	11707110	N/A	NCT01767454	Official title: MEK Inhibitor Trametinib	inhibitor
Melanoma	BRAF	MEK	MAP2k7	5609	Trametinib	trametinib	11707110	N/A	NCT01767454	Official title: MEK Inhibitor Trametinib	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01767623	Purpose:  vemurafenib in patients with BRAF V600 mutation positive cancer. %Official title: Vemurafenib in BRAF V600 Mutation Positive Cancer Patients. %Inclusion criteria: confirmed BRAF V600 mutation	inhibitor
Melanoma	BRAF	CD4	CD4	920	LEE011	N/A	N/A	N/A	NCT01777776	Keywords: CDK4/6	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01777776	Keywords: BRAF inhibitor	inhibitor
Melanoma	BRAF	CD6	N/A	N/A	N/A	N/A	N/A	N/A	NCT01777776	Keywords: CDK4/6	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01781026	Purpose: study the activity of vemurafenib in untreated melanoma brain metastases harboring BRAF mutations. %Official title: Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations. 	inhibitor
Melanoma	BRAF	ERK1	MAPK3	5595	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Melanoma	BRAF	ERK2	MAPK1	5594	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Nivolumab	N/A	N/A	N/A	NCT01783938	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01813214	Purpose: Vemurafenib has been approved by the FDA for treatment of patients with advanced melanoma that harbors a B-RAF mutation. Vemurafenib works by blocking a protein called B-RAF. %Inclusion criteria: Melanoma must be documented to contain a BRAFV600 mutation. %Exclusion criteria: Prior therapy with a MEK inhibitor or an inhibitor of mutant BRAF.	inhibitor
Melanoma	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01820364	Exclusion criteria: Previous treatment with RAF-inhibitor.	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	PLX3397	N/A	N/A	N/A	NCT01826448	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	vemurafenib	Vemurafenib	42611257	N/A	NCT01826448	N/A	inhibitor
Melanoma	BRAF	N/A	N/A	N/A	abraxane	TAXOL	36314	ABI-007	NCT01827111	N/A	inhibitor
Melanoma	BRAF	PARP	PARP1	142	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Melanoma	BRAF	PARP	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Melanoma	BRAF	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01827384	Detailed description: Everolimus (mTOR inhibitor)	inhibitor
Melanoma	BRAF	Wee1	Wee1	7465	MK-1775	MK 1775	24856436	N/A	NCT01827384	Detailed description: MK-1775 (Wee1 inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2k1	5604	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2k2	5605	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2K3	5606	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2K4	6416	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2K5	5607	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2k6	5608	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Melanoma	BRAF	MEK	MAP2k7	5609	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Melanoma	CTNNB1	c-Met	MET	4237	ARQ 197	ARQ 197	11494412	N/A	NCT01468922	Purpose: ARQ 197 is an experimental drug that blocks a protein called c-MET, which cancer cells need to grow.	inhibitor
Melanoma	GNA11	N/A	N/A	N/A	selumetinib	Selumetinib	10127622	N/A	NCT01143402	N/A	inhibitor
Melanoma	GNA11	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Melanoma	GNA11	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Melanoma	GNA11	HDAC	N/A	N/A	vorinostat	Vorinostat	5311	N/A	NCT01587352	Exclusion criteria: Patients receiving histone deacetylase (HDAC) inhibitors or compounds with HDAC inhibitor-like activity.	inhibitor
Melanoma	GNAQ	N/A	N/A	N/A	selumetinib	Selumetinib	10127622	N/A	NCT01143402	N/A	inhibitor
Melanoma	GNAQ	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Melanoma	GNAQ	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Melanoma	GNAQ	HDAC	N/A	N/A	vorinostat	Vorinostat	5311	N/A	NCT01587352	Exclusion criteria: Patients receiving histone deacetylase (HDAC) inhibitors or compounds with HDAC inhibitor-like activity.	inhibitor
Melanoma	Kit	c-Kit	KIT	3815	Sunitinib	Sunitinib	5329102	SU011248	NCT00577382	Purpose: SU011248 is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. 	inhibitor
Melanoma	Kit	Fms	CSF1R	1436	PLX3397	N/A	N/A	N/A	NCT01004861	Purpose: PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.	inhibitor
Melanoma	Kit	Abl	Abl	45821	Nilotinib	Nilotinib	644241	N/A	NCT01099514	Purpose: Nilotinib is a novel tyrosine kinase inhibitor (TKI) targeting KIT, PDGFR, and Bcr-Abl. 	inhibitor
Melanoma	Kit	KIT	KIT	3815	Nilotinib	Nilotinib	644241	N/A	NCT01099514	Purpose: Nilotinib is a novel tyrosine kinase inhibitor (TKI) targeting KIT, PDGFR, and Bcr-Abl. 	inhibitor
Melanoma	Kit	PDGFR	PDGFRA	5156	Nilotinib	Nilotinib	644241	N/A	NCT01099514	Purpose: Nilotinib is a novel tyrosine kinase inhibitor (TKI) targeting KIT, PDGFR, and Bcr-Abl. 	inhibitor
Melanoma	Kit	PDGFR	PDGFRB	5159	Nilotinib	Nilotinib	644241	N/A	NCT01099514	Purpose: Nilotinib is a novel tyrosine kinase inhibitor (TKI) targeting KIT, PDGFR, and Bcr-Abl. 	inhibitor
Melanoma	Kit	c-KIT	KIT	3815	Nilotinib	Nilotinib	644241	N/A	NCT01168050	Official title:  Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification. 	inhibitor
Melanoma	Kit	cKIT	KIT	3815	Masitinib	Masitinib	10074640	N/A	NCT01280565	Purpose: Masitinib is a novel TKI that potently inhibits wild type (WT) c-kit and its activated form, mutated in the juxtamembrane region (JM c-kit) PDGFRs, the intracellular kinase Lyn, and to a lesser extent fibroblast growth factor receptor 3 (FGFR3).	inhibitor
Melanoma	Kit	FGFR3	FGFR3	2261	Masitinib	Masitinib	10074640	N/A	NCT01280565	Purpose: Masitinib is a novel TKI that potently inhibits wild type (WT) c-kit and its activated form, mutated in the juxtamembrane region (JM c-kit) PDGFRs, the intracellular kinase Lyn, and to a lesser extent fibroblast growth factor receptor 3 (FGFR3).	inhibitor
Melanoma	Kit	Lyn	LYN	4067	Masitinib	Masitinib	10074640	N/A	NCT01280565	Purpose: Masitinib is a novel TKI that potently inhibits wild type (WT) c-kit and its activated form, mutated in the juxtamembrane region (JM c-kit) PDGFRs, the intracellular kinase Lyn, and to a lesser extent fibroblast growth factor receptor 3 (FGFR3).	inhibitor
Melanoma	Kit	PDGFR	PDGFRA	5156	Masitinib	Masitinib	10074640	N/A	NCT01280565	Purpose: Masitinib is a novel TKI that potently inhibits wild type (WT) c-kit and its activated form, mutated in the juxtamembrane region (JM c-kit) PDGFRs, the intracellular kinase Lyn, and to a lesser extent fibroblast growth factor receptor 3 (FGFR3).	inhibitor
Melanoma	Kit	PDGFR	PDGFRB	5159	Masitinib	Masitinib	10074640	N/A	NCT01280565	Purpose: Masitinib is a novel TKI that potently inhibits wild type (WT) c-kit and its activated form, mutated in the juxtamembrane region (JM c-kit) PDGFRs, the intracellular kinase Lyn, and to a lesser extent fibroblast growth factor receptor 3 (FGFR3).	inhibitor
Melanoma	Kit	VEGFR	FLT1	2321	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Melanoma	Kit	VEGFR	KDR	3791	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Melanoma	Kit	VEGFR	FLT4	2324	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Melanoma	Kit	cKIT	KIT	3815	nilotinib	Nilotinib	644241	N/A	NCT01395121	Purpose: The aim of this study is to see if a drug called nilotinib (Tasigna) is effective in the treatment of patients with a rare group of acral and mucosal melanomas that have a change (mutation) in a protein called cKIT. %Official title: Nilotinib in the Treatment of Patients With c-KIT Mutated Advanced Acral and Mucosal Melanoma. %Inclusion criteria: Patients with c-KIT mutated histologically proven advanced mucosal or acral melanoma.	inhibitor
Melanoma	Kit	Abl	Abl	45821	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
Melanoma	Kit	c-Kit	Kit	16590	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
Melanoma	Kit	EPHA2	EPHA2	1696	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
Melanoma	Kit	PDGFRb	PDGFRB	5159	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
Melanoma	Kit	VEGF	VEGFA	7422	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
Melanoma	Kit	VEGF	VEGFB	7423	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
Melanoma	Kit	VEGF	VEGFC	7424	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
Melanoma	Kit	CD30	TNFRSF8	943	brentuximab	N/A	N/A	N/A	NCT01461538	Purpose: brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies. %Official title: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies.	inhibitor
Melanoma	Kit	MDM2	MDM2	4193	RO5503781	N/A	N/A	N/A	NCT01462175	Official title: RO5503781, a Small Molecule MDM2 Antagonist. 	inhibitor
Melanoma	Kit	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Melanoma	Kit	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Melanoma	Kit	VEGFR-1	FLT1	2321	Pazopanib	pazopanib	10113978	N/A	NCT01543763	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
Melanoma	Kit	VEGFR-2	KDR	3791	Pazopanib	pazopanib	10113978	N/A	NCT01543763	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
Melanoma	Kit	VEGFR-3	FLT4	2324	Pazopanib	pazopanib	10113978	N/A	NCT01543763	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
Melanoma	Kit	HDAC	N/A	N/A	PCI-24781	PCI-24781	11749858	N/A	NCT01543763	Purpose: PCI-24781 is a pan HDAC inhibitor.	inhibitor
Melanoma	MEK	Mek1	MAP2k1	5604	GSK1120212	Trametinib	11707110	N/A	NCT01658553	Detailed description: GSK1120212 is an orally administered, potent and highly selective small molecule inhibitor of MEK1. %Exclusion criteria: History of prior exposure to a MEK(activated extracellular signal-regulated kinase) inhibitor.	inhibitor
Melanoma	MEK	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01721603	Purpose: dabrafenib (a BRAF inhibitor). 	inhibitor
Melanoma	MEK	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01726738	Purpose: BRAF inhibitor (dabrafenib) %Exclusion criteria: Prior treatment with a BRAF inhibitor (including but not limited to dabrafenib (GSK2118436), vemurafenib, and LX281/BMS-908662)	inhibitor
Melanoma	MEK	MEK1	MAP2k1	5604	trametinib	trametinib	11707110	N/A	NCT01726738	Purpose: MEK inhibitor (trametinib) %Exclusion criteria: prior treatment with MEK inhibitor (including but not limited to trametinib (GSK1120212), AZD6244, and RDEA119)	inhibitor
Melanoma	MEK	MEK2	MAP2k2	5605	trametinib	trametinib	11707110	N/A	NCT01726738	Purpose: MEK inhibitor (trametinib) %Exclusion criteria: prior treatment with MEK inhibitor (including but not limited to trametinib (GSK1120212), AZD6244, and RDEA119)	inhibitor
Melanoma	NRAS	c-KIT	KIT	3815	Nilotinib	Nilotinib	644241	N/A	NCT01168050	Official title:  Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification. 	inhibitor
Melanoma	NRAS	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	NRAS	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	NRAS	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	NRAS	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	NRAS	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	NRAS	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	NRAS	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01320085	Exclusion criteria: Prior treatment with a MEK- inhibitor	inhibitor
Melanoma	NRAS	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Melanoma	NRAS	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Melanoma	NRAS	N/A	N/A	N/A	Pasireotide	Pasireotide	9941444	N/A	NCT01652547	N/A	inhibitor
Melanoma	NRAS	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01726738	Purpose: BRAF inhibitor (dabrafenib) %Exclusion criteria: Prior treatment with a BRAF inhibitor (including but not limited to dabrafenib (GSK2118436), vemurafenib, and LX281/BMS-908662)	inhibitor
Melanoma	NRAS	MEK1	MAP2k1	5604	trametinib	trametinib	11707110	N/A	NCT01726738	Purpose: MEK inhibitor (trametinib) %Exclusion criteria: prior treatment with MEK inhibitor (including but not limited to trametinib (GSK1120212), AZD6244, and RDEA119)	inhibitor
Melanoma	NRAS	MEK2	MAP2k2	5605	trametinib	trametinib	11707110	N/A	NCT01726738	Purpose: MEK inhibitor (trametinib) %Exclusion criteria: prior treatment with MEK inhibitor (including but not limited to trametinib (GSK1120212), AZD6244, and RDEA119)	inhibitor
Melanoma	NRAS	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01763164	Exclusion criteria: Prior therapy with a MEK- inhibitor.	inhibitor
Melanoma	NRAS	N/A	N/A	N/A	LEE011	N/A	N/A	N/A	NCT01781572	N/A	inhibitor
Melanoma	NRAS	N/A	N/A	N/A	MEK162	MEK162	10288191	N/A	NCT01781572	N/A	inhibitor
Neuroblastoma	ALK	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Neuroblastoma	ALK	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Neuroblastoma	ALK	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00790816	N/A	inhibitor
Neuroblastoma	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01283516	Purpose: assess the safety and efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK). %Official title:  LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK). %Keywords: LDK378	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90AA1	3320	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90B1	7184	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Neuroblastoma	ALK	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Neuroblastoma	ALK	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01358331	N/A	inhibitor
Neuroblastoma	ALK	Alk	ALK	238	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. %Inclusion criteria: No prior ALK inhibitor therapy. 	inhibitor
Neuroblastoma	ALK	EGFR	EGFR	1956	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. 	inhibitor
Neuroblastoma	ALK	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Neuroblastoma	ALK	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Neuroblastoma	ALK	ALK	ALK	242	Crizotinib	crenolanib 	10366140	N/A	NCT01548144	Purpose: Crizotinib is designed to block a protein called ALK. 	inhibitor
Neuroblastoma	ALK	c-MET	MET	4241	crizotinib	crenolanib 	10366136	PF-02341066	NCT01606878	Intervention: c-met/hepatocyte growth factor receptor tyrosine kinase inhibitor PF-02341066.	inhibitor
Neuroblastoma	ALK	ALK	ALK	238	X-396	N/A	N/A	N/A	NCT01625234	Brief_title: Alk inhibitor. %Intervention: X-396, Oral ALK inhibitor	inhibitor
Neuroblastoma	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01634763	Purpose: LDK378 as a single agent when administered orally to Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK). %Inclusion criteria: Only patients with tumors characterized by genetic alterations in ALK.	inhibitor
Neuroblastoma	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01742286	Official title: Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK). %Purpose: LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose pharmacokinetics when administered orally to pediatric patients with ALK-activated tumors. %Detailed description: LDK378 is a novel inhibitor of ALK	inhibitor
Neuroblastoma	ALK	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Neuroblastoma	ALK	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Neuroblastoma	ALK	N/A	N/A	N/A	GS-5745	N/A	N/A	N/A	NCT01803282	N/A	inhibitor
Neuroblastoma	ALK	N/A	N/A	N/A	GSE	N/A	N/A	N/A	NCT01820299	N/A	inhibitor
Neuroblastoma	ALK	PARP	PARP1	142	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Neuroblastoma	ALK	PARP	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Neuroblastoma	ALK	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01827384	Detailed description: Everolimus (mTOR inhibitor)	inhibitor
Neuroblastoma	ALK	Wee1	Wee1	7465	MK-1775	MK 1775	24856436	N/A	NCT01827384	Detailed description: MK-1775 (Wee1 inhibitor)	inhibitor
Neuroblastoma	ALK	MEK	MAP2k1	5604	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Neuroblastoma	ALK	MEK	MAP2k2	5605	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Neuroblastoma	ALK	MEK	MAP2K3	5606	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Neuroblastoma	ALK	MEK	MAP2K4	6416	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Neuroblastoma	ALK	MEK	MAP2K5	5607	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Neuroblastoma	ALK	MEK	MAP2k6	5608	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Neuroblastoma	ALK	MEK	MAP2k7	5609	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01231594	Purpose: provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors. %Official title: Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.	inhibitor
Ovarian cancer	BRAF	tubulin	N/A	N/A	Crolibulin	Crolibulin	23649181	N/A	NCT01240590	Purpose: Crolibulin (EPC2407) is a microtubulin inhibitor.	inhibitor
Ovarian cancer	BRAF	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CB	5291	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CG	5294	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CD	5293	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R1	5295	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R2	5296	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R3	8503	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R4	30849	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R5	23533	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R6	146850	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	Mek	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	Mek	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	Mek	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	Mek	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	Mek	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	Mek	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	Mek	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Ovarian cancer	BRAF	CD27	CD27	939	CDX-1127	N/A	N/A	N/A	NCT01460134	Detailed description: CDX-1127 is a fully human monoclonal antibody that binds to a molecule called CD27. 	inhibitor
Ovarian cancer	BRAF	N/A	N/A	N/A	CDX-1127	N/A	N/A	N/A	NCT01524978	N/A	inhibitor
Ovarian cancer	BRAF	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Ovarian cancer	BRAF	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01531361	Official title: Vemurafenib (BRAF Inhibitor). %Inclusion criteria: Patients with advanced or metastatic cancers and BRAF mutations 	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CA	5290	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CB	5291	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CG	5294	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3CD	5293	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R1	5295	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R2	5296	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R3	8503	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R4	30849	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R5	23533	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	PI3K	PIK3R6	146850	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	PLX4032	NCT01636622	Purpose: Vemurafenib is designed to block a protein (called mutated BRAF). %Inclusion criteria: Patient must have histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma harboring a BRAF mutation	inhibitor
Ovarian cancer	BRAF	N/A	N/A	N/A	SAR260301	N/A	N/A	N/A	NCT01673737	N/A	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01738451	N/A	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01739764	Purpose: This open-label, multicenter, non-randomized study will provide continued access to vemurafenib for eligible patients with BRAF V600 mutation-positive malignancy. %Official title: A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies. %Inclusion criteria: BRAF V600 mutation-positive malignancy. 	inhibitor
Ovarian cancer	BRAF	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Ovarian cancer	BRAF	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01765543	Purpose: in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Inclusion criteria: positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01767623	Purpose:  vemurafenib in patients with BRAF V600 mutation positive cancer. %Official title: Vemurafenib in BRAF V600 Mutation Positive Cancer Patients. %Inclusion criteria: confirmed BRAF V600 mutation	inhibitor
Ovarian cancer	BRAF	ERK1	MAPK3	5595	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Ovarian cancer	BRAF	ERK2	MAPK1	5594	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Ovarian cancer	BRAF	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Ovarian cancer	BRAF	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Ovarian cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Ovarian cancer	BRAF	PARP	PARP1	142	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Ovarian cancer	BRAF	PARP	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Ovarian cancer	BRAF	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01827384	Detailed description: Everolimus (mTOR inhibitor)	inhibitor
Ovarian cancer	BRAF	Wee1	Wee1	7465	MK-1775	MK 1775	24856436	N/A	NCT01827384	Detailed description: MK-1775 (Wee1 inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k1	5604	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k2	5605	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K3	5606	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K4	6416	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2K5	5607	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k6	5608	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	BRAF	MEK	MAP2k7	5609	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	KRAS	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Ovarian cancer	KRAS	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Ovarian cancer	KRAS	N/A	N/A	N/A	Sirolimus	rapamycin	5284616	N/A	NCT00940381	N/A	inhibitor
Ovarian cancer	KRAS	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT00980239	N/A	inhibitor
Ovarian cancer	KRAS	EGFR	EGFR	1956	Sym004	N/A	N/A	N/A	NCT01117428	Inclusion criteria: Documented disease progression during or within 6 months after cessation of anti-EGFR Ab treatment.	inhibitor
Ovarian cancer	KRAS	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	KRAS	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	KRAS	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	KRAS	VEGFR-1	FLT1	2321	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Ovarian cancer	KRAS	VEGFR-2	KDR	3791	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Ovarian cancer	KRAS	VEGFR-3	FLT4	2324	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Ovarian cancer	KRAS	mTOR	mTOR	2475	everolimus	Everolimus	6442177	N/A	NCT01334073	N/A	inhibitor
Ovarian cancer	KRAS	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	KRAS	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	KRAS	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	KRAS	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	KRAS	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	KRAS	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	KRAS	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	KRAS	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	KRAS	EGFR	EGFR	1956	Panitumumab	N/A	N/A	N/A	NCT01388621	Purpose: The purpose of this trial is to estimate the therapeutic efficacy of the experimental targeted regimen including the EGFR antibody panitumumab. %Exclusion criteria: Prior anti-EGFR therapy/	inhibitor
Ovarian cancer	KRAS	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Ovarian cancer	KRAS	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Ovarian cancer	KRAS	N/A	N/A	N/A	TAS-117	N/A	N/A	N/A	NCT01610479	N/A	inhibitor
Ovarian cancer	KRAS	EWS-FLI4	N/A	N/A	Mithramycin	Plicamycin	163662	N/A	NCT01610570	Purpose:  Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript. %Inclusion criteria: Ewing sarcoma with EWS-FLI1 fusion transcript.	inhibitor
Ovarian cancer	KRAS	N/A	N/A	N/A	Ipilimumab	N/A	N/A	N/A	NCT01611558	N/A	inhibitor
Ovarian cancer	KRAS	EGFR	EGFR	1956	necitumumab	N/A	N/A	N/A	NCT01624467	Exclusion criteria: Have received necitumumab or any other monoclonal antibody targeting the EGFR as the most recent prior treatment	inhibitor
Ovarian cancer	KRAS	elF4e	ELF4	2000	ISIS 183750	N/A	N/A	N/A	NCT01675128	Detailed description: ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the human eukaryotic translation initiation factor 4E (eIF4E) protein. 	inhibitor
Ovarian cancer	KRAS	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Ovarian cancer	KRAS	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Ovarian cancer	KRAS	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Ovarian cancer	PIK3CA	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Ovarian cancer	PIK3CA	PIK3CA	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01219699	Purpose: Advanced Solid Tumors With an Alteration of the PIK3CA Gene. 	inhibitor
Ovarian cancer	PIK3CA	Akt	Akt1	207	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Ovarian cancer	PIK3CA	Akt	Akt2	208	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Ovarian cancer	PIK3CA	Akt	Akt3	10000	AZD5363	AZD4547	51039095	N/A	NCT01226316	Inclusion criteria: breast, ovarian, cervical, endometrial cancer, or other solid cancers, resistance to standard therapies with a PIK3CA gene mutation (Part C), AKT1 gene mutation (Part D) or a dysregulatory aberration on the PIK/AKT pathway (Part D	inhibitor
Ovarian cancer	PIK3CA	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	PIK3CA	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	PIK3CA	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k1	5604	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k2	5605	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K3	5606	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K4	6416	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K5	5607	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k6	5608	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k7	5609	GSK1120212	Trametinib	11707110	N/A	NCT01248858	Purpose: MEK inhibitor GSK1120212. %Detailed description: MEK inhibitor GSK1120212.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	GSK2126458	GSK2126458	25167777	N/A	NCT01248858	Purpose: PI3K inhibitor GSK2126458. %Detailed description: PI3K inhibitor GSK2126458.	inhibitor
Ovarian cancer	PIK3CA	N/A	N/A	N/A	BMS-906024	UNII-DRL23N424R	66550890	N/A	NCT01292655	N/A	inhibitor
Ovarian cancer	PIK3CA	PDGFR	PDGFRA	5156	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	PDGFR	PDGFRB	5159	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	RAF	BRAF	673	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	RAF	RAF1	5894	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	VEGFR	KDR	3791	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	VEGFR	FLT4	2324	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	VEGFR-1	FLT1	2321	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	VEGFR-3	FLT4	2324	Sorafenib	Sorafenib	406563	BAY 43-9006	NCT01303341	Purpose: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	N/A	N/A	N/A	DMUC5754A	N/A	N/A	N/A	NCT01335958	N/A	inhibitor
Ovarian cancer	PIK3CA	PARP1	PARP1	142	ABT-767	N/A	N/A	N/A	NCT01339650	Purpose: ABT-767 is a potent oral inhibitor of the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2). %Exclusion criteria: Subject has previously received a poly (ADP-ribose) polymerase (PARP) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PARP2	PARP2	10038	ABT-767	N/A	N/A	N/A	NCT01339650	Purpose: ABT-767 is a potent oral inhibitor of the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2). %Exclusion criteria: Subject has previously received a poly (ADP-ribose) polymerase (PARP) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01349660	Purpose: BKM120, an oral inhibitor of PI3 kinase. %Inclusion criteria: No previous treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	 BAY80-6946	 BAY80-6946	24989044	N/A	NCT01392521	Purpose: PI3K (phosphoinositol 3-Kinase) inhibitor BAY80-6946.	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k1	5604	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k2	5605	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K3	5606	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K4	6416	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K5	5607	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k6	5608	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k7	5609	 BAY86-9766	 BAY869766	44182295	N/A	NCT01392521	Purpose: MEK (mitogen-activated protein kinase) inhibitor BAY86-9766. 	inhibitor
Ovarian cancer	PIK3CA	PIK3CA	PIK3CA	5290	MLN1117	N/A	N/A	N/A	NCT01449370	N/A	inhibitor
Ovarian cancer	PIK3CA	Alk	ALK	238	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. %Inclusion criteria: No prior ALK inhibitor therapy. 	inhibitor
Ovarian cancer	PIK3CA	EGFR	EGFR	1956	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. 	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	BEZ235	dactolisib	11977753	N/A	NCT01508104	Purpose: BEZ235 is an agent that was developed to slow down or halt cell growth and proliferation. It works by inhibiting two pathways that are important for cell growth and replication, one is called mTOR and the other is called PI3K.	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01508104	Purpose: Everolimus is an agent that also targets mTOR. 	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01540253	Purpose: studies the side effects and best dose of PI3K inhibitor BKM120. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Exclusion criteria: Previous treatment with a phosphatidylinositol 3-kinase (P1-3K) inhibitor.	inhibitor
Ovarian cancer	PIK3CA	Ang1	ANGPT1	284	trebananib	N/A	N/A	AMG386	NCT01548482	Purpose: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	Ang2	ANGPT2	285	trebananib	N/A	N/A	AMG386	NCT01548482	Purpose: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PIK3CA	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01570296	Purpose: Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa). %Inclusion criteria: Patients with histologically or cytologically proven NSCLC who meet the clinical definition of EGFR TKI resistance, and are progressing on existing treatment or have previously progressed on EGFR TKI	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Ovarian cancer	PIK3CA	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PIK3CA	N/A	N/A	N/A	ASP9853	N/A	N/A	N/A	NCT01705483	N/A	inhibitor
Ovarian cancer	PIK3CA	N/A	N/A	N/A	AMG 479	N/A	N/A	N/A	NCT01708161	N/A	inhibitor
Ovarian cancer	PIK3CA	N/A	N/A	N/A	BYL719	BYL719	56649450	N/A	NCT01708161	N/A	inhibitor
Ovarian cancer	PIK3CA	Notch1	Notch1	4851	OMP-52M51	N/A	N/A	N/A	NCT01778439	Exclusion criteria: Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors	inhibitor
Ovarian cancer	PIK3CA	Mct1	SLC16A1	6566	AZD3965	N/A	N/A	N/A	NCT01791595	Purpose: AZD3965 is a type of drug called a monocarboxylate transporter 1 inhibitor. %Official title:  AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1)	inhibitor
Ovarian cancer	PIK3CA	PARP	PARP1	142	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Ovarian cancer	PIK3CA	PARP	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Ovarian cancer	PIK3CA	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01827384	Detailed description: Everolimus (mTOR inhibitor)	inhibitor
Ovarian cancer	PIK3CA	Wee1	Wee1	7465	MK-1775	MK 1775	24856436	N/A	NCT01827384	Detailed description: MK-1775 (Wee1 inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k1	5604	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k2	5605	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K3	5606	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K4	6416	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2K5	5607	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k6	5608	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	MEK	MAP2k7	5609	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PIK3CA	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01833169	Official title: BKM120 for Patients With PI3K-activated Tumors. %Inclusion criteria: Patient's tumor has been evaluated and pre-identified to have activation of the PI3K pathway.	inhibitor
Ovarian cancer	PTEN	N/A	N/A	N/A	Bevacizumab	N/A	N/A	N/A	NCT00756340	N/A	inhibitor
Ovarian cancer	PTEN	N/A	N/A	N/A	Everolimus	Everolimus	6442177	N/A	NCT00756340	N/A	inhibitor
Ovarian cancer	PTEN	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Ovarian cancer	PTEN	N/A	N/A	N/A	AMG479	N/A	N/A	N/A	NCT01122199	N/A	inhibitor
Ovarian cancer	PTEN	N/A	N/A	N/A	RAD001	Everolimus	6442177	N/A	NCT01122199	N/A	inhibitor
Ovarian cancer	PTEN	mTOR	mTOR	2475	temsirolimus	Temsirolimus	23724530	N/A	NCT01196429	Exclusion criteria: Previous treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).	inhibitor
Ovarian cancer	PTEN	mTOR	mTOR	2475	temsirolimus	Temsirolimus	23724530	N/A	NCT01196429	Exclusion criteria: Previous treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).	inhibitor
Ovarian cancer	PTEN	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	PTEN	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	PTEN	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Ovarian cancer	PTEN	N/A	N/A	N/A	Endostar	N/A	N/A	N/A	NCT01327235	N/A	inhibitor
Ovarian cancer	PTEN	PTEN	PTEN	5728	GSK2636771	1372540-25-4	56949517	N/A	NCT01458067	Inclusion criteria: Subjects must have tumors with a documented PTEN deficiency. 	inhibitor
Ovarian cancer	PTEN	NY-ESO-1	CTAG1-B	255753	DEC-205-NY-ESO-1 fusion protein vaccine	N/A	N/A	N/A	NCT01522820	Purpose: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. 	inhibitor
Ovarian cancer	PTEN	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Ovarian cancer	PTEN	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01570296	Purpose: Oral Pan-class I PI3K Inhibitor. %Inclusion criteria: Activated PI3K status.	inhibitor
Ovarian cancer	PTEN	EGFR	EGFR	1956	Gefitinib	Gefitinib	123631	N/A	NCT01570296	Purpose: Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa). %Inclusion criteria: Patients with histologically or cytologically proven NSCLC who meet the clinical definition of EGFR TKI resistance, and are progressing on existing treatment or have previously progressed on EGFR TKI	inhibitor
Ovarian cancer	PTEN	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Ovarian cancer	PTEN	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Ovarian cancer	PTEN	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Ovarian cancer	PTEN	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Ovarian cancer	PTEN	N/A	N/A	N/A	ASP9853	N/A	N/A	N/A	NCT01705483	N/A	inhibitor
Ovarian cancer	PTEN	Mct1	SLC16A1	6566	AZD3965	N/A	N/A	N/A	NCT01791595	Purpose: AZD3965 is a type of drug called a monocarboxylate transporter 1 inhibitor. %Official title:  AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1)	inhibitor
Rhabdomyosarcoma	ALK	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Rhabdomyosarcoma	ALK	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Rhabdomyosarcoma	ALK	N/A	N/A	N/A	Lapatinib	lapatinib ditosylate	9941095	lapatinib ditosylate	NCT00790816	N/A	inhibitor
Rhabdomyosarcoma	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01283516	Purpose: assess the safety and efficacy of LDK378 in patients with genetic abnormalities in anaplastic lymphoma kinase (ALK). %Official title:  LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK). %Keywords: LDK378	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90AA1	3320	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90B1	7184	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Rhabdomyosarcoma	ALK	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Rhabdomyosarcoma	ALK	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01358331	N/A	inhibitor
Rhabdomyosarcoma	ALK	Alk	ALK	238	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. %Inclusion criteria: No prior ALK inhibitor therapy. 	inhibitor
Rhabdomyosarcoma	ALK	EGFR	EGFR	1956	AP26113	AP26113	57390074	N/A	NCT01449461	Official title: Oral ALK/EGFR Inhibitor AP26113. %Detailed description: The objectives of the expansion phase are to describe the preliminary anti-tumor activity (overall response rate) of AP26113 in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement or mutated epidermal growth factor receptor (EGFR), and in patients with any cancers with abnormalities in ALK or other targets against which AP26113 is active. 	inhibitor
Rhabdomyosarcoma	ALK	ALK	ALK	238	Crizotinib 	crenolanib 	10366136	N/A	NCT01524926	Purpose: assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways. The targeted patient population will include patients with tumors harboring specific alterations leading to ALK and/or MET activation. 	inhibitor
Rhabdomyosarcoma	ALK	Met	MET	4233	Crizotinib 	crenolanib 	10366136	N/A	NCT01524926	Purpose: assess the antitumor activity of crizotinib in a variety of tumors with alterations in ALK and/or MET pathways. The targeted patient population will include patients with tumors harboring specific alterations leading to ALK and/or MET activation. 	inhibitor
Rhabdomyosarcoma	ALK	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Rhabdomyosarcoma	ALK	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Rhabdomyosarcoma	ALK	ALK	ALK	243	Crizotinib	crenolanib 	10366141	N/A	NCT01548144	Purpose: Crizotinib is designed to block a protein called ALK. 	inhibitor
Rhabdomyosarcoma	ALK	c-MET	MET	4241	crizotinib	crenolanib 	10366136	PF-02341066	NCT01606878	Intervention: c-met/hepatocyte growth factor receptor tyrosine kinase inhibitor PF-02341066.	inhibitor
Rhabdomyosarcoma	ALK	ALK	ALK	238	X-396	N/A	N/A	N/A	NCT01625234	Brief_title: Alk inhibitor. %Intervention: X-396, Oral ALK inhibitor	inhibitor
Rhabdomyosarcoma	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01634763	Purpose: LDK378 as a single agent when administered orally to Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK). %Inclusion criteria: Only patients with tumors characterized by genetic alterations in ALK.	inhibitor
Rhabdomyosarcoma	ALK	ALK	ALK	238	LDK378	1032900-25-6	57379345	N/A	NCT01742286	Official title: Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK). %Purpose: LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose pharmacokinetics when administered orally to pediatric patients with ALK-activated tumors. %Detailed description: LDK378 is a novel inhibitor of ALK	inhibitor
Rhabdomyosarcoma	ALK	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Rhabdomyosarcoma	ALK	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Rhabdomyosarcoma	ALK	N/A	N/A	N/A	GS-5745	N/A	N/A	N/A	NCT01803282	N/A	inhibitor
Rhabdomyosarcoma	ALK	N/A	N/A	N/A	GSE	N/A	N/A	N/A	NCT01820299	N/A	inhibitor
Rhabdomyosarcoma	ALK	PARP	PARP1	142	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Rhabdomyosarcoma	ALK	PARP	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Rhabdomyosarcoma	ALK	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01827384	Detailed description: Everolimus (mTOR inhibitor)	inhibitor
Rhabdomyosarcoma	ALK	Wee1	Wee1	7465	MK-1775	MK 1775	24856436	N/A	NCT01827384	Detailed description: MK-1775 (Wee1 inhibitor)	inhibitor
Rhabdomyosarcoma	ALK	MEK	MAP2k1	5604	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Rhabdomyosarcoma	ALK	MEK	MAP2k2	5605	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Rhabdomyosarcoma	ALK	MEK	MAP2K3	5606	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Rhabdomyosarcoma	ALK	MEK	MAP2K4	6416	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Rhabdomyosarcoma	ALK	MEK	MAP2K5	5607	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Rhabdomyosarcoma	ALK	MEK	MAP2k6	5608	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Rhabdomyosarcoma	ALK	MEK	MAP2k7	5609	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Thymic Carcinoma	KIT	Fms	CSF1R	1436	PLX3397	N/A	N/A	N/A	NCT01004861	Purpose: PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.	inhibitor
Thymic Carcinoma	KIT	VEGFR	FLT1	2321	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Thymic Carcinoma	KIT	VEGFR	KDR	3791	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Thymic Carcinoma	KIT	VEGFR	FLT4	2324	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Lung cancer	Akt1	PDGFRA	PDGFRA	5156	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Thymic Carcinoma	KIT	Kit	KIT	3815	Sunitinib	Sunitinib	5329102	N/A	NCT01306045	Purpose: KIT or PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression of some cancers, including kidney cancer.	inhibitor
Thymic Carcinoma	KIT	Abl	Abl	45821	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
Thymic Carcinoma	KIT	c-Kit	Kit	16590	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
Thymic Carcinoma	KIT	EPHA2	EPHA2	1696	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
Thymic Carcinoma	KIT	PDGFRb	PDGFRB	5159	Dasatinib	Dasatinib	3062316	N/A	NCT01445509	Purpose:  Dasatinib inhibits the action of proteins called tyrosine kinases, which promote and stimulate blood vessel formation and cancer growth and spread. %Detailed description: Dasatinib is an inhibitor of SRC family kinases, BCR-ABL, c-KIT, EPHA2 and PDGF beta receptor.	inhibitor
Thymic Carcinoma	KIT	VEGF	VEGFA	7422	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
Thymic Carcinoma	KIT	VEGF	VEGFB	7423	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
Thymic Carcinoma	KIT	VEGF	VEGFC	7424	Bevacizumab	N/A	N/A	N/A	NCT01445509	Background: Bevacizumab inhibits blood vessel growth in cancer cells by blocking a growth factor called VEGF. %Detailed description: Bevacizumab is a humanized IgG1 monoclonal antibody (MAb) that binds all biologically active isoforms of human vascular endothelial growth factor (VEGF, or VEGF-A)	inhibitor
Thymic Carcinoma	KIT	CD30	TNFRSF8	943	brentuximab	N/A	N/A	N/A	NCT01461538	Purpose: brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies. %Official title: Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies.	inhibitor
Thymic Carcinoma	KIT	MDM2	MDM2	4193	RO5503781	N/A	N/A	N/A	NCT01462175	Official title: RO5503781, a Small Molecule MDM2 Antagonist. 	inhibitor
Thymic Carcinoma	KIT	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Thymic Carcinoma	KIT	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Thymic Carcinoma	KIT	VEGFR1	FLT1	2321	Pazopanib	pazopanib	10113978	N/A	NCT01543763	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
Thymic Carcinoma	KIT	HDAC	N/A	N/A	PCI-24781	PCI-24781	11749858	N/A	NCT01543763	Purpose: PCI-24781 is a pan HDAC inhibitor.	inhibitor
Thymic Carcinoma	KIT	VEGFR2	KDR	3791	Pazopanib	pazopanib	10113978	N/A	NCT01529593	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
Thymic Carcinoma	KIT	VEGFR3	FLT4	2324	Pazopanib	pazopanib	10113978	N/A	NCT01529593	Purpose: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-_ and -_ and c-kit. 	inhibitor
Thymic Carcinoma	KIT	c-KIT	KIT	3815	Imatinib Mesylate	Imatinib Mesylate	123596	N/A	NCT01738139	Official title: Imatinib Mesylate (c-Kit Inhibitor). 	inhibitor
Thymic Carcinoma	KIT	N/A	N/A	N/A	Ipilimumab	N/A	N/A	N/A	NCT01738139	N/A	inhibitor
Thyroid Cancer	RET	RET	RET	5979	Vandetanib	Vandetanib	3081361	ZACTIMA	NCT00514046	Purpose: Vandetanib is an experimental drug that blocks a defective protein receptor (RET receptor). 	inhibitor
Thyroid Cancer	RET	ROS	ROS1	6098	PF-02341066	Crizotinib	11626560	N/A	NCT00585195	Purpose: PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. %Inclusion criteria: Histologically confirmed advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS. 	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	cediranib maleate	cediranib maleate	11226834	N/A	NCT01208051	N/A	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01231594	Purpose: provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors. %Official title: Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.	inhibitor
Thyroid Cancer	BRAF	tubulin	N/A	N/A	Crolibulin	Crolibulin	23649181	N/A	NCT01240590	Purpose: Crolibulin (EPC2407) is a microtubulin inhibitor.	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	BBI608	N/A	N/A	N/A	NCT01325441	N/A	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CA	5290	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CB	5291	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CG	5294	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CD	5293	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R1	5295	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R2	5296	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R3	8503	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R4	30849	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R5	23533	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R6	146850	BYL719	BYL719	56649450	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	Mek	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	Mek	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	Mek	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	Mek	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	Mek	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	Mek	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	Mek	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01449058	Keywords: PI3K inhibitor, MEK inhibitor.	inhibitor
Thyroid Cancer	BRAF	VEGF	VEGFA	7422	sorafenib tosylate	Sorafenib Tosylate	406563	N/A	NCT01502410	Objective:  To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. 	inhibitor
Thyroid Cancer	BRAF	VEGF	VEGFB	7423	sorafenib tosylate	Sorafenib Tosylate	406563	N/A	NCT01502410	Objective:  To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. 	inhibitor
Thyroid Cancer	BRAF	VEGF	VEGFC	7424	sorafenib tosylate	Sorafenib Tosylate	406563	N/A	NCT01502410	Objective:  To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. 	inhibitor
Thyroid Cancer	BRAF	VEGFR-2	KDR	3791	sorafenib tosylate	Sorafenib Tosylate	406563	N/A	NCT01502410	Objective:  To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. 	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	CDX-1127	N/A	N/A	N/A	NCT01524978	N/A	inhibitor
Thyroid Cancer	BRAF	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Thyroid Cancer	BRAF	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	Zelboraf	NCT01531361	Official title: Vemurafenib (BRAF Inhibitor). %Inclusion criteria: Patients with advanced or metastatic cancers and BRAF mutations 	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	LGX818	N/A	N/A	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k1	5604	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k2	5605	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K3	5606	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K4	6416	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K5	5607	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k6	5608	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k7	5609	MEK162	MEK162	10288191	N/A	NCT01543698	Exclusion criteria: Progressive disease following prior treatment with RAF-inhibitors in combination with MEK-inhibitors. %Official title:  Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors	inhibitor
Thyroid Cancer	BRAF	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Thyroid Cancer	BRAF	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CA	5290	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CB	5291	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CG	5294	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3CD	5293	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R1	5295	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R2	5296	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R3	8503	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R4	30849	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R5	23533	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	PI3K	PIK3R6	146850	PX-866	PX-866	9849735	N/A	NCT01616199	Purpose: The purpose of the phase 1 portion of the study is to determine PX-866 in combination vemurafenib in patients with any advanced BRAF-mutant cancer. %Official title: Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) %Inclusion criteria: must have histologically or cytologically-confirmed advanced cancer that is BRAF mutation-positive	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	PLX4032	NCT01636622	Purpose: Vemurafenib is designed to block a protein (called mutated BRAF). %Inclusion criteria: Patient must have histologically or cytologically confirmed diagnosis of advanced solid tumor or lymphoma harboring a BRAF mutation	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	SAR260301	N/A	N/A	N/A	NCT01673737	N/A	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01677741	Purpose: dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. %Official title: Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation. %Inclusion criteria: BRAF V600 mutation-positive tumor.	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01709292	Inclusion criteria: BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor.	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	GSK2118436	NCT01713972	Purpose: Dabrafenib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. %Assigned intervention: BRAF inhibitor GSK2118436. %Inclusion criteria: Tumors must carry the BRAF mutation	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	dabrafenib	Dabrafenib mesylate	44516822	GSK2118436	NCT01723202	Official title: GSK2118436 (BRAFi). %Intervention: BRAF inhibitor GSK2118436	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k1	5604	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k2	5605	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K3	5606	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K4	6416	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K5	5607	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k6	5608	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k7	5609	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k1	5604	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k2	5605	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K3	5606	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K4	6416	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K5	5607	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k6	5608	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k7	5609	trametinib	trametinib	11707110	GSK1120212	NCT01723202	Official title: GSK1120212 (MEKi)	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	GSK2118436	GSK2118436	44516822	N/A	NCT01738451	N/A	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	vemurafenib	Vemurafenib	42611257	N/A	NCT01739764	Purpose: This open-label, multicenter, non-randomized study will provide continued access to vemurafenib for eligible patients with BRAF V600 mutation-positive malignancy. %Official title: A Phase IV, PostMarketing, Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies. %Inclusion criteria: BRAF V600 mutation-positive malignancy. 	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	Crizotinib	crenolanib 	10366136	N/A	NCT01744652	N/A	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	Dasatinib	Dasatinib	3062316	N/A	NCT01744652	N/A	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01765543	Purpose: in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF. %Inclusion criteria: positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01767623	Purpose:  vemurafenib in patients with BRAF V600 mutation positive cancer. %Official title: Vemurafenib in BRAF V600 Mutation Positive Cancer Patients. %Inclusion criteria: confirmed BRAF V600 mutation	inhibitor
Thyroid Cancer	BRAF	ERK1	MAPK3	5595	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Thyroid Cancer	BRAF	ERK2	MAPK1	5594	BVD-523	N/A	N/A	N/A	NCT01781429	Official title: BVD-523, an ERK 1/2 Inhibitor. 	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Thyroid Cancer	BRAF	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Thyroid Cancer	BRAF	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Thyroid Cancer	BRAF	MET	MET	4233	cabozantinib-s-malate	Cabozantinib	25102846	N/A	NCT01811212	Exclusion criteria: Prior treatment with cabozantinib or any tyrosine kinase inhibitor that targets MET.	inhibitor
Thyroid Cancer	BRAF	PARP	PARP1	142	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Thyroid Cancer	BRAF	PARP	PARP2	10038	ABT-888	Veliparib	11960529	N/A	NCT01827384	Detailed description: ABT-888 (PARP inhibitor) 	inhibitor
Thyroid Cancer	BRAF	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01827384	Detailed description: Everolimus (mTOR inhibitor)	inhibitor
Thyroid Cancer	BRAF	Wee1	Wee1	7465	MK-1775	MK 1775	24856436	N/A	NCT01827384	Detailed description: MK-1775 (Wee1 inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k1	5604	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k2	5605	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K3	5606	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K4	6416	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2K5	5607	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k6	5608	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Thyroid Cancer	BRAF	MEK	MAP2k7	5609	Trametinib	trametinib	11707110	N/A	NCT01827384	Detailed description: Trametinib DMSO (MEK inhibitor)	inhibitor
Thyroid Cancer	HRAS	N/A	N/A	N/A	Hydroxychloroquine	Hydroxychloroquine	3652	N/A	NCT01023737	N/A	inhibitor
Thyroid Cancer	HRAS	N/A	N/A	N/A	Vorinostat	Suberoylanilide Hydroxamic Acid	N/A	N/A	NCT01023737	N/A	inhibitor
Thyroid Cancer	HRAS	N/A	N/A	N/A	cediranib maleate	cediranib maleate	11226834	N/A	NCT01208051	N/A	inhibitor
Thyroid Cancer	HRAS	N/A	N/A	N/A	TAS-118	N/A	N/A	N/A	NCT01610479	N/A	inhibitor
Thyroid Cancer	HRAS	EWS-FLI5	N/A	N/A	Mithramycin	Plicamycin	163663	N/A	NCT01610570	Purpose:  Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript. %Inclusion criteria: Ewing sarcoma with EWS-FLI1 fusion transcript.	inhibitor
Thyroid Cancer	HRAS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	NCT01661972	N/A	inhibitor
Thyroid Cancer	HRAS	FGFR1	FGFR1	2260	JNJ-42756493	N/A	N/A	N/A	NCT01703481	Purpose: JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. %Official title: JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor.%Inclusion criteria: participants must have tumors that are K-ras wild-type and also express FGFR 1, 2, or 4 gene amplifications.	inhibitor
Thyroid Cancer	HRAS	FGFR2	FGFR2	2263	JNJ-42756493	N/A	N/A	N/A	NCT01703481	Purpose: JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. %Official title: JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor.%Inclusion criteria: participants must have tumors that are K-ras wild-type and also express FGFR 1, 2, or 4 gene amplifications.	inhibitor
Thyroid Cancer	HRAS	FGFR3	FGFR3	2261	JNJ-42756493	N/A	N/A	N/A	NCT01703481	Purpose: JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. %Official title: JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor.%Inclusion criteria: participants must have tumors that are K-ras wild-type and also express FGFR 1, 2, or 4 gene amplifications.	inhibitor
Thyroid Cancer	HRAS	FGFR4	FGFR4	2264	JNJ-42756493	N/A	N/A	N/A	NCT01703481	Purpose: JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. %Official title: JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor.%Inclusion criteria: participants must have tumors that are K-ras wild-type and also express FGFR 1, 2, or 4 gene amplifications.	inhibitor
Thyroid Cancer	HRAS	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Thyroid Cancer	HRAS	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Thyroid Cancer	HRAS	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Thyroid Cancer	KRAS	N/A	N/A	N/A	Abraxane	TAXOL	36314	N/A	NCT00748553	N/A	inhibitor
Thyroid Cancer	KRAS	N/A	N/A	N/A	Temsirolimus	Temsirolimus	23724530	N/A	NCT00770263	N/A	inhibitor
Thyroid Cancer	KRAS	N/A	N/A	N/A	Sirolimus	rapamycin	5284616	N/A	NCT00940381	N/A	inhibitor
Thyroid Cancer	KRAS	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT00980239	N/A	inhibitor
Thyroid Cancer	KRAS	EGFR	EGFR	1956	Sym004	N/A	N/A	N/A	NCT01117428	Inclusion criteria: Documented disease progression during or within 6 months after cessation of anti-EGFR Ab treatment.	inhibitor
Thyroid Cancer	KRAS	Akt	Akt1	207	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Thyroid Cancer	KRAS	Akt	Akt2	208	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Thyroid Cancer	KRAS	Akt	Akt3	10000	MK2206	MK2206	46930998	N/A	NCT01245205	Purpose: Akt inhibitor MK2206	inhibitor
Thyroid Cancer	KRAS	VEGFR-1	FLT1	2321	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Thyroid Cancer	KRAS	VEGFR-2	KDR	3791	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Thyroid Cancer	KRAS	VEGFR-3	FLT4	2324	Axitinib	Axitinib	6450551	N/A	NCT01334073	N/A	inhibitor
Thyroid Cancer	KRAS	mTOR	mTOR	2475	everolimus	Everolimus	6442177	N/A	NCT01334073	N/A	inhibitor
Thyroid Cancer	KRAS	MEK	MAP2k1	5604	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	KRAS	MEK	MAP2k2	5605	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	KRAS	MEK	MAP2K3	5606	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	KRAS	MEK	MAP2K4	6416	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	KRAS	MEK	MAP2K5	5607	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	KRAS	MEK	MAP2k6	5608	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	KRAS	MEK	MAP2k7	5609	 PD-0325901	PD 0325901	9826528	N/A	NCT01347866	Purpose: PD-0325901 (oral MEK inhibitor)	inhibitor
Thyroid Cancer	KRAS	mTOR	mTOR	2475	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3CA	5290	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3CB	5291	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3CG	5294	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3CD	5293	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R1	5295	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R2	5296	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R3	8503	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R4	30849	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R5	23533	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R6	146850	PF-05212384	PKI-587	44516953	N/A	NCT01347866	Purpose: PF-05212384 (intravenous PI3K/mTOR inhibitor). %Official title: Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384.	inhibitor
Thyroid Cancer	KRAS	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Thyroid Cancer	KRAS	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3CA	5290	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3CB	5291	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3CG	5294	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3CD	5293	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R1	5295	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R2	5296	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R3	8503	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R4	30849	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R5	23533	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	PI3K	PIK3R6	146850	BKM120	Buparlisib hydrochloride	66577015	N/A	NCT01571024	Exclusion criteria: Patients with history of prior treatment with a PI3K inhibitor	inhibitor
Thyroid Cancer	KRAS	N/A	N/A	N/A	TAS-119	N/A	N/A	N/A	NCT01610479	N/A	inhibitor
Thyroid Cancer	KRAS	EWS-FLI6	N/A	N/A	Mithramycin	Plicamycin	163664	N/A	NCT01610570	Purpose:  Mithramycin in Children and Adults With Refractory Extracranial Solid Tumors (Phase I) or Ewing Sarcoma and EWSFLI1 Fusion Transcript. %Inclusion criteria: Ewing sarcoma with EWS-FLI1 fusion transcript.	inhibitor
Thyroid Cancer	KRAS	EGFR	EGFR	1956	necitumumab	N/A	N/A	N/A	NCT01624467	Exclusion criteria: Have received necitumumab or any other monoclonal antibody targeting the EGFR as the most recent prior treatment	inhibitor
Thyroid Cancer	KRAS	elF4e	ELF4	2000	ISIS 183750	N/A	N/A	N/A	NCT01675128	Detailed description: ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the human eukaryotic translation initiation factor 4E (eIF4E) protein. 	inhibitor
Thyroid Cancer	KRAS	N/A	N/A	N/A	Cetuximab	N/A	N/A	N/A	NCT01787500	N/A	inhibitor
Thyroid Cancer	KRAS	N/A	N/A	N/A	Irinotecan	Irinotecan	60838	N/A	NCT01787500	N/A	inhibitor
Thyroid Cancer	KRAS	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01787500	Purpose: Vemurafenib is designed to block BRAFV600 inside the cancer cells. %Inclusion criteria: Cancers with positive BRAF V600 mutation. %Keywords: BRAF mutant, BRAF V600 Mutant Advanced Solid Malignancies.	inhibitor
Thyroid Cancer	NRAS	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Thyroid Cancer	NRAS	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Thyroid Cancer	RET	VEGFR	FLT1	2321	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Thyroid Cancer	RET	VEGFR	KDR	3791	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Thyroid Cancer	RET	VEGFR	FLT4	2324	Sunitinib	Sunitinib	5329102	N/A	NCT01286896	Detailed description: Sunitinib is an orally available inhibitor of vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGF), cytokine receptor (c-KIT), and receptor tyrosine kinase (FLT-3) activity.	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90AA1	3320	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Inflammatory Myofibroblastic Tumor	ALK	Heat Shock Protein 90	HSP90B1	7184	DS-2248	N/A	N/A	N/A	NCT01288430	Official title:  DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor. 	inhibitor
Thyroid Cancer	RET	ARAF	ARAF	369	MLN2480	1096708-71-2	25161177	N/A	NCT01425008	Exclusion criteria: Dose Expansion phase: Previous treatment with RAF or MEK inhibitors.	inhibitor
Thyroid Cancer	RET	BRAF	BRAF	673	MLN2480	1096708-71-2	25161177	N/A	NCT01425008	Exclusion criteria: Dose Expansion phase: Previous treatment with RAF or MEK inhibitors.	inhibitor
Thyroid Cancer	RET	C-RAF	RAF1	5894	MLN2480	1096708-71-2	25161177	N/A	NCT01425008	Exclusion criteria: Dose Expansion phase: Previous treatment with RAF or MEK inhibitors.	inhibitor
Thyroid Cancer	RET	N/A	N/A	N/A	dinaciclib	dinaciclib	46926350	SCH727965	NCT01434316	N/A	inhibitor
Thyroid Cancer	RET	N/A	N/A	N/A	veliparib	Veliparib	11960529	ABT-888	NCT01434316	N/A	inhibitor
Thyroid Cancer	RET	VEGF	VEGFA	7422	sorafenib tosylate	Sorafenib Tosylate	406563	N/A	NCT01502410	Objective:  To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. 	inhibitor
Thyroid Cancer	RET	VEGF	VEGFB	7423	sorafenib tosylate	Sorafenib Tosylate	406563	N/A	NCT01502410	Objective:  To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. 	inhibitor
Thyroid Cancer	RET	VEGF	VEGFC	7424	sorafenib tosylate	Sorafenib Tosylate	406563	N/A	NCT01502410	Objective:  To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. 	inhibitor
Thyroid Cancer	RET	VEGFR-2	KDR	3791	sorafenib tosylate	Sorafenib Tosylate	406563	N/A	NCT01502410	Objective:  To assess the biologic activity of sorafenib on vascular endothelial growth factor (VEGF) and soluble vascular endothelial growth factor receptor-2 (VEGFR-2) in peripheral blood samples. 	inhibitor
Thyroid Cancer	RET	mTOR	mTOR	2475	Metformin	Metformin	4091	N/A	NCT01529593	Purpose: Metformin was designed to treat patients with diabetes. It may be able to block the protein mTOR and slow the growth of tumors.	inhibitor
Thyroid Cancer	RET	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01529593	Purpose: Temsirolimus is designed to block a protein called mTOR. 	inhibitor
Thyroid Cancer	RET	mTOR	mTOR	2475	Everolimus	Everolimus	6442177	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Thyroid Cancer	RET	mTOR	mTOR	2475	Temsirolimus	Temsirolimus	23724530	N/A	NCT01596140	Official title: mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel)	inhibitor
Thyroid Cancer	RET	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01596140	Purpose: Vemurafenib is designed to block BRAF. %Official title:  BRAF Inhibitor Vemurafenib. 	inhibitor
Thyroid Cancer	RET	mTOR	mTOR	2475	SAR245409	N/A	N/A	N/A	NCT01596270	N/A	inhibitor
Thyroid Cancer	RET	PI3K	PIK3CA	5290	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3CB	5291	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3CG	5294	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3CD	5293	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3R1	5295	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3R2	5296	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3R3	8503	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3R4	30849	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3R5	23533	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	PI3K	PIK3R6	146850	SAR245409	N/A	N/A	N/A	NCT01596270	Exclusion criteria: Intolerance of prior treatment with a PI3K inhibitor.	inhibitor
Thyroid Cancer	RET	BRAF	BRAF	673	Dabrafenib	Dabrafenib mesylate	44516822	N/A	NCT01677741	Purpose: dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. %Official title: Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years With Advanced BRAF V600-Mutation. %Inclusion criteria: BRAF V600 mutation-positive tumor.	inhibitor
Thyroid Cancer	RET	BRAF	BRAF	673	Vemurafenib	Vemurafenib	42611257	N/A	NCT01709292	Inclusion criteria: BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor.	inhibitor
Thyroid Cancer	RET	MET	MET	4233	cabozantinib-s-malate	Cabozantinib	25102846	N/A	NCT01811212	Exclusion criteria: Prior treatment with cabozantinib or any tyrosine kinase inhibitor that targets MET.	inhibitor
Thyroid Cancer	RET	RET	RET	5979	Ponatinib	Ponatinib	24826799	N/A	NCT01838642	Purpose: Ponatinib, a drug that is FDA approved as a therapy for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), has been well tolerated in clinical trials, and is a potent inhibitor of RET kinase. %Inclusion criteria: Previous therapy targeting RET kinase is permitted if the last dose was given at least 4 weeks prior to the first dose of ponatinib.	inhibitor